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WNK, SPAK and OSR1 kinases are three serine/threonine protein kinases that 
regulate the function of cation chloride co-transporters (CCC). Such function has 
implicated these kinases in the regulation of electrolyte balance and hence blood 
pressure. This was confirmed by the discovery that genetic mutations in WNK kinases 
cause an inherited form of hypertension knowns as Gordon’s syndrome. At the 
molecular level, WNK kinases become activated under osmotic stress leading to 
phosphorylation of SPAK and OSR1 kinases, which are their physiological substrates. 
Consequently, SPAK and OSR1 kinases phosphorylate CCCs and therefore switches 
on or off the transport of electrolytes inside and outside cells. To date, the only 
physiological substrates of SPAK and OSR1 reported are ion co-transporters. Aiming 
to identify novel substrates of SPAK and OSR1 kinases, we discovered that the human 
β2-adrenergic receptors (β2AR) contains an RFxV tetrapeptide, a unique peptide 
sequence of SPAK and OSR1 substrates. Thus, in this work, we focused on studying 
the possible interaction between the β2AR and SPAK /OSR1 kinases, and the role of 
such interaction on the function of this receptor.  
Using peptide pulldown assays, we showed that the β2AR-derived RFHV 
peptide binds endogenous SPAK and OSR1. Additionally, the binding of 
overexpressed SPAK and OSR1 kinases to overexpressed β2AR in HEK293 cells was 
competed out by titration of the RFQV peptide. Notably, SPAK and OSR1 binding to 
the β2AR was inhibited by mutating the β2AR-RFHV motif to AFHV or by single point 
mutations in SPAK and OSR1 C-terminal domains, the site that binds the RFxV 
tetrapeptides.  Critically, the binding of the β2AR to SPAK and OSR1 kinases was 
confirmed using the pulldown assays of over-expressed proteins. Using in vitro kinase 
assays, OSR1 was able to phosphorylate the human β2AR and this phosphorylation 
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was significantly reduced when the mutant β2AR-R239A was used or SPAK and 
OSR1 kinase inhibitors were used. Stimulation of the β2AR in cells by the agonist 
isoproterenol did not induce WNK-mediated SPAK and OSR1 activation.  
Overall, our results confirm a novel interaction between the human β2AR and 
SPAK and OSR1 kinases. Given, the central role the β2AR plays in many human 
diseases such as blood pressure, heart failure, asthma and COPD, our findings 
provide a link between the electrolyte balance regulation by SPAK and OSR1 kinases 
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Chapter  1 : Introduction. 
 
 
WNK-SPAK/OSR1 signalling pathway and hypertension. 
 
Hypertension (HPT) is a health condition defined by rise the blood pressure 
(BP) above 140/90 mmHg. The ethnicity plays vital role in prevalence of HPT, South 
Asian and Afro-Caribbean are the most affected groups in the UK while white 
populations showed less prevalence (Khan and Beevers, 2005). HPT is a considerable 
problem in public health as it affects a billion people globally (Murthy et al., 2017). 
Although if it is managed properly, the health damage caused by HPT could be 
minimal, it is the case where HPT is not well managed where major health issues arise 
Indeed, poorly managed HPT leads to other complications such as renal failure, heart 
failure and stroke, with this latter alone causing a worldwide 9.4 million deaths 
annually. Despite the continuous educational health campaigns about the dangers of 
HPT, the number of individuals suffering from HPT is constantly rising due to the sharp 
increase of causative factors such as lack of exercise, increased fatty food 
consumption and obesity (O'Shaughnessy and Karet, 2006).  
The adjustment of the BP is a complex multifactorial process, which is affected 
by genetic predisposition, stress, quality of food and eating habits (O'Shaughnessy 
and Karet, 2006). Although lifestyle modulation could be adopted to manage HPT for 
a significant number of hypertensive patients, a combination of various 
antihypertensive drugs is often needed to achieve substantial reduction in BP. The 
currently used antihypertensive medications include furosemide (a loop diuretics) or 
thiazide in combination with either atenolol (beta-blocker) or Doxazosin (alpha-
blocker) have been commonly prescribed (Richardson and Alessi, 2008). Moreover, a 
                                                                                                                                  
2 
 
class of drugs known as angiotensin converting enzyme (ACE) inhibitors, e.g. 
Ramipril, or angiotensin 2 receptor antagonists e.g. Losartan are also used (Table 
1.1). Like other medications, these antihypertensive agents are associated with 
various side effects and their used in combinations, especially if they are prescribed 
for long term for patients with chronic cardiovascular diseases that could be led to the 
development of drug resistance (O'Shaughnessy and Karet, 2006, Richardson and 
Alessi, 2008).   
Class Example 
1. Targeting renin-angiotensin 
system: 
 
Angiotensin-converting enzyme inhibitors Captopril, ramipril and lisinopril.  
Angiotensin receptor antagonists Candesartan, losartan and 
valsartan. 
Direct renin antagonists Aliskiren. 
2. Adrenoceptor antagonists:  
β-blockers Atenolol, metoprolol and 
propranolol 
α-blockers Doxazosin, labetalol, phentolamine 
and phenoxybenzamine 
3. Calcium channel blockers:   
Phenylalkamines Verapamil 
Dihydropyridines Amlodipine, nifedipine and 
nimodipine. 
Benzodiazepines Diltiazem. 
4. Diuretics  
Thiazides  Hydrochlorothiazide and 
Bendroflumethiazide.     
Loop Furosemide and Bumetanide 
5. Potassium sparing/ aldosterone 
antagonists 
 
Ganglion block Trimetaphan 
Centrally acting agents Clonidine and methyldopa. 
Vasodilators Hydralazine and minoxidil. 
Table 1.1: Classification and examples of antihypertensive drugs. Table adapted from 
(Jackson and Bellamy, 2015). 
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According to Guyton’s theory, HPT is driven by the inability of kidneys to excrete 
of excess salt in to urine (Guyton, 1991). Thus, since the early 1990s, there has been 
a great focus on the physiology and movement of electrolytes a cross the membrane 
of renal cells, which are tightly controlled by ions channels and co-transporters 
(Richardson and Alessi, 2008). These transmembrane carriers are electroneutral 
cation chloride co-transporters (CCC), which are a group of secondary active trans-
membrane carrier proteins. They passively transport ions in and out of the cells by 
utilizing the electrochemical gradient that is generated from primary active transport of 
sodium (Na)/ potassium (K) ATPase pump (Alessi et al., 2014). Therefore, CCC can 
be divided into two categories; Na-mediated chloride (Cl) influx co-transporter such as 
Na/Cl co-transporter (NCC) and Na/K/Cl co-transporters (NKCC1 and NKCC2) and K-
induced Cl efflux through K-Cl co-transporters (KCC) (Alessi et al., 2014). 
NKCC1, NKCC2 and NCC belong to the solute carrier (SLC12A) family which 
are the molecular target of loop and thiazide diuretics that are used to modulate BP 
(Gamba, 2005). These co-transporters have critical roles in the regulation of cell 
volume and cellular protection from osmotic stress. In term of their role in regulating 
electrolytes balance, they control Na and Cl reabsorption at loop of Henle’s and distal 
convoluted tubules (DCT) of renal nephrons, also they regulate Na/Cl levels in arterial 
smooth muscles leading to the direct modulation of calcium (Ca2+) and smooth muscle 
contractility (Flatman, 2007). Although at the molecular level, the function of the 
SLC12A family of solute carriers is known to be regulated by post-translational 
phosphorylation, the distinct signalling pathway and the kinases that mediate this are 
not completely understood (Lytle and Forbush, 1996). Among of the key discoveries 
in this area was that by Wilson et al 2001 who reported that genetic mutations in the 
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with-no-lysine-kinases 1 and 4 (WNK1 and WNK4) caused an inherited form of HPT 
known as Gordon’s Syndrome (Wilson et al., 2001). 
1.1 WNK kinases: 
The notion of protein phosphorylation as a regulatory mechanism of protein 
function began in last century when Krebs and Fischer found that glycogen 
phosphatase was dynamically regulated by reversible phosphorylation (Krebs et al., 
1959). This pioneering study was the ground for discovering of the superfamily of 
human protein kinases (PKs). To date, more than 500 kinases have been identified 
and these are encoded by the largest genomic set called the human ‘kinome’. A 
plethora of metabolic and biochemical reactions in eukaryotes are mediated by these 
enzymes, especially those that are related to the intracellular protein’s 
communications (signaling transduction). Such phosphorylation mediated signal 
transduction is critical for cell growth and differentiation, cellular homeostasis, cell 
cycle and rearrangement of cytoskeleton. Therefore, PKs became of a major interest 
in the deep genetic analysis of the human kinome (Manning et al., 2002, Taylor et al., 
2012).    
PKs are categorised in to seven main groups as illustrated in (Figure 1.1A). 
They share a catalytic domain which consists of around 300 residues and the 
functional active site, adenosine triphosphate (ATP) binding site, which is formed by 
less than 10 conserved sequences (Hanks et al., 1988, Plowman et al., 1999). Within 
the ATP-binding site, one of the main amino acids that is crucial for the kinase function 
is a lysine (Lys) residue, which is primarily located near to amino-terminus (N-
terminus) in subdomain 2 (β3 strand) of the most kinases (Figure 1.2).  Among those 
kinases is protein kinase A (PKA), in which N-terminal Lys72 is vital in binding to and 
orientation of ATP, which it catalyses the kinase-mediated phosphorylation reaction. 
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Given the importance of this residue in ATP binding, it is unsurprising to find that 
mutations of this highly conserved Lys residue abolishes the catalytic activity of the 












In 2000, a comprehensive study conducted by the Cobb laboratory, which was 
intended for detection of new members of mitogen-activated protein kinase (MAPK) in 
rat brain by polymerase chain reaction (PCR), resulted in the identification of the cDNA 
of a novel serine/threonine protein kinase named as WNK1. This kinase is composed 
of 2,126 amino acids and had a molecular weight of 230 kilo Daltons (kD) (Xu et al., 
2000). Unlike the majority of protein kinases, WNK1 has unique structural feature, as 
it lacks the standard functioning Lys residue in β3 strand, which is critical for ATP 
binding. Interestingly, in WNK1 the catalytic lysine residue is replaced with cysteine 
Figure 1.1: Human kinome tree showing families and subfamilies of protein kinases. 
A) Kinome Render tree showing human protein kinases were organised in seven main 
groups. WNK kinases are highlighted and magnified. B) Zoomed section to show the close 
proximity of evolutionary WNKs (blue) to the STE serine/threonine kinase group, which 
includes SPAK (SPS-related proline-alanine rich protein kinase) and OSR1 (oxidative 
stress responsive 1) kinases in  (red). Figure adapted from (Murthy et al., 2017). 
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250 (Cys250) within the ATP binding pocket. The Lys residue (Lys233) in WNK1 is 
located in subdomain 1 (β2 strand), which is uncommon for protein kinases. This 
unusual structural feature gave rise to with no lysine (K), WNK kinases name (Murthy 














A year after WNK1 discovery, the successful isolation and characterisation of 
four paralogs of human WNK kinases was achieved, these were named WNK2, WNK3 
and WNK4. Interestingly, all of these WNK isoforms were devoid of the Lys in β3 strand 
Figure 1.2: The active site of protein kinase A. Stereo diagram illustrates the active 
site of PKA. Residues involved in ATP binding are shown in balls and sticks. The 
interactions between Lys72 and Glu91 and the hydrogen bonds between Thr201 and 
Lys168 and Asp166 are displayed in green dotted lines. Figure adapted from (Min et al., 
2004). 
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similar to what was found with WNK1 (Verissimo and Jordan, 2001). Despite the 
displacement of catalytic Lys233 residue to β2 strand, WNK kinases are constitutively 
active, could auto-phosphorylate and form homo- and hetero-WNK complexes 
(Lenertz et al., 2005, Xu et al., 2002). As mentioned above, although mutation of 
catalytic Lys residue results in an inactive kinase, reversing the Cys250 residue that 
is in the ATP-active site in β3 strand in to Lys, and Lys233 in β2 strand to glycine (Gly) 
does not restore the activity of  WNK1 (Xu et al., 2002). Therefore, WNK kinases have 
been classified in a distinct branch of serine/threonine protein kinases subfamily, 
which is located between the tyrosine kinase like proteins and sterile 20 (STE20) 
kinases in the human kinome tree (Figure 1.1B) (Verissimo and Jordan, 2001). 
 
1.1.1 The key features of WNK kinases 
WNK kinases are ancient enzymes, they have been identified in all mammals 
and multiple cellular organisms including nematodes such as Caenorhabditis elegans, 
where a single WNK was identified (McCormick and Ellison, 2011). WNKs are also 
found in plants such e.g. in Arabiodpsis thaliana where at least nine WNK homologous 
were reported (Nakamichi et al., 2002). Additionally, they are found in fungus like as 
Phycomces. However, they are absent in mono-cellular organisms such as yeast and 
bacteria except Giardia lamblia and Chlamydomonas (McCormick and Ellison, 2011). 
Interestingly, all WNK homologous either in mammals or invertebrates regulate the 
activity of NKCCs and NCCs though intermediate kinases e.g. SPAK and OSR1 or 
their orthologs respectively. This emphasis the vital role of WNK kinases in the 
physiology and development of diseases (Rodan and Jenny, 2017).   
                                                                                                                                  
8 
 
1.1.1.1 Topology of WNK kinase: 
The first crystal structure of WNK1 was that of an inactive rat WNK1(194-483) 
mutant where serine-283 was mutated to alanine (Min et al., 2004). Although the 
general topology of WNK1 was similar to other serine/threonine protein kinases, N-
terminus of WNK1 contains six rolled up β-sheets instead of five. While WNK1 
carboxyl-terminus (C-terminus) possesses standard structure with absence the 
extension of the catalytic domain. The unique feature of WNK1 is that, in the β3 strand, 
Cys250 occupies the usual catalytic Lys in other kinases, but the side chain of this Cys 
residue is away from the ATP-binding site, thereby it is unlikely to be participated in 












Figure 1.3: The WNK1 active site versus the PKA active site. Ribbon illustration of the active 
site of the WNK1 kinase in comparison to usual kinase active site, PKA in this case. (A) WNK1 
T-loop in red. Seven residues that are involved in the catalysis process are illustrated in ball 
and stick. Lys233 is 13 Angstrom (Å) away from glutamate residue 268 (Glu268). (B) The active 
site of PKA with ATP molecule in its binding pocket. Both ionic pairing between Lys72 and 
Glu91 and the hydrogen bonds between threonine 201 (Thr201), Lys168 and the aspartic acid 
166 (Asp166) are demonstrated in green dotted lines. However, these interactions are absent 
in WNK1. Figure was adapted from (Min et al., 2004). 
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Interestingly, the side chain of Lys233 in the β2 strand extended to the active 
site, generating a large cavity behind the active site. This allows Lys233 to adapt a 
particular rearrangement and ability to bind to ATP (Figure 1.3). Furthermore, in the 
ATP binding pocket there is a glutamate residue e.g. Glu127 of PKA that is critically 
involved in the binding with ATP, however it is completely absent in WNK1, indicating 
that WNK1 differently interact with ATP  (Min et al., 2004). Remarkably, mutation of 
Lys233 inhibited the enzymatic activity of WNK1 protein, which is confirming that the 
catalytic Lys is in β2 strand (Xu et al., 2000).  
The activation loop (T-loop) of WNK1 is made up by a wedge consisting of a 
double-turn helix 3₁₀-helix termed as 3₁₀-L₁₂ helix (Figure 1.4), reaches the active site, 
where hydrophobic interactions take place between Leu369 and Leu374 residues of 
3₁₀-L₁₂ helix and Phe265 and Leu272 residues of helix C (Min et al., 2004). The other 
striking characteristic of WNK1 is that it possesses a glutamate-268 (Glu268) in helix 
C. This residue usually participates in ionic interaction with Lys at the catalytic domain 
in other protein kinases, but in WNK1 it interacts with arginine Arg348 instead. Also, 
Glu268 forms a hydrogen bond with Thr373 of activation loop (T- loop). The Glu268 
protein mutated version of WNK kinases could not be expressed in Escherichia coli 
suggesting that this residue could be important in stabilizing the WNK protein 

















    
Figure 1.4: Structural topology of WNK1. Crystal structure of rat WNK1-S283A 
showing the conserved β strands (blue), α helices (magenta) and the extra N-
terminal β strand (gold). The (red) is the activation loop and (yellow) the catalytic 
loop. The atypical placement of Lys233 in β2 strand provides the catalytic side 
chain. Cys250 occupies the β3 strand in place of the catalytic lysine residue in other 
protein kinases (Min et al., 2004). 
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1.1.1.2 The structural domain of WNK isoforms: 
The human WNK family share ~ 85% sequence similarity of their N-terminal 
kinase domain. They are relatively large enzymes with amino acid sequences ranging 
from 1,243 (WNK4) to 2,382 (WNK1). Therefore, they exhibit extended molecular 
weight of 135-250 kD (McCormick et al., 2011, Richardson and Alessi, 2008). 
Although, WNK kinases have four prominent conserved regions, the analysis of their 
protein sequences revealed that their C-terminal region varies in length and are less 
conserved across the four isoforms, while their N-terminus kinase domain is well 














Figure 1.5: Structural domains of the human WNK isoforms. A schematic 
diagram of the domain structures of the four human WNK isoforms showing the N-
terminal kinase domain (green), the autoinhibitory domain (purple), the putative 
coiled coil domain (blue), and the conserved Ser382 (red). (RFxV/I) The site of the 
SPAK/OSR1 binding domains on WNK kinases are labelled. KS-WNK1: kidney 
specific-WNK1 (Richardson and Alessi, 2008).    
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A. The WNK kinase domain: 
As acronym of WNK kinases, with no lysine kinases, indicates that these 
enzymes have unusual serine/threonine catalytic domain, which is highly conserved 
in all of the four human WNK isoforms (Cope et al., 2005). This active site contains an 
atypical residue, Lys233 that occupies β2 strand instead of β3 strand (Figure 1.4). 
The kinase domain of WNK1 is located at the N-terminus between amino acids 221 - 
479 and includes the conserved serine-382 (Ser382) whose phosphorylation is 
required for full WNK1 activation (Figure 1.5). WNK1 kinases with mutations in this 
Ser residue are catalytically inactive (McCormick and Ellison, 2011, Zagórska et al., 
2007). 
B.  The autoinhibitory domain and autophosphorylation: 
WNK kinases possess a preserved autoinhibitory domain. It is located outside 
the N-terminus of the kinase domain, between residues 515 and 569 of WNK1 at C-
terminus of the kinase region (Figure 1.5). This autoinhibitory domain plays a vital role 
in suppression the activity of WNK kinases through intramolecular interaction with the 
kinase domain. The activation of WNK kinases leads to the release of the kinase 
domain from inhibitory site. Additionally, the autoinhibitory region is capable to supress 
the activity of other WNK homologous, a phenomenon known as ‘cross inhibition’ 
(Lenertz et al., 2005, Xu et al., 2002). Interestingly, mutation of two residues within the 
autoinhibitory region, namely Phe524 and Phe526, resulted in a loss of the inhibitory 
effect of the autoinhibitory region and a constitutively active WNK1 was generated 
(Lenertz et al., 2005, Richardson and Alessi, 2008, Xu et al., 2002).  
Interestingly, the activity of WNK kinases is also regulated by trans-
autophosphorylation (Xu et al., 2002), where WNKs autophosphorylate each other in 
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their T-loop, leading to a rapid and sufficient activation of WNK isoform. This process 
may be used by cells to handle rapidly osmotic stress (Richardson and Alessi, 2008). 
It has been reported, at least in vitro that Ser382 of WNK1 could be directly 
phosphorylated either intrinsic ability of WNK1 or by other WNK isoforms such as 
WNK2 or WNK3 but not WNK4 (Thastrup et al., 2012). 
C. WNK kinases coiled coil motifs: 
Structurally, WNK kinase also contain one to three coiled coil domain (CCD) 
(Figure 1.5) (Richardson and Alessi, 2008). These share a unique feature where the 
first and fourth residues are hydrophobic while the fifth and the seventh residues are 
primarily polar (McCormick and Ellison, 2011). The main role of CCD is to mediate 
protein-protein interactions between WNKs or other protein partners. To date these 
have been studies extensively in the formation of WNK homo- or hetero-dimerization 
or tetramer complex formation, as confirmed by co-immunoprecipitation and 
mutational analysis studies (Lenertz et al., 2005, Thastrup et al., 2012). 
D. Proline-rich segments: 
WNK kinases contain an unusually large number of proline residues, which 
make up proline rich region, which are known as the (PxxP) domains. Akin to the CCD, 
these PxxP domains are also involved in mediating the binding of WNK kinases to 
their protein partners (Richardson and Alessi, 2008). For instance, the PxxP stretch 
interacts with Src homology domains 3 (SH3), the most common structural feature 
used by proteins to mediate protein-protein interactions (He et al., 2007). The SH3-
binding sequences play vital roles in several cell processes such as immune response, 
cell proliferation and protein regulation (McCormick and Ellison, 2011). For example, 
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He et al reported that such PxxP-SH3 interaction was important for WNK1 and WNK4 
regulation of renal outer medulla potassium1 (ROMK1) (He et al., 2007). In particular, 
WNK1 and WNK4 were shown to internalize ROMK1 through endocytosis, a process 
mediated by the activation of the intersectin that possesses SH3 motif (He et al., 2007). 
This PxxP mediated interactions are also relevant for human diseases, since the 
WNK4 Pseudohypoaldosteronism type 2 (PHA2) causing mutations, E562K, D564A 
and Q565E were found to induce the elevation of ROMK1 endocytosis, as a result of 
increased the interaction between WNK4 and intersectin (He et al., 2007). Notably, 
these mutations are located within the conserved acidic motif, which is adjacent to 
PxxP motif (McCormick et al., 2011).  
Beyond the PxxP motifs, WNK kinases possess two to five RFxV/I motifs, which 
are distributed throughout the protein kinase (Richardson and Alessi, 2008, Vitari et 
al., 2006). These sequences significantly contributed to the interactions between WNK 
kinases and their substrates, namely STE20-SPS-related proline/alanine rich kinase 
(SPAK) and oxidative stress responsive kinase 1 (OSR1) (Figure1.5), which are the 
effector substrates of osmotic stress (McCormick and Ellison, 2011) 
1.1.1.3 The tissue expression of WNK proteins: 
The human WNK proteins have different levels of tissue expression even 
though their mRNAs are widely expressed (Xu et al., 2000). WNK1 is the most 
abundant of the four human WNK isoforms. It is present in all tissues with higher 
expression in gonads, kidneys, heart, lungs and voluntary muscles (O'Reilly et al., 
2003). Interestingly, in renal tissues, two isoforms of WNK1 have been detected; a full 
length WNK1 (L-WNK1), which is ubiquitously expressed, and a truncated WNK1 , 
which is appeared to be exclusive to the kidney hence denoted , kidney-specific WNK1 
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(KS-WNK1) (Delaloy et al., 2003). Unlike L-WNK1, KS-WNK1 was characterised by 
the absence of kinase domain (Figure 1.5) and is thought to be involved in regulating 
the kinase activity of L-WNK1 in renal cells (Subramanya et al., 2006).  
WNK2 exists mainly in colon, small gut and brain, though it has also been 
detected in skeletal muscle and heart thought with lower expression levels (Moniz et 
al., 2008, Verissimo and Jordan, 2001). WNK3 is highly expressed in pituitary gland 
and through the brain mainly in the basal ganglia, hippocampus and frontal lobe of 
cerebral cortex while it appears to be of low levels in the lung, kidneys, liver, spleen 
and pancreas. Moreover, it is of very low levels in fetal organs including placenta, 
heart, thymus, and brain (Holden et al., 2004). The expression of WNK4 is strangely 
restricted to the secretory epithelium, e.g. pancreas, bile ducts, colon, skin, prostate 
and epididymis and it is significantly expressed in kidney especially in distal convoluted 
tubules (DCT) and collecting ducts (CD) (Kahle et al., 2004, Verissimo and Jordan, 
2001).  
1.1.2 Cellular regulation of WNK kinases: 
1.1.2.1 Activation of WNKs and cellular osmolarity: 
After the discovery of WNK kinases, numerous endeavours in animals and cell 
lines have been performed to explore the roles of these enzymes in health and disease 
conditions, and to identify how these enzymes are regulated as well as the conditions 
that activate them (Richardson and Alessi, 2008). Different conditions and signalling 
stimuli have been tested e.g. serum, insulin like growth factor-1 (IGF1), tumour 
necrotic factor (TNFα), phorbol ester, and phosphatase enzyme inhibitors to examine 
their effect on WNK kinases especially their activation (Zagórska et al., 2007). 
Although these conditions were successful in manipulating other signalling cascades, 
                                                                                                                                  
16 
 
however they failed to activate WNK1 (Zagórska et al., 2007). Interestingly, WNK1 
was only reproducibly activated by osmotic stress, either in hyperosmotic condition 
(NaCl, KCl or sorbitol) (Lenertz et al., 2005, Zagórska et al., 2007) or in hypotonic low 
Cl stress (Moriguchi et al., 2005, Richardson et al., 2008). In order to avoid irreversible 
cell damage, the cells responded quickly and thus the activation of WNK1 was fast 
and was detected in less than a minute (min) with 0.5 molar (M) sorbitol and 5 min 
with exposure to hypotonic low Cl stress (Lenertz et al., 2005, Moriguchi et al., 2005, 
Zagórska et al., 2007). 
In fact, osmotic stress activated WNK1 by triggering its phosphorylation on 
multiple Ser and Thr residues (Lenertz et al., 2005). Investigating WNK1 fragments by 
phosphopeptide screening, resulted in the detection of several phosphorylated 
serine/threonine residues, two serine, Ser15 and Ser167, proximal to WNK1 kinase 
domain, and Ser382 in catalytic kinase domain at T- loop. Moreover C-terminal domain 
phosphorylated residues such Ser1261, Thr1848, Ser2012, Ser2029, Ser2032 and 
Ser2372 were also identified. Surprisingly, apart from Ser15 , all of the mentioned 
residues were only conserved in rat and mouse WNK1 while Ser382 was conserved 
cross all human WNK homologous (Zagórska et al., 2007). This supported the notion 
that phosphorylation of this residue is essential for activating WNK kinases (Figure 
1.5). Indeed, mutation of this residue to alanine (Ala) inhibited the WNK kinase, even 
if cells were exposed to osmotic stress, whereas mutation of Ser382 to glutamine (Glu) 
not only increased the kinase phosphorylation activity but also prevented its further 
stimulation by sorbitol (Zagórska et al., 2007) 
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1.1.2.2 WNKs activity and intracellular chloride: 
Chloride (Cl) is one of many electrolytes that play a vital role in cell physiology 
(Piala et al., 2014). It participates primarily in the regulation of cell volume, BP, 
controlling membrane excitability and nerve conduction (Piala et al., 2014). Cl levels 
are strictly adjusted in cells, and its intracellular concentration is almost maintained 
within 30 – 60 mM (Russell, 2000, Salomonsson et al., 1991). It is well established 
that members of the cation chloride co-transporters (CCC) group regulate the cellular 
levels of Cl, by moving Cl in and out the cells. Examples include, NKCC1, NKCC2, 
NCC and KCC, which are all controlled by post-translational phosphorylation. The 
activity of these co-transporters has been shown to be regulated by WNK kinases 
(Richardson et al., 2008, Richardson et al., 2011). The mechanism by which WNK 
kinases sense intracellular Cl concentration [Cl] leading to its activation and 
subsequent phosphorylation of CCC is still not entirely defined (Alessi et al., 2014). 
Although the binding of Cl to proteins is poorly unclear, studying chloride channels 
(CLC) family gave clues as to how Cl binds to proteins. There was a large thought that 
the Cl binding is mainly mediated through hydrophobic pairings and interactions with 
amide backbone (Dutzler et al., 2002).  
Moreover, other Cl-binding sites have been observed in angiotensin converting 
enzyme (ACE), serotonin transporter and in α-amylase, suggesting that chloride ions 
bind to proteins e.g. with WNK1, may be more common than previously thought 
(Pokhrel et al., 2011, Tavoulari et al., 2011, Tzakos et al., 2003). Interestingly, in 2014 
a study by Cobb and Goldsmith groups hypothesised that a protein kinase located 
upstream to CCC serve as a Cl sensor (Piala et al., 2014). They demonstrated that 
WNK1 is the protein kinase, and it was crystalized in presence of Cl (Piala et al., 2014). 
Impressively, it was noticed that Cl directly bound to the WNK active site and formed 
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hydrogen bonds with the amide backbone of two leucine residues (Leu369) and 
(Leu371), which they generate a Cl-binding pocket. Additionally, the Cl also formed 
hydrophobic interactions with Phe283 of β3 strand, Leu299 of β4 strand and with 
Leu369 of Asp368-Leu369-Gly370 sequences (DLG-motif) (Figure 1.6) (Piala et al., 
2014). This interaction prevented WNK1 autophosphorylation. In fact, the study 
indicated that Cl inhibited WNK1 activity with IC50 about 20 mM (Piala et al., 2014).  
 
Mechanistically, this suggesting that when [Cl] was reduced by osmotic perturbation, 
the WNK1 bound Cl dissociates from the kinase active site, thereby leading to its 
activation (Alessi et al., 2014).       
Figure 1.6: The crystal structure of WNK1 with chloride. A) Cartoon diagram of WNK1, 
PDB ID: 3FPQ. α-helices (pink), β sheets (cyan), and  loops (grey). In the magnified 
square, the position of the Cl (green ball) and distance of the hydrogen bonds between the 
Cl and amide backbones of Gly370 and Lys371. B) Graph of in vitro kinase assay 
illustrating the relationship of SPAK phosphorylation by WNK1, WNK3 and WNK4 and Cl 
concentration. WNK4 appeared to be the most sensitive WNK isoform to Cl concentration 
within the physiological range (pink). C) Sequence alignment of the human WNK1, WNK2, 
WNK3 and WNK4 showing conserved putative Cl binding site (Leu369, Gly370, Leu371), 
LGL motif (highlighted in yellow). Figures adapted from (Murthy et al., 2017, Piala et al., 
2014).  
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In another report, it was shown that all WNK homologous have a Cl-binding site 
(Figure 1.6 C), though they responded differently to [Cl].  Among the four human WNK 
kinase isoforms, WNK4 is the most sensitive to the [Cl], it is inhibited by the chloride 
ion within the physiological range in cells of renal DCT (Figure 1.6B). Furthermore, 
mutations in the Cl-binding site of WNK4 made it constitutively active, and resulted in 
the activation of NCC (Terker et al., 2016). Additionally, a study carried out in Xenopus 
oocytes showed that NCC was inhibited by WNK4 at physiological levels of Cl, a 
phenomenon that was reversed by low Cl condition (Bazúa-Valenti et al., 2015). Also, 
it was shown that mutation of Leu322 in WNK4 to Phe, which is equivalent to Leu369 
in WNK1 (Cl-binding site), resulted in a persistent activation and autophosphorylation 
of WNK4 that led to increased NCC activity even if [Cl] was of normal concentrations 
(Bazúa-Valenti et al., 2015). Additionally, the stimulatory effect of WNK4-L322F on 
NCC was inhibited by introducing mutations either in active site D321A or D321K-
K186D or in autophosphorylation residue S335A (Bazúa-Valenti et al., 2015).  
1.1.2.3 Upstream regulation of WNK kinases: 
The WNK kinase activity could be intracellular regulated by different 
mechanisms; 1) the alteration of cellular tonicity, which directly affects their kinase 
activity, and 2) the adjustment of the WNKs cellular abundance, by overexpression or 
increase degradation, which plays an important role in development of diseases, for 
instance PHA2 (Uchida et al., 2014). PHA2 is an infrequent autosomal dominant 
syndrome, featuring HPT, hyperkalaemia, metabolic acidosis and hyperchloremia 
(Wilson et al., 2001). It also known as familial hyperkaliaemic hypertension (FHH) or 
Gordon’s syndrome (Cope et al., 2005, Gordon, 1986). The disease is caused by 
mutations in WNK1 and WNK4 genes (Richardson and Alessi, 2008). WNK1- causing 
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mutations are primarily deletions in intron1, likely to result with overexpression of 
WNK1 without alteration in protein sequence (Dbouk et al., 2016). As for WNK4 
mutations, there are gene missense mutations, which are translated into protein point 
mutation that lead to an inhibition of WNK4 protein degradation (Murthy et al., 2017). 
Together, WNK1 and WNK4 mutations account for approximately 13 % of PHA2 
patients (Dbouk et al., 2016).      
In 2012, mutations in two genes termed cullin 3 (CUL3) and kelch-like 3 
(KLHL3) were found to cause PHA2, a link that was subsequently shown to involve 
the WNK-signalling pathway (Boyden et al., 2012, Louis-Dit-Picard et al., 2012). CUL3 
is a scaffolding protein that belongs to the cullin family proteins, which is composed of 
seven members (Uchida et al., 2014). These are relatively large proteins, 80 – 100 
kD, that are involved in the central nucleation of ubiquitin E3-ligase subunits and in 
delivering of targeted proteins for degradation (Ferdaus and McCormick, 2016, Murthy 
et al., 2017). The most key step in protein ubiquitination is the final stage, in which the 
targeted protein is ubiquitinated by assembled E3-ligase, a process preceded by the 
activation of the E1 and conjugation of the E2 enzymes (Genschik et al., 2013, 
Hershko and Ciechanover, 1998). 
KLHL3 belongs to of bric-a-brac/tramtrack/ broad complex (BTB) protein family 
(Dhanoa et al., 2013, Murthy et al., 2017). It contains single BTB motif, and five to six 
kelch domains (Uchida et al., 2014). KLHL3 interacts with CUL3 and WNKs via BTB 
and kelch segments respectively (Sohara and Uchida, 2016, Uchida et al., 2014). 
Thus, the substrate (WNK) is connected to CUL3-RING-E3 ubiquitin-ligase complex 
through KLHL3 (Murthy et al., 2017). It is now established that both WNK1 and WNK4 
bind the kelch domain of KLHL3 via the acidic segment, which is situated near to the 
autoinhibitory domain and it is conserved in all WNK isoforms (Ohta et al., 2013, 
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Wakabayashi et al., 2013). Ubiquitination of WNK kinases is mediated by this cascade 
to their proteosomal degradation, which ultimately manifested in decreased WNK 












The above mechanism provided a compelling explanation of how WNK1 and 
WNK4 mutations causing PHA2. Interestingly, five of six mutations of WNK4 in PHA2, 
have been identified in the acidic region, which inhibited the binding of WNK4 to KLHL3 
and led to defective degradation and subsequent WNK4 protein accumulation (Figure 
1.7). As mentioned above, WNK1 mutations are deletions and these, result in an 
increase of protein transcription (Golbang et al., 2005, Gong et al., 2008). 
Furthermore, two further independent reports demonstrated that both WNK1 and 
WNK4 were substrates of KLHL3 and they were ubiquitinated by the CUL3-RING E3 
Figure 1.7: Molecular pathogenesis of the PHA2 syndrome. Diagram showing 
the mechanism of regulating WNK kinases by KLHL3 and CUL3 E3 ubiquitin 
ligases. WNK1 and WNK4 total levels are tightly maintained in physiological state 
(left). Mutations in WNK4 or KLHL3 cause interruption of their interaction with 
KLHL3 and CUL3 leading to the inhibition of the ubiquitination and degradation of 
WNK1 and WNK4 and subsequently their accumulation. Figure adapted from 
(Sohara and Uchida, 2016). 
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ubiquitin ligase (Shibata et al., 2013, Wu and Peng, 2013). Lastly, to establish the in 
vivo roles of WNK mutations, elevated phosphorylation and activation of NCC had 
been observed because of overexpression of L-WNK1 and WNK4 accumulations in 
the kidneys of transgenic mice model with WNK1+/FHH or WNK4-D461A/+ that exhibited 
PHA2-like phenotype (Vidal-Petiot et al., 2013, Wakabayashi et al., 2013). 
Genes Type of Mutation Effect References 
WNK1 Intron 1 deletion 
 
↑ L-WNK1 (Vidal-Petiot et al., 2013) 
WNK4 Missense in acidic motif 
E562K, D564A, Q565E 
 
↑ L-WNK4 (Vidal-Petiot et al., 2013) 
 WNK4-D561A/+ (mouse) 
 
↑ L-WNK4 (Wakabayashi et al., 2013) 
KLHL3 Missense in Kelch domain 
Q309R, A340V, R348Q, 
L387P, S410L, S432N, 




(Boyden et al., 2012, Louis-
Dit-Picard et al., 2012, Ohta 
et al., 2013, Shibata et al., 






Missense in BTB or BACK 












(Boyden et al., 2012, 
McCormick et al., 2014, 
Ohta et al., 2013) 
Table 1.2: Genetic mutations in PHA2 syndrome and their effects on the expression of 
WNK isoforms. ↑ indicates increased expression, ↓ indicates decreased expression. Both 
reduction of KLHL3 levels and elevation of WNKs expression rise BP via increasing renal Na 
reabsorption. Table adapted from (Murthy et al., 2017). 
 
Furthermore, mutations in CUL3 and KLHL3 prevent either the assembly of 
ubiquitination RING-CUL3 or block their binding WNK isoforms. For instance, in an 
extensive study by the Alessi group, out of the substrate binding site thirteen PHA2 
causing mutations in KLHL3, eight occurred within the substrate binding site, kelch 
motif, and inhibiting significantly the interaction with WNK1 and the other five 
mutations interfered with KLHL3 binding with CUL3 (Ohta et al., 2013). These results 
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have been validated in mice carrying KLHL3 or CUL3 mutations where elevated of 
both WNK1 and WNK4 proteins and increased activity of NCC were noted (Table 1.2). 
In summary, these findings confirmed that mutations in CUL3 and KLHL3 lead to 
elevated protein levels of WNK kinases as a sequence of the inability of these mutated 
E3 ubiquitin ligases to degrade WNKs (Murthy et al., 2017). 
 
1.2 SPAK/OSR1 kinases 
Given the direct genetic link between WNK kinases, the regulation of BP and 
hence human HPT, identifying the WNK kinases physiological substrates became very 
important in dissecting the mechanism by which WNK kinases regulated BP. Although 
initial studies made a connection between WNK kinases and CCC, these studies 
showed that these ion-co-transporters are not the direct substrates of WNK kinases, 
despite early studies showing WNK1 was able to directly phosphorylate KCC2 and 
KCC3 in their C-terminal region, precisely (Thr906 and Thr991) respectively (Alessi et 
al., 2014). In 2002, a pulldown assay and yeast two hybrid (Y2H) analysis, aimed at 
identifying substrates of the sterile20 (STE20)-related proline/alanine rich kinase 
(SPAK) and oxidative stress responsive 1 kinase (OSR1), resulted in NKCC1, NKCC2 
and KCC3 as possible substrates (Piechotta et al., 2002). Three years later, the link 
between SPAK/OSR1 and WNK kinases was established, when two research groups 
showed that SPAK/OSR1 were direct physiological substrates of WNK kinases 
(Moriguchi et al., 2005, Vitari et al., 2005).  
1.2.1 The discovery of SPAK/OSR1: 
SPAK and OSR1 are two serine/threonine kinases that belong to the germinal 
centre kinase (GCK-VI) family of protein kinases, which itself is a subfamily of a large 
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family of protein kinases named Ste20-related (Ste20) (Figure 1.1B). This family of 
protein kinases is conserved in both the animal and plant kingdoms (Gagnon and 
Delpire, 2012). The mammalian Ste20 contains about thirty enzymes, which are 
organised based on the localisation of their catalytic domain into two main categories; 
1) C-terminal position as in p21 activated kinases (PAKs) and 2) N-terminal side as in 
GCKs. Each group is subsequently subdivided according to their structure and 
function (Figure 1.8). Moreover, PAKs are characterised by a conserved regulatory 
region at their N-termini (Boyce and Andrianopoulos, 2011). PAKs are involved in cell 
motility, tumour invasion and modulation of cytoskeleton (Hoffman and Cerione, 2000). 
In addition to their N-terminal kinase domain, the C-termini of GCKs varies in 
sequences and is composed of motifs that participate in protein-protein interaction 
(Dan et al., 2001). These kinases have roles in cell migration, proliferation, apoptosis, 
and osmotic shock responses (Dan et al., 2001).      
SPAK was firstly identified by immunoblotting (IB) and PCR analysis in rat brain 
(Ushiro et al., 1998). It showed molecular weight 60-64 kD, it has an N-terminal kinase 
domain preceded by proline-rich N-terminal domain (Johnston et al., 2000). The OSR1 
gene was detected in chromosome 3 by genetic mapping of the human genome 
(Tamari et al., 1999). The protein is 527 amino acids in length, with N-terminal kinase 
domain and interestingly it was found to play a role in oxidative stress (Tamari et al., 
1999). Notably, unlike SPAK, OSR1 does not have a proline-rich N-terminal region 
(Chen et al., 2004). Sequence alignment of human SPAK and OSR1 demonstrated 
that they have 68 % overall sequence identity and about 89 % homology in their kinase 
domains (Chen et al., 2004). Unlike WNK kinases, the orthology of SPAK and OSR1 
indicated that OSR1 was recognised in protist, plant and in the animal kingdom, 
through worms to human (Gagnon and Delpire, 2012). However, there was no 
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evidence of SPAK in monocellular organisms or even plants, which makes it exclusive 









Figure 1.8: Classification of mammalian Ste20-protein kinase family. The tree 
illustrates all Ste20-protein kinases arranged in nine subfamilies. SPAK and OSR1 
located in GCK-VI between STRAD and MAP4K kinases. Figure adapted from 
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1.2.2 Tissue expression and cellular localisation of SPAK/OSR1: 
Initially, primary searches that employed Northern blotting for detection of 
SPAK/OSR1 mRNAs indicated that these kinases have variable expression in mouse 
organs (Delpire and Gagnon, 2008). OSR1 is highly transcribed in cardiac tissue, liver, 
skeletal muscles and colon, and to lesser extent in small intestine, kidney, brain, 
pancreas, spleen, testis, ovary and thymus (Piechotta et al., 2003, Tamari et al., 1999). 
SPAK protein and mRNA distribution overlapped largely with OSR1 distribution and 
was abundant in salivary glands, brain, adrenal glands, testis, and pancreas, and to a 
lesser extent in spleen, heart, kidneys, lungs, ovary, uterus, thymus and skeletal 
muscles (Delpire and Gagnon, 2008, Johnston et al., 2000).  
The determination of tissue SPAK and OSR1 protein levels showed variation in 
expression between the two kinases. SPAK and OSR1 are highly homological 
proteins, so the generation of a kinase-specific antibodies (Ab) with high specificity 
was challenging (Delpire and Gagnon, 2008). A 74 amino acids domain in their C-
terminal domains with very low conservation (approximately 9 %) was used to 
generate specific Ab against SPAK and OSR1 (Piechotta et al., 2003). The first 
polyclonal anti-SPAK Ab was developed in 2000 by Harrison group who showed that 
mouse tissues such as pancreas, testis, brain, spleen and liver had high levels of 
SPAK while it was less in the lung and kidneys (Johnston et al., 2000). The OSR1 
protein was shown to be expressed in the spleen, heart, liver, lung, small and large 
intestine whereas the kidneys and stomach had low expression and it was not 
detected in the thymus (Chen et al., 2004).  
Immunoblotting (IB) studies revealed that three SPAK analogous exist in the 
kidneys; 1) full length SPAK (FL-SPAK), which is ubiquitously expressed, 2) SPAK-2 
is also ubiquitously expressed but lacks the N-terminal proline rich region, and a part 
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of catalytic domain, and 3) kidney specific SPAK (KS-SPAK) which was only 
expressed in the kidneys (Murthy et al., 2017). OSR1, however, appeared as single 
species (i.e.OSR1 exists as a single band in Western blot analysis) and truncated- or 
kidney-specific analogues have not been reported (Rafiqi et al., 2010).  
Immunofluorescent (IF) and IB analysis of renal segments was performed, and 
these demonstrated that the FL-SPAK was prominent in thick ascending limb (TAL) of 
Henle and DCT, whereas SPAK2 and KS-SPAK were found in renal medulla, which 
is composed of only TAL (McCormick et al., 2011). However, OSR1 expression was 
predominantly in TAL and to a lesser extent in the DCT (Lin et al., 2011, Yang et al., 
2010). Additionally, immunohistological investigations showed that SPAK and OSR1 
are mostly cytoplasmic enzymes (Ushiro et al., 1998). In the kidneys, SPAK/OSR1 
were shown to have an apical and basolateral distribution at cellular levels (Gagnon 
and Delpire, 2012). This suggested that SPAK and OSR1 are primarily co-localised 
with NCC and NKCC2 respectively (McCormick et al., 2011).    
Similar observations were made in immunohistological studies in nerve 
samples, where SPAK was detected in the apical apart of cytoplasm in cells of 
choroidal plexus (Gagnon and Delpire, 2012) . Interestingly, this apical translocation 
was completely lost in choroidal epithelium of homozygote NKCC1 knockout mice 
(Gagnon and Delpire, 2012, Piechotta et al., 2003). This indicated that the co-
localisation of SPAK was a strategy for targeting NKCC1, because NKCC1 is 
considered to be a physiological substrate of SPAK. Moreover, both SPAK and 
NKCC1 were found to be highly expressed in the sciatic nerve and were less 
expressed in the white and grey matter of spinal cord (Gagnon and Delpire, 2012). 
Notably, OSR1 also existed in neurons but in much less quantity (Piechotta et al., 
2003).   
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1.2.3 Structure of SPAK/OSR1: 
Among the GCK subfamily of protein kinases SPAK/OSR1 have been 
extensively studied, due to their disease relevance, primarily through their ability to 
regulate the activity of SLC12A family in ion homeostasis (Gagnon and Delpire, 2012).  
1.2.3.1 Domain structure of SPAK/OSR1: 
Like other Ste20 kinases, the structural parts of these proteins revealed that 
they share a highly conserved N-terminal kinase domain and a regulatory region at 
their C-termini. Interestingly, SPAK harbours a unique extension at N-terminus prior 
to catalytic region, which composed of proline/alanine residues, known as PAPA box, 
a feature that is absent in OSR1 (Figure 1.9). Several biochemical studies showed 
that removing the PAPA box from SPAK does not disturb its kinase activity, and the 
precise function of this segment yet to be established (Delpire and Gagnon, 2008). 
Figure 1.9: Structural domains of human SPAK and OSR1. Schematic diagram of 
SPAK and OSR1 kinases showing the key structural domains. SPAK contains a unique 
proline/alanine (P/A) rich segment. * indicates the catalytic threonine (T) residues on SPAK 
and OSR1 kinase. T233, T185, S373 and S325 are WNK phosphorylation sites. The 
conserved C-terminal (CCT) domains mediate the binding to RFxV/I-possessing proteins 
(Richardson and Alessi, 2008). 
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The kinase domain is situated between residues 17-291 of OSR1 and 65-339 
of SPAK (Figure 1.9). The kinase domains encompass key threonine residues, 
Thr185 for OSR1 and Thr233 for SPAK, which are phosphorylated by upstream WNK 
kinases (Richardson and Alessi, 2008). Mutagenesis analysis illustrated that the only 
phosphorylation of OSR1 at Thr185 and SPAK at Thr233 by WNK1 or WNK4 was 
essential for their activation, as mutations of these residues to alanine abolished their 
kinase activity (Vitari et al., 2005, Zagórska et al., 2007). Additionally, the replacement 
of these threonine residues by glutamic acid, resulted in constitutively active kinases 
independent of WNK phosphorylation (Vitari et al., 2005). 
SPAK/OSR1 have two conserved regulatory sections; 1) a serine rich domain, 
(termed the S-motif) in which WNK kinases also phosphorylate this segment at Ser373 
in SPAK and Ser325 in OSR1, and 2) a highly conserved 92 amino acid C-terminal 
domains called (the CCT domain) (Figure 1.9). This latter domain is highly significant, 
as it acts as the docking site in the interaction of SPAK/OSR1 with Arg-Phe-Xaa-
Val/Iso (RFxV/I) motifs, from the upstream activators, WNKs (Figure 1.5), and the 
downstream substrates, e.g. NKCC co-transporters (Piechotta et al., 2002). In addition 
to these large domains, SPAK and OSR1 kinase have small region of propinquity, 
termed the PF1 domain, a typical feature of GCK-VI members. PF1 is located 
immediately after the kinase domain. Moreover, although SPAK is largely a 
cytoplasmic protein, SPAK has a short sequence that is known for protein location to 
the nucleus (RAKKVRR) (Johnston et al., 2000). Finally, both kinases have a site for 
caspase cleavage, which it shares with other Ste20 kinases such as the MST1 kinases 
(Chen et al., 2004, Johnston et al., 2000).     
                                                                                                                                  
30 
 
1.2.3.2 The topology of SPAK/OSR1: 
The crystal structures of SPAK/OSR1 co-crystallised with nonhydrolyzable ATP 
revealed that they were similar in configuration (Taylor et al., 2015). Both kinases do 
possess a canonical bi-lobal fold, with small N-terminus made up of β1 to β5, and a 
larger C-terminus, (Figure 1.10 A) which is composed primarily α-helices C to α F and 
β-sheets (β6 - β8) (Gagnon and Delpire, 2012, Taylor et al., 2015). The OSR1 
conserved catalytic Lys, Lys46, is located in the last part of β3 strand, which is the 
ATP binding site. Additionally, the conserved magnesium (Mg) binding motif, 
composed of Asp, Phe and Gly (DFG), was found to be located between β8 strand 
and α-helix AL (Gagnon and Delpire, 2012). Interestingly, the most distinctive feature 
of OSR1 structures, is the exchange of T-loops (activation loops) between symmetric 
linked dimers, a phenomenon termed domain swapping (Figure 1.10 B and C) (Lee 
et al., 2009, Villa et al., 2008). The swapped part encompasses the αEF helix and P+1 
loop, which it includes the essential Thr residues, e.g. (OSR1 Thr185 and SPAK 
Thr233), indicating that the vital role of domain swapping in dimers formation and 
kinase activation by trans-phosphorylation mechanism (Gagnon and Delpire, 2012, 
Villa et al., 2008). In addition, SPAK was also found to form dimers by the same 
mechanism, and this may suggest the role of dimerization in the multistep activation 































Figure 1.10: Crystal structure of the domain-swapped OSR1. (A) Monomeric 
structure of OSR1 kinase domain showing N-terminal and C-terminal lobes as well as 
the disordered activation loop in dotted line. (B) Illustration of the domain swapped 
segment in the dimer formation, one OSR1 monomer shown in blue and the other 
monomer is in yellow. (C) The interface of the domain swapped in OSR1, showing the 
interaction of E219 from αF and W192 residue from P+1 loop of the other monomer. 
Figure adapted from (Lee et al., 2009).   
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1.2.3.3 Role of CCT domain in SPAK/OSR1-protein interactions: 
After the discovery of SPAK and OSR1 being the upstream regulators of 
NKCCs, decoding such interaction at molecular level was pursued (Piechotta et al., 
2002). Delpire and Ganon performed a genome wide screening of nine residues 
containing the WNK RFxV/I motif, where (x) represented any amino acids, in the 
mouse proteomic data base. This led to identification of 131 proteins contained SPAK 
and OSR1 binding motifs. Interestingly, WNK1 and WNK4 were also identified as 
possible binders to SPAK and OSR1, as they have RFxV motifs (Delpire and Gagnon, 
2007). Also, various screening were performed by yeast 2 hybridisation (Y2H) and 
immunoprecipitation (IP) from mouse tissues and cells, and these showed that SPAK 
and OSR1 kinases bind to WNK1, WNK4 and NKCC1, NKCC2 and NCC, and that 
binding was mediated by direct interaction of RFxV tetrapeptide into the CCT domain 
of SPAK and OSR1(Alessi et al., 2014).  
Although the four WNK isoforms have more than one RFxV domains (Figure 
1.5), it remains unclear whether these multiple RFxV motifs in the same WNK kinase 
facilitate their binding to multiple SPAK and OSR1 simultaneously (Anselmo et al., 
2006, Moriguchi et al., 2005, Richardson and Alessi, 2008). Intriguingly, Y2H analysis 
using the SPAK-CCT domain, led to the identification of several possible protein 
partners such as the tumour necrosis factor (TNF), otoferlin, heat shock protein 105 
(HSP105), gelsolin and the apoptosis associated tyrosine kinase (AATYK) (Piechotta 
et al., 2003). Admittedly, to date none of these possible SPAK binders has been 
extensively validated. 
In order to understand the binding of the WNK RFxV peptide to the CCT 
domains, the co-crystal structure of the human WNK4 RFQV with the OSR1 CCT 
domain was solved (Villa et al., 2007). This structure revealed that the CCT domain 
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was arranged in a unique fold, called SPAK/OSR1 C-terminus (SPOC) fold that forms 
a long groove (Villa et al., 2007). Within this fold, there was a negatively charged 
fragment known as primary pocket, which serves as a docking site of the WNK4 RFQV 
peptide. Apart from glutamine (Q) residue, which was facing outward, the other three 
residues from the RFQV motif were faced inward and formed key interactions with the 
CCT domain (Figure 1.11). Interestingly, in addition to the primary pocket that acts as 
the docking site for the RFQV peptide, a second smaller pocket, termed the secondary 
pocket, was also observed through this groove, and it had no influence on the binding 













Figure 1.11: Structure of SPAK/OSR1 CCT-domains and their binding to the 
WNK4-derived RFQV-peptide. Figure on the left shows the structural surface of 
OSR1 CCT, the residues in CCT domain are differentiated according the surface 
electrical charge in to positive (blue areas) and negative (red areas). The positions 
of primary and secondary pockets are also indicated. The middle and right figures 
show stick representation, showing the molecular interaction of RFQV-peptide 
(green) with residues in CCT domain (grey). Ile, isoleucine; Leu, leucine; Phe, 
phenylalanine; Glu, glutamine; Asp, aspartic acid; Val, valine; Gln, glutamine. 
Figure adapted from (Villa et al., 2007).     
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Mutational analysis of OSR1 CCT binding to the WNK4-RFQV peptide 
indicated that mutations in the primary pocket either reduced or completely abolished 
the binding to the RFQV. The most prominent inhibition of the binding was observed 
when the OSR1 CCT domain residues Asp479 and Leu493 of SPAK and Asp459 and 
Leu473 of OSR1 were mutated (Vitari et al., 2006). A pulldown assay utilizing 
mutations of R, F or V to alanine of the RFQV peptide indicated that only the RFAV 
peptide binds the CCT domain of OSR1 with similar affinity to the RFQV peptide  (Villa 
et al., 2007, Vitari et al., 2006). In contrast, individual point mutations in secondary 
pockets did not affect the binding of the CCT domain. Recently, mutations in this 
secondary pocket were found to affect the catalytic activity of the kinase suggesting 
that the secondary pocket could have a regulatory role of SPAK and OSR1 kinase 
activities (Villa et al., 2007, AlAmri et al., 2017a) 
1.2.4 Activation of SPAK and OSR1 by WNK kinases: 
As mentioned above, WNK kinases phosphorylate SPAK and OSR1 at the 
highly conserved threonine residues Thr233 and Thr185 respectively, which are 
located in their threonine-rich loops, termed the T-loops (Richardson and Alessi, 
2008). Moreover, WNK kinases also phosphorylate Ser325 in OSR1 and Ser373 in 
SPAK, which are located in the S-motifs. Although the function of this phosphorylation 
site remains unclear, in vitro phosphorylation of SPAK and OSR1 kinases by WNK1 
showed that the phosphorylation of S-motif was of higher stoichiometry than that of 
the T-loop (Vitari et al., 2005). Mutational analysis of these WNK-phosphorylation sites 
revealed that SPAK and OSR1 activity is only affected by T-loop phosphorylation and 
not the S-motif phosphorylation (Richardson and Alessi, 2008, Murthy et al., 2017). To 
support the WNK phosphorylation of SPAK and OSR1 by WNK1, knockdown of WNK1 
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led to reduce SPAK and OSR1 kinase activity, which was found to be a result of 
reduced SPAK and OSR1 phosphorylation of their T- loops and S-motifs (Anselmo et 
al., 2006, Moriguchi et al., 2005, Zagórska et al., 2007). 
The phosphorylation of SPAK and OSR1 kinases by WNKs is now established 
as the first activation step. This is because the Alessi group discovered that the WNK-
activated SPAK/OSR1 are further activated by binding the scaffolding protein MO25 
(Alessi et al., 2014). Indeed, mouse protein 25 (MO25) of which there are two isoforms 
in humans ( and ), was found to bind SPAK and OSR1 kinases, leading to 70–100 
fold increase in their catalytic activity in vitro (Filippi et al., 2011). The fully activated 
SPAK and OSR1 kinases then phosphorylate and activate CCCs (Murthy et al., 2017). 
Knockout of MO25 in human embryonic cells (HEK293) cells did not lead to 
alterations in the phosphorylation of SPAK and OSR1 at the WNK-phosphorylation 
sites, but as expected a decrease in the phosphorylation and activation of NKCC1, the 
physiological substrate of SPAK and OSR1 kinases, was observed (Filippi et al., 
2011). This observation indicated that the interaction of MO25 with SPAK and OSR1 
kinases did not affect their activation by WNK kinases, but rather increases the activity 
pre-WNK-phosphorylated SPAK and OSR1 kinases. This finding was reinforced by a 
study examining the function of MO25 in Drosophila (dr). Malpighian tubular cells, in 
which Fray kinase (insect analogous of human Ste20 kinases) was incubated with dr-
WNK and dr-MO25 in in vitro assays led to increased activity of Fray protein (Sun et 
al., 2018).  In contrast, dr-MO25 knockout in Malpighian system reduced ions transport 
in stimulated epithelial cells (Sun et al., 2018). This study provided another evidence 
that MO25 enhances the catalytic activity of SPAK and OSR1 kinases.   
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The function of SPAK and OSR1 could also be affected by trans-
autophosphorylation (Rodan and Jenny, 2017). Indeed, it was proposed that trans-
autophosphorylation of OSR1 could be mediated by its homodimerization (Rodan and 
Jenny, 2017), which allows the swapping of identical elements of the T-loops between 
SPAK and OSR1 monomers without distorting the intramolecular interactions of each 
monomer (Rodan and Jenny, 2017, Lee et al., 2009, Villa et al., 2008, Taylor et al., 
2015).  
The function of MO25 on the dimerization of SPAK and OSR1 was investigated 
in Xenopus oocytes where the ability of a complex of monomers or dimers of wild type 
(WT) alone or with various mutant SPAK to phosphorylate NKCC1 in the presence or 
absence of MO25 was explored (Ponce-Coria et al., 2012). This showed that MO25 
was required to increase the catalytic activity of WT-SPAK dimers, as indicated by 
NKCC1 phosphorylation in the presence or absence of MO25. Interestingly, in the co-
expression of MO25 with SPAK concatemer, which was composed of functional WT-
SPAK monomer and inactive mutant SPAK monomer, the activation of NKCC1 was 
also observed. It was hypothesised that the activation resulted by exchange of the 
activation loop between the two SPAK monomers, this could substitute mutant inactive 
SPAK monomer (Ponce-Coria et al., 2012). Moreover, it was shown that the 
overexpression of the OSR1-WT rescued the activity of the mutant SPAK, that further 
supporting the possibility of heterodimer formation (Ponce-Coria et al., 2012). 
Together, these observations emphasise the role of MO25 in SPAK and OSR1 
activation by possible stabilisation of the active form of the kinases as well as the 
facilitation of their dimerization (Gagnon et al., 2011).  
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1.2.5 Role of WNK-SPAK/OSR1 in ion homeostasis: 
Ion homeostasis is a vital process for maintaining cell volume and proper 
cellular function in all tissues (Kahle et al., 2010). The precise tuning of [Cl] was found 
to be the crucial mechanism in intracellular osmoregulation, and it is strictly regulated 
by a family of CCCs known as SLC12A co-transporters (Kahle et al., 2010). This family 
comprises NKCCs, NCC and KCCs which mediate Na-derived Cl influx and K-derived 
Cl outflux respectively. These proteins play an important role in renal physiology, 
regulating BP and neurotransmission (Alessi et al., 2014). CCCs have been 
extensively explored over the last two decades and some of the key findings was that 
these co-transporters are activated and deactivated by phosphorylation at serine and 
threonine residues in either N- or C-terminal domains (Bazúa-Valenti et al., 2016). 
WNK-enzymes along with their downstream substrates, SPAK/OSR1, and upstream 
regulators, CUL3/KLHL3 (section 1.3.3), all of which comprise the WNK-signalling 
cascade, regulate the function of the SLC12A co-transporters and therefore 
electrolytes homeostasis (Shekarabi et al., 2017). Despite the progress achieved, the 
role of phosphatases, which dephosphorylate proteins, in the function of these co-
transporters is still not as well investigated as the role of protein kinases.  
In humans, the SLC12A family contains nine members, (Table 1.2), two of 
which NKCC2 and NCC, are kidney specific (Richardson and Alessi, 2008). The rest 
of the co-transporters are widely distributed except KCC2, which is neuronal specific 
protein (Richardson and Alessi, 2008). Mutations in these co-transporters could lead 
to a series of diseases in humans. For instance, Gitelman’s syndrome is now 
understood to result from malfunctioning of NCC (Simon et al., 1996b), while Bartter’s 
type-1 is caused by a mutation in the NKCC2 gene (Simon et al., 1996a). Both 
syndromes are characterised by hypotension that is associated with electrolytes 
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Member Symbol Ion co-
transporter 
Expression 
SLAC12A1 NKCC2 Na+/K+/2Cl- Kidney (Thich ascending 
limb) 
SLAC12A2 NKCC1 Na+/K+/2Cl- Ubiquitous 
SLAC12A3 NCC Na+/Cl- Kidney (distal convoluted 
tubules) 
SLAC12A4 KCC1 K+/Cl- Ubiquitous 
SLAC12A5 KCC2 K+/Cl- Nerve 
SLAC12A6 KCC3 K+/Cl- Ubiquitous 
SLAC12A7 KCC4 K+/Cl- Ubiquitous 
SLAC12A8 CCC9 Unknown  Ubiquitous 
SLAC12A9  CIP Unknown Ubiquitous 
Table 1.3: Co-transporter protein members of the SLC12A family. Table adapted 
from (Richardson and Alessi, 2008). 
 
 
1.2.5.1 Regulation of NKCC1 by WNK-SPAK/OSR1: 
NKCC1 was the first SPAK and OSR1 kinase substrate identified (Piechotta et 
al., 2003, Piechotta et al., 2002). Indeed, SPAK and OSR1 bind NKCC1 and 
phosphorylate it at a series of N-terminal threonine residues, Thr203, Thr207, Thr212 
and Thr217 (Figure 1.12), leading to its activation. Interestingly, single point mutation 
of Thr217 or Thr212 into alanine inhibited NKCC1 activity (Dowd and Forbush, 2003, 
Gagnon et al., 2007a). It is ubiquitously expressed and possesses twelve 
transmembrane segments (TM) with cytoplasmic N- and C-termini (Markadieu and 
Delpire, 2014). It has an ability to dimerize though the monomers have also been 
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shown to be fully functional (Markadieu and Delpire, 2014). The NKCC1 co-transporter 
takes up Cl, which co-transported with Na, and counter-transport it with K, enabling 
the regulation of cell osmolarity and volume equilibrium with the extracellular 
environment (Flatman, 2007, Gerelsaikhan and Turner, 2000). Not long after the 
discovery of NKCC1, NKCC2 and KCC, were also found to bind SPAK and OSR1 
kinases, which phosphorylate them following osmotic stress (Vitari et al., 2005). 
At the molecular level, NKCC1 interacts with SPAK and OSR1 via the docking 
of RFxV stretch of NKCC1 into the CCT domain of SPAK and OSR1, akin to WNK 
kinases docking to these CCT domain motifs (Alessi et al., 2014). NKCC1 has two 
RFxV motifs in N-terminus (Figure 1.12). Mutations in these RFxV sequences 
prevented the binding to SPAK and OSR1, resulting in inhibition of NKCC1 activation 
(Vitari et al., 2006, Gagnon et al., 2007a). Interestingly, it has been found that the 
SPAK and OSR1 CCT domain could bind either WNK or NKCC1, which both contain 
multiple RFxV motifs. This indicated that the dissociation of WNK-activated SPAK and 
OSR1 from WNK kinases is essential for the subsequent binding to NKCC1 as the 
CCT domain could only accommodate one protein at a time. Zagoroska et al 
demonstrated that Ser1261 of WNK1, which is located immediately after the RFQV 
motif, was phosphorylated under osmotic stress in HEK293 cell line, suggesting that 
SPAK and OSR1 kinases dissociated from WNK kinases following this WNK1 Ser1261 
phosphorylation (Zagórska et al., 2007).  
This finding was supported by the failure to pulldown SPAK and OSR1 kinases 
using a WNK4-derived RFxV peptide phosphorylated at a threonine residue that falls 
immediately after the RFQV sequence (Villa et al., 2007). The kinase that 
phosphorylates these threonine residues that are located immediately after the RFQV 
motifs remains elusive. In 2012, the Alessi group found that WNK1 Ser1261 was not 
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phosphorylated by SPAK and OSR1 kinases since the phosphorylation of this residue 
by osmotic stress was completely unaffected by the loss of SPAK and OSR1 kinase 
activity (Thastrup et al., 2012). Thus, it was suggested that these threonine sites could 
be phosphorylated either by WNK isoforms themselves, in a trans-phosphorylation 













1.2.5.2 WNK-SPAK/OSR1 regulation of NKCC2: 
NKCC2 is a pivotal SLC12A member and it possesses 60 % sequence similarity 
to NKCC1 (Markadieu and Delpire, 2014). In contrast to NKCC1, NKCC2 is only 
expressed in renal TAL and it contributes to the reabsorption of 25 % of filtrated 
Figure 1.12: The structural domains of human the SLC12A transporters 
NKCC1 and NKCC2. Schematic diagram of NKCC1 and NKCC2 showing the 
transmembrane domains (yellow), the key domains and phosphorylation sites in 
both the N-terminus as well as the SPAK/OSR1 binding regions. The bottom panel 
is sequence alignments of human NKCC1 and NKCC2 showing the conserved 
residues (grey) and SPAK/OSR1 phosphorylated sites (red) (Richardson and 
Alessi, 2008). 
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glomerular salts. NKCC2 is the molecular target of the antihypertensive loop diuretics 
(Flatman, 2007). WNK-activated SPAK and OSR1 kinases interact with and 
phosphorylate NKCC2 at N-terminal serine and threonine residues, Ser91, Thr95, 
Thr100 and Thr105 (Figure 1.12). Phosphorylation analysis of NKCC2 N-terminus 
revealed that the SPAK/OSR1-phosphorylated residues are also conserved in NKCC1 
and NCC (Richardson et al., 2011). Subsequent studies have shown that only three 
sites on NKCC2, Thr95, Thr100 and Thr105, are exclusively phosphorylated by the 
SPAK and OSR1 kinases.  
Interestingly, under osmotic stress five of seven phosphorylation sites on the 
N-terminus of NKCC2 were identified, some of which were WNK-SPAK/OSR1-
independent (Richardson et al., 2011). For example, Ser130 was found to be 
phosphorylated by AMPK (AMP-activated protein kinase) in response to hypotonic 
condition (Richardson et al., 2011). Out of the identified five phosphorylation sites, 
Thr105 and Ser130 were confirmed to play important roles in switching on and off the 
activity of NKCC2. Single point mutation of one of these residues reduced the NKCC2 
activity by 30-40 %, while mutations of both led to complete abolition of the co-
transporter function (Richardson et al., 2011). Notably, this finding contrasted NKCC1 
regulation, where single point mutation of NKCC1 Thr217, which is equivalent to 
NKCC2 Thr105, was enough to abolish the function of NKCC1 (Richardson et al., 
2011).  
Beyond the direct effect of SPAK and OSR1 on the function of NKCC2, the 
SPAK and OSR1 phosphorylation of NKCC2 has been shown to have an effect on the 
co-transporter total protein levels. For instance, it was demonstrated that the 
expression and phosphorylation of NKCC2 were elevated in universal SPAK knockout 
mice (Yang et al., 2010). This was hypothesised to be a result of the compensatory 
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effect exerted by OSR1 in TAL (Grimm et al., 2012). Interestingly, viable transgenic 
mice with SPAKT243A/T243A mutation that could not be activated by WNK isoforms, they 
displayed Gitelman’s like syndrome and the expression as well as the phosphorylation 
of all co-transporters including NKCC2 were diminished (Rafiqi et al., 2010). These 
data revealed that OSR1 is the predominant regulator of NKCC2 in TAL and SPAK is 
regulating NCC in renal DCT (Bazúa-Valenti et al., 2016). Although the protein 
phosphatases that regulate NKCC2 activity have not been fully defined, calcineurin, a 
serine/threonine protein phosphatase, had been shown to regulate the function of 
NKCC2 (Borschewski et al., 2016). The inhibition of calcineurin by cyclosporine, led 
to elevated levels of NKCC2 phosphorylation by SPAK and OSR1 (Borschewski et al., 
2016).  
As mentioned above, osmotic stress could lead to SPAK/OSR1-independent 
phosphorylation of NKCC2. This notion is supported by previous studies that NKCC2 
could be phosphorylated by protein kinase A (PKA) signalling and increased levels of 
cyclic adenosine monophosphate (cAMP) in TAL (Gunaratne et al., 2010). Given the 
role of PKA is regulating the function of G protein coupling receptors (GPCR), this may 
link WNK-signalling to the function of GPCRs  (Gunaratne et al., 2010, Bazúa-Valenti 
et al., 2016). Beyond PKA, various reagents that increase cAMP levels, e.g. 
vasopressin (VAP), β-adrenergic agonists (such norepinephrine and isoproterenol), 
glucagon, parathormone and calcitonin, are known to modulate Na and Cl 
reabsorption in TAL and thus they may produce these effects through the PKA-
mediated phosphorylation of CCCs (Ares et al., 2011b). An example of this is VAP, 
which has been shown to induce phosphorylation of NKCC2 at Ser126 and Ser874 
via PKA-signalling, which translates into increased activity of the NKCC2 co-
transporter (Gunaratne et al., 2010). 
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1.2.6 Regulation of WNK-SPAK/OSR1-CCCs cascade: 
1.2.6.1 Physiological regulators of WNK signalling: 
Since the WNK-SPAK/OSR1 signalling pathway responds to intracellular ionic 
levels, it was hypothesised that the activity of this signalling cascade is adjusted by 
amount of salt intake (Uchida et al., 2014). Indeed, low intake of Na/Cl increased the 
phosphorylation of SPAK/OSR1 and NCC (Thr53, Thr58 and Ser71) in the kidneys 
(Vallon et al., 2009). The phosphorylation of SPAK/OSR1 and NCC was reduced with 
high salt diet and administration of spironolactone (Chiga et al., 2008). However, 
aldosterone administration reverses this phosphorylation reduction. This suggesting 
that the aldosterone effects could be mediated via the WNK-SPAK/OSR1 signalling 
cascade (Chiga et al., 2008). Similarly, dietary potassium (K) regulates this pathway, 
as high dietary K down regulated WNK-SPAK/OSR1-NCC cascade (Uchida et al., 
2014). Whereas, low ingested K increases the levels of NCC expression and 
phosphorylation as consequence of raised activity of WNK4-SPAK signalling 
(Castañeda-Bueno et al., 2014, Sorensen et al., 2013, Vallon et al., 2009). With this 
in mind, it was not surprising to find that the kinase activity of WNK1 and OSR1 was 
stimulated when cells were treated with low K medium and inhibited by high K buffers 
(Naito et al., 2011).  
Recent in vivo studies demonstrated that K- deficient diet triggers NCC activity, 
causes Na retention and increases BP even with the intake of high salt diet (Terker et 
al., 2015). This effect was found to be mediated by low plasma K, hypokalaemia, which 
causes membrane hyperpolarization of DCT cells that diminishes [Cl] (Terker et al., 
2015). This Cl efflux though chloride channel consequently activates WNK kinases to 
limit the loss of K (Terker et al., 2015, Nomura et al., 2018). This explains how WNK 
kinases are activated in response to hypokalaemia.  
                                                                                                                                  
44 
 
In addition to the salt effect on WNK signalling, the body hormones are also 
involved in the regulation of WNK-SPAK/OSR1. Vasopressin (Vas) (Rieg et al., 2013, 
Saritas et al., 2013), angiotensin 2 (Ang2) (Castaneda-Bueno et al., 2012, van der 
Lubbe et al., 2011) have been shown to induce the activation of WNK-signalling. 
Moreover, insulin was shown to activate SPAK/OSR1 by reducing activity of WNK4 
via the phosphatidylinositol 3 kinase/Akt signalling cascade (Takahashi et al., 2014, 
Chavez-Canales et al., 2013, Nishida et al., 2012). These findings could explain the 
elevated sensibility to the salt in patients with hyperinsulinemic metabolic syndromes 
(Uchida et al., 2014). 
1.2.6.2 Drug regulation of WNK-SPAK/OSR1 cascade: 
Since the discovery of the association of WNK kinases with HPT in 2001, this 
signalling cascade emerged as an attractive target for the discovery of new 
antihypertensive drugs. In 2013, the first small WNK-signalling inhibitors were reported 
(Mori et al., 2013). These compounds were designed to bind the highly conserved 
CCT domains of SPAK and OSR1 kinases and inhibit their binding to the upstream 
WNK kinases. Then, several other WNK-signalling inhibitors that targeted different 
components of the WNK-SPAK/OSR1 signalling pathway were discovered (AlAmri et 
al., 2017b, Cheng et al., 2017). The WNK-signalling inhibitors discovered to date were 
classified into four categories according to their mechanism of inhibition. The first were 
WNK kinases inhibitors, which were divided into competitive and non-competitive ATP 
inhibitors, e.g. WNK463 and WNK476, respectively. Secondly, inhibitors of WNK 
binding to SPAK and OSR1 kinases and these include STOCK1S-50699 and 
STOCK1S-26016. The third group composed of compounds that acted as direct SPAK 
and OSR1 kinase inhibitors, e.g. STOCK1S-14279, Closantel and Rafoxanide, all of 
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which are non-ATP-competitive inhibitors. Whereas, the fourth group is composed of 
molecules that inhibit the binding of SPAK and OSR1 kinases to MO25 (AlAmri et al., 
2017b). To date, only one compound, HK01, has been discovered as an inhibitor of 
this interaction and it is an indirect inhibitor of SPAK and OSR1 kinases (Kadri et al., 
2017, AlAmri et al., 2017b).  
 
1.3 The beta 2-adrenergic receptor (β2AR) 
 
1.3.1 β2AR overview:   
The human guanosine triphosphate protein (GTP)-binding protein (G-protein) 
coupled receptors (GPCRs) are the largest superfamily of cell membrane receptors 
(Rasmussen et al., 2011b). GPCRs have been the targets of many drug discovery 
initiatives because their ability to respond to a variety of stimuli, hormones, peptides, 
ions, protons, small molecules and light, and their involvement in many human 
diseases such as pulmonary, cardiac diseases, cancer, metabolic and monogenic 
disorders (Shoichet and Kobilka, 2012). Human GPCRs are classified into four main 
classes; class A, B, C, and F based on their sequence homology and function 
(Fredriksson et al., 2003).  
Historically, the adrenergic receptors (AR) belong to the aminergic group of 
Class-A non-rhodopsin GPCRs (Basith et al., 2018, Cherezov et al., 2007). They have 
been classified into two major subfamilies; α- and β-receptors, which is subdivided into 
β1-, β2- and β3-AR. Although, the β-subtypes share 60-70 % resemblance, they vary 
in tissue expression, function and in the pattern of agonist binding (Mutlu and Factor, 
2008). The β1AR is found in the heart, brain, kidney and blood vessels. The β2AR is 
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expressed in the lung, heart, smooth and skeletal muscles, blood vessels, kidney and 
uterus. The β3 subtype is expressed mainly in adipose tissues, heart and vasculature 
(Mutlu and Factor, 2008). In terms of their function, the β1AR is primarily implicated in 
the elevation of heart rate and force of contraction. The β2AR is involved in the 
stimulation and relaxation of the smooth muscles whereas the β3AR has a significant 
role in obesity (Kurose, 2004). 
The β2AR is a heptahelical transmembrane protein, interconnected with three 
intracellular loops (ICL) and three extracellular loops (ECL). Its C-terminus is 
cytoplasmic while the N-terminus is projected extracellularly (Kobilka, 1992). It 
conveys the signals into cytosolic proteins through predominantly triggering of its 
cognate heterotrimeric G-protein, however other G-protein-independent signalling 
transductions have also been reported, such as recruitment of β-arrestin (Lefkowitz, 
2000, Cherezov et al., 2007).  
Like other GPCRs, the β2AR has high ability to stimulate Gs protein even when 
it is not engaged to an agonist (Manglik and Kobilka, 2014).This phenomenon is known 
as ‘basal activity’, which could be reduced by inverse agonists and elevated by 
agonists (Manglik et al., 2015). GPCRs, including the β2AR, are highly dynamic and 
flexible which exist in multiple functional conformations with low energetic barriers 
(Deupi and Kobilka, 2010). Therefore, the term bimodal switch (inactive/active) could 
not be used with these GPCRs (Manglik and Kobilka, 2014). The receptor dynamics 
are influenced by various stimuli such as ligands, cytosolic protein binding, pH, lipids, 
ions and perhaps alteration in membrane potential (Latorraca et al., 2017). In addition 
to their structural flexibility, homo- and hetero-dimerization of these receptors also 
takes place and this could also be an issue for understanding the biological functions 
of these receptors in health  and disease (Manglik and Kobilka, 2014). Most of GPCRs 
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exist in monomer-dimer equilibrium state, also the half-life of monomeric association 
is less than seconds, resulted in a failure of crystallization of multimeric forms of 
receptors that make several questions related to the role of dimerization have not been 
solved yet (Lambert, 2010). In addition, single activated monomer has ability to interact 
to and activates G-proteins (Gurevich and Gurevich, 2008) which make the 
understanding of the role of dimerization/oligomerization in receptor function is unclear 
(Manglik and Kobilka, 2014).       
1.3.2 The crystal structure of the β2AR: 
The human β2AR gene is about 1,200 base pairs and is located on 
chromosome 5, which encodes 413 amino acids of 46.5 kD (Mutlu et al., 2004b). 
Although, it was firstly discovered in the 1990s, the β2AR crystal structure had not 
been solved until 2007 in complex with the inverse agonist, Carazolol (Cz)  (Cherezov 
et al., 2007).  
Figure 1.13: General topology of GPCRs and structure of the β2AR. (A) The overall 
structure of GPCRs showing the seven transmembrane (TM) segments in grey, the N-
terminus and ECL in orange, the ICL and the C-terminus end in purple. (B) Diagram 
showing the structure of the β2AR, highlighting the TM orientation, loops, N- and C-terminal 
ends. Figure adapted from (Latorraca et al., 2017).   
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Unlike rhodopsin GPCRs, structural analysis of the β2AR revealed that it shows 
inherited conformational flexibility, and substantial basal activity, which could be 
observed in the absence of a ligand (Manglik et al., 2015). The β2AR possesses a 
long resilient ICL3, which is thought to make the crystallization of the receptor 
challenging (Bang and Choi, 2015). Thus, for its crystallisation, β2AR was complexed 
with Cz to reduce the receptor fluctuation and stabilize it in an inactive state. 
Additionally, to overcome the plasticity of the ICL3, stabilisation of receptor at 
cytoplasmic side is required, either by creating a complex of the ICL3 with a Fab, an 
antibody fragment against ICL3, or by replacing the ICL3 by T4-lysozyme, an 
engineered β2AR incorporated protein (Cherezov et al., 2007, Rosenbaum et al., 
2007, Rasmussen et al., 2007).  
These advanced techniques enabled a favourable packing interactions of the 
β2AR crystals in high resolution where the β2AR appeared to be monomeric although 
several biophysical and biochemical studies indicated that the β2AR existed in well 
organised oligomers in biological membranes (Bulenger et al., 2005). The crystal 
structures of the β2AR revealed that it possesses the GPCRs common spanning 
seven hydrophobic transmembrane (7TM) helices, which are intervened with 
intracellular and extracellular hydrophilic loops (Figure 1.13). Each TM domain 
consists of 20-25 amino acids, which harbour the highest conserved residues among 
the β2AR sequence (Strader et al., 1989). Also, it was noted that the β2AR has N-
terminal glycosylation sites at Asn6, Asn15 and Asn187 which had been shown to be 
essential for receptor integration into plasma membranes and in agonist-mediated 
trafficking processes (Mialet-Perez et al., 2004).  
Comparison of the β2AR to rhodopsin revealed that active rhodopsin has closer 
arrangement of TM helices than in the β2AR because of the presence of a conserved 
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[E/D]R[Y/W] sequences on TM3 (Bang and Choi, 2015). These sequences are 
involved in the formation of hydrogen bonds between Glu134 and Arg135 of 
[E/D]R[Y/W] on TM3 and Glu247 on TM6 (Figure1.14A), interactions that have been 
termed the ionic lock. Such interactions appear to be responsible for the structural 
stability of the receptor and it is thought to limit the receptor basal activity (Rasmussen 
et al., 2007). Since the β2AR also possesses the [E/D]R[Y/W] motif, similar function 
of these sequences were predicted and this was later shown to be the case as 
mutations within these sequences produced constitutively active β2AR (Ballesteros et 
al., 2001). Nevertheless, the β2AR appeared to have broader TM segments than that 
in rhodopsin because the distance between Arg131 on TM3 (Cz binding site) and 
Glu268 of TM6 was wider and thus disrupting the ionic lock (Figure1.14A). This 
structural arrangement of the β2AR TM regions could explain the receptor’s basal 
activity in the absence of ligand binding (Rasmussen et al., 2007).  
In addition, the other key residue that could be vital in minimizing the β2AR 
basal activity is Leu272 on TM6, which has been shown to participate in van der Waals 
interactions with Ile135 on TM3, Tyr141 of ICL2, Val222 and Tyr219 on TM5 residues 
(Rasmussen et al., 2007). This observation was supported by the mutation of Leu272 
into Ala, which resulted in continuously active β2AR (Samama et al., 1993).    
The T4-lysozyme replacement and lipid cubic phase crystallization technique 
provided a high-resolution structure of the β2AR ligand binding site (Bang and Choi, 
2015).  Among the key insights provided was that Cz formed hydrogen bonds with 
Asp113, Asn312 and Tyr316. Also, it formed hydrophobic interactions with Val114, 
Phe193 and Phe290 (Bang and Choi, 2015). In contrast to rhodopsin, the Cz docking 
site in the β2AR is not as deep, and ECL2 of the β2AR does not interact with the N-
terminus. This makes the ligand binding site in the β2AR slightly open to the 
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surrounding solvent thus permitting Cz to simply diffuse in and out of the binding site 
(Bang and Choi, 2015).  
Interestingly, other inactive conformations of the β2AR in complex with different 
ligands e.g., timolol, ICI118551 (inverse agonists) or alprenolol (antagonist) have been 
reported (Hanson et al., 2008, Wacker et al., 2010). These revealed that the general 
structure of the receptor was preserved, but only minor differences in the ligand 













The most notable feature from these studies was that although hydrogen bonds 
between the various ligands and the Asp113, Asn312 and Tyr316 residues of the 
Figure 1.14: β2AR in comparison with rhodopsin. (A) Topology of TM3 and 
TM6, showing the conserved E/DRY/W motif in TM3 of both β2AR and rhodopsin. 
(B) Carazolol chemical structure in right, and its binding site at β2AR between TM3 
and TM6, the i volved residues (Asp113, Val114, Phe290 and P e289) are also 
illustrated. Figure and ligand adapted from (Rasmussen et al., 2007).      
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β2AR were preserved, extra hydrogen bonds and hydrophobic interactions take place 
depending on the ligand’s structure from these ligands and could be related to their 
strength (Bang and Choi, 2015).  
 
1.3.3 Activation of the β2AR: 
Following the first report of the β2AR structure in 2007, there were several 
attempts at obtaining the agonist-bound active form of the receptor. Due to the 
structural dynamics of the β2AR even in the unstimulated form where it is in equilibrium 
between different conformations, stabilizing receptor on one structural conformation 
that allows crystallisation was a challenge (Bang and Choi, 2015). To achieve this, the 
agonist FAUC50 was designed to covalently bind the mutant β2AR-H93C by forming 
a disulphide bond with Cys93 at the end of TM2. However, this showed that, 
unexpectedly, the binding of agonist alone to the β2AR was insufficient to achieve a 
steady active conformation (Figure1.15A) (Rosenbaum et al., 2011). Thus, to capture 
the β2AR active conformation, a combined use of high affinity agonist, BI-167107, and 
cytoplasmic stabilization approaches either by G-protein or antibody (nanobody 80) 
have been used (Rasmussen et al., 2011a, Rasmussen et al., 2011b). 
By comparing the BI-167107-bound active and Cz-bound inactive β2AR 
structures, only little differences on the extracellular side of the receptor were noted 
and these were slight alterations in the agonist-binding pocket to accommodate the 
agonist. However, significant changes were observed in the cytoplasmic side (Bang 
and Choi, 2015). Indeed, once the full agonist BI-167107 bound the β2AR, it formed 
hydrogen bounds with Ser204 and Ser207 at TM5 attracting the upper segment of 
TM5 to TM6, which lead to the rearrangement of the hydrophobic connector region 
                                                                                                                                  
52 
 
that is made up of Pro211, Ile121 and Phe282. These interactions caused outward 
rotation and swaying of TM6 by about 14 Å (Figure1.15B) (Rasmussen et al., 2011a, 
Rasmussen et al., 2011b). This outer movement of TM6 was accompanied with a 
relative inward rearrangement of TM5 and TM7 that enabled the insertion of a G-
protein or its mimetic (Manglik et al., 2015). The residues on TM3-7, referred to above 
as the connector region, are thought to serve as a central pivot that senses and 
rearranges the TM segments in response to agonist binding (Latorraca et al., 2017, 
Rasmussen et al., 2011a).  
 
Figure 1.15: The β2AR dynamic activation and loose allosteric regulation. (A) 
Schematic diagram of the β2AR showing loose allosteric regulation between the 
binding pocket and the cytoplasmic ends of the TM segments (Top). The role of the 
outward movement of TM6 in the β2AR activation (bottom) (Manglik et al., 2015). (B) 
Topology of the β2AR showing the ligand-binding pocket and rearrangement of the 
TM segment in the β2AR activation. The dark purple (active β2AR) and light purple 
(inactive β2AR). Figure adapted from (Latorraca et al., 2017).   
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All of these structural insights must be understood in light of the fact that in each 
case, the β2AR was captured in a constant conformation, so the observations made 
are most likely specific to that conformation and the many β2AR conformations are 
undetected, that they take place during the activation process (Bang and Choi, 2015). 
Hence, to achieve better understanding of the molecular dynamics of the β2AR 
activation and the link between the agonist-binding pocket and the cytoplasmic G-
protein incorporation site, double electron electron resonance (DEER) and nuclear 
magnetic resonance (NMR) spectroscopy have been used. To simplify the analysis, 
the β2AR was divided into three functional regions; the ligand binding pocket, the 
connector and the cytoplasmic domains (Figure 1.16A) (Latorraca et al., 2017).  
Figure 1.16: Activation mechanism of the β2AR. (A)Diagram illustrating the 
three regions involved in the loose allosteric coupling of the active β2AR. Ligand 
binding pocket (orange), the connector region (green) and cytoplasmic binding 
domain (purple). (B) The dynamic changes of the cytoplasmic domains during the 
β2AR activation showing the intermediate state in a simulation model. (C) 
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The spectroscopic findings agreed with the notion that binding of a high affinity 
agonist, e.g. BI167107 alone was not enough to stabilize the β2AR cytoplasmic 
domain in the active state (Nygaard et al., 2013). Although agonist binding leads to 
fluctuation of the cytoplasmic domain from inactive to active-like state, the full 
activation could only be detected after the incorporation of the G-protein and with 
gradual dissociation of agonist (Manglik et al., 2015). It was supposed that this G-
protein binding enhances agonist binding affinity (endogenous allosteric regulation) 
(Latorraca et al., 2017). However, interestingly, the recent findings revealed that the 
association between the ligand-binding site and the cytoplasmic domains is loosely 
allosteric (Figure 1.16) (Manglik et al., 2015, Ring et al., 2013). This proposed 
hypothesis of loose allosteric regulation is delivered by unbiased simulation analysis 
of the β2AR molecular dynamic where agonist-conjugated β2AR was rapidly 
interconverting between active and inactive conformations (Dror et al., 2011). This 
showed that the three parts of the β2AR, agonist binding pocket, the connector and 
the cytoplasmic domain do not behave like an interconnected gear, but rather than 
each part interconverts independently between inactive, intermediate or active 
conformations, although the conformation of a region probably depended on the 
conformation of other regions (Latorraca et al., 2017). This notion of loose association 
between the three parts was also confirmed by NMR results (Manglik et al., 2015). 
1.3.4 The β2AR-signalling: 
The β2AR is a versatile receptor that could regulate multiple signalling 
pathways through different second messengers and mostly in response to particular 
ligand binding (Nygaard et al., 2013). The β2AR could be engaged by a rich variety of 
ligands, which are generally categorised according to their efficacy (ability to generate 
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cAMP). These categories are: 1) neutral antagonist that does not alter the basal 
activity, 2) a partial agonist that induces submaximal response, 3) full agonist that 
produces maximum response, 4) inverse agonist that reduces the receptor’s basal 
activity (Figure 1.17) (Rosenbaum et al., 2009).  
Figure 1.17: The β2AR signalling pathways, recycling and desensitization. 
The β2AR modulates the activity of adenylate cyclase via activation of G-proteins 
(Gsα and Giα). Adenylate cyclase catalyses cAMP to trigger protein kinase A 
(PKA), Also, the activation of the β2AR results in the activation of G protein coupled 
receptor kinase (GRK) and arrestin (G-protein independent pathway), which 
phosphorylate and promote the receptor’s internalization, respectively. Also, 
recruitment of arrestin stimulate gene expression through ERK1/2 MAP kinase 
pathway. Protein kinase C (PKC) also phosphorylates the β2AR and reduces its 
interaction with Gαs. Biological response to ligands (lower left corner), which are 
classified according to their efficacy on GPCRs including the β2AR. Figure adapted 
from (Rosenbaum et al., 2009).     
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Full or partial agonist engagement to the β2AR triggers the canonical pathway 
Gsα protein by dissociating it from Gsβγ complex (Mutlu and Factor, 2008). This 
subsequently activates adenylate cyclase (AC) that catalyses cAMP formation, which 
in turn stimulates PKA (Mutlu and Factor, 2008). In cases where the binding of the 
inverse agonist or antagonist does not produce biological response, the Gs pathway 
is inactivated (Mutlu and Factor, 2008). The β2AR also couples to the Giα, which plays 
a vital role in cardiac pathophysiology by regulating the excitatory effect of the β1AR 
in the heart (Zhu et al., 2001). Over stimulation of the β2AR-Gᵢα could be involved in 
over relaxation of cardiac muscles and ultimately the development of dilated 
cardiomyopathy (McCloskey et al., 2008).  
The β2AR interacts with protein kinases such as PKA, and the G-protein 
coupling receptor kinase 2 (GRK2). These phosphorylate the receptor  leading to 
conformational alterations and hence converting the receptor towards inactive state 
(Lefkowitz and Shenoy, 2005). Moreover, the β2AR phosphorylation by GRK2 enables 
the binding of arrestin proteins resulting in the dissociation of the receptor from Gs, a 
process that initiates the endocytosis of the β2AR through a clathrin-mediated 
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Interacting proteins Effect References 
Protein kinase A (PKA) Phosphorylation of β2AR 
• ↓ coupling with Gs 
• ↑ coupling with Gi 
 
(Okamoto et al., 1991) 
Protein kinase C (PKC) Phosphorylation of β2AR. 
• ↓ coupling with Gs 
 
(Benovic et al., 1985). 
Arrestin • Regulates receptor ubiquitination. 
• ↑ Receptor internalization.  
• Interacts with GRK-activated 
receptor.  
  
(DeFea et al., 2000, Miller 
and Lefkowitz, 2001). 
G-protein coupling 
receptor kinase (GRK2) 
Phosphorylation of agonist bound β2AR. 
• ↑ binding to arrestin. 
• ↓ coupling with Gs. 
 
(Cong et al., 2001). 
GRK5 Phosphorylation of agonist bound β2AR. 
• ↓ binding to PDZ motif proteins. 
• ↑ binding to arrestin. 
 
(Cao et al., 1999). 
Insulin receptor Phosphorylation of β2AR at Tyr residues. 
• ↑ cAMP (Tyr350/354). 
• ↓ cAMP (Tyr141). 
 
(Hadcock et al., 1992, 
Karoor et al., 1995). 
Insulin like 
growthfactor-1  
Phosphorylation of β2AR at Tyr residues. 
Activation of ERK1/2. 
 
(Maudsley et al., 2000). 
PDZ-motif containing 
proteins 
• ↓ Activity of Na+/H+ exchanger. 
• ↑ Receptor recycling. 
 
(Cao et al., 1999) 
A-kinase anchoring 
proteins AKAP79 / 
AKAP250 
 
• Tethering PKA with the receptor at 
C-terminus. 
(Gardner et al., 2006, Tao 





• Involved in activation of Na+/H+ 
exchanger 
 
(Hall et al., 1998) 
Table 1.4: Summary of the proteins involved in the β2AR signalling pathway. Table 
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1.3.5 Roles of the β2AR in ions homeostasis: 
Stimulation of the β2AR modulates several key proteins through cAMP-
dependent and -independent cascades (Mutlu and Factor, 2008). Examples of these 
proteins include the Na/K-ATPase, cystic fibrosis transmembrane conductor regulator 
(CFTR) and amiloride-sensitive epithelial Na-channels (eNaC), which are all required 
for ions and fluid homeostasis (Mutlu and Factor, 2008).  
1.3.5.1 Stimulation of sodium channels: 
Early investigations in the 1980s demonstrated that non-selective βAR-agonists 
induced influx of ions in monolayer alveolar cells that were isolated from rat lungs 
(Mutlu and Sznajder, 2004). Subsequent studies showed that catecholamines 
stimulated the βARs on alveolar fluid clearance (AFC) (Mutlu and Factor, 2008). 
Several non-selective β2AR agonists (e.g. isoproterenol, epinephrine and 
dobutamine) and selective β2AR agonists (e.g. procaterol, terbutaline and salmeterol) 
have been used and showed increase in AFC in many animal models such as rats 
(Jayr et al., 1994), mice (Fukuda et al., 2000, Icard and Saumon, 1999), dogs 
(Berthiaume et al., 1988), guinea pigs (Norlin et al., 1998), as well as in ex vivo human 
pulmonary cells (Sakuma et al., 1997). A β2AR knockout mice confirmed the role of 
the β2AR in AFC regulation (Mutlu et al., 2004a). Together, these revealed that the 
β2AR plays an important role in the adjustment of Na active transport probably through 
the Na/K-ATPase pump (Mutlu et al., 2004a).  
In an in vitro study, it was shown that non-selective cation channels, and 
selective Na channels e.g. eNaC and high selective-Na channels, could be stimulated 
by βAR-agonists (Chen et al., 2002, Mutlu and Factor, 2008). Additionally, terbutaline 
stimulated βARs in alveolar type-2 cells, where it accelerated Na flow in the apical 
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membrane by enhancing the eNaC abundance in plasma membrane and prolonging 
the channel’s opening time (Yue et al., 1994). This up-regulatory mechanism was 
found to be mediated by the cAMP-PKA pathways, which phosphorylate cytoskeleton 
proteins that regulate membrane trafficking of Na channels (Berdiev et al., 1996).  
Furthermore, it was shown that the β2AR stimulation enhances Na/K-ATPase activity 
in pulmonary epithelium by increasing the assembly of the Na/K-pump and its 
exocytosis into the plasma membrane through the activation of PKA and Rho-
associated kinase (Lecuona et al., 2003). The regulation of the Na/K-pump could also 
be prolonged by modulating the transcription of the α1-subunit via the activation of 
PKA and mitogen activated protein (MAP) kinases and the extracellular-signal 
regulatory kinase (ERK) (Pesce et al., 2003).  
1.3.5.2 CFTR regulation:  
In addition to Na regulation, the β2AR also regulates Cl movement through 
cystic fibrosis transmembrane conductor regulator (CFTR) (Mutlu and Factor, 2008, 
Nielsen et al., 1998). A number of studies revealed that Cl transport elevation was 
mediated by the β2AR-stimulated CFTR (Fang et al., 2002, Huang et al., 2001, Jiang 
et al., 2001, O'Grady et al., 2000). CFTR plays a vital role in prevention  of pulmonary 
oedema (excess fluid in air spaces), but is not in the normal lung where the β2AR 
accelerates AFC (Mutlu and Factor, 2008). Additionally, CFTR overexpression in 
transgenic mice that lack the β2AR failed to accelerate the rate of AFC likewise in 
CFTR knockout mice (Mutlu et al., 2005, Mutlu and Factor, 2008). These findings 
indicated the critical roles of both the β2AR and CFTR in ions and fluid homeostasis 
in the pulmonary system.   
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1.3.5.3 Role of the β2AR in renal salts reabsorption:  
BP can be elevated by increased salt intake due to an increase in the activity 
of the renal sympathetic system (SPS) supply, which causes salt retention (Campese 
et al., 1982, Fujita et al., 1980, Mu et al., 2011). Overactivity of the renal SPS could 
play a key role in developing salt-dependent HPT by rising Na reabsorption (Mu et al., 
2011). Patients with salt-dependent HPT and who are on high salt diet have higher 
levels of norepinephrine in their blood than that in salt-resistant individuals. This 
indicates persistent overactivity of the adrenergic system in these patients  (Fujita, 
2014). Therefore, the kidneys have central roles in regulating BP and this has led to 
several attempts to treat salt-sensitive hypertensive patients with renal sympathetic 
denervation (Esler et al., 2010, Krum et al., 2009).   
Interestingly, the β2AR mediates norepinephrine- and isoproterenol-induced 
HPT, as the salt-induced HPT was only developed in wild type and the β1AR knock 
out mice but did not in the β2AR knock out mice (Mu et al., 2011). The βARs have 
been shown to be expressed in the renal nephrons using combined labelling 
autoradiography with light microscopy (Summers et al., 1985).  Immunofluorescence 
(IF) imaging in rat kidneys (Boivin et al., 2001) revealed that the β1AR is abundant 
and diffusely expressed in TAL, DCT and glomeruli. The β2AR comprises only about 
37 % of the βARs expressed in the kidney and is predominantly expressed in the DCT 
and the collected ducts (CD) (Morla et al., 2016). Notably, the DCT has also been 
shown to contains several types of salt transporting carriers including NCC, eNaC, 
Na/H exchanger and Na/K ATPase (McCormick and Ellison, 2015).  
In the literature, there has been some indirect links between the β2AR and 
NCC, the established physiological substrate of SPAK and OSR1 kinases. For 
instance, the total amount and activity of NCC was increased in salt-sensitive 
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hypertensive rat models though the underlining mechanism was not investigated (Li 
and Wang, 2007). In another study, stimulation of the βARs in mice by isoproterenol 
(Iso) indicated that the activation of the β2AR but not the β1AR is responsible for 
developing salt-sensitive HPT (Mu et al., 2011). This was hypothesised, as a result of 
decreased expression of WNK4 through a cAMP-PKA dependent mechanism with 
involvement of glucocorticoid receptors following β2AR stimulation (Mu et al., 2011). 
This suppression of WNK4 eventually led to increased expression and 
phosphorylation of NCC in the DCT. Glucocorticoid receptors are crucially required to 
this pathway because knocking out of this receptor abolished the Iso-mediated WNK4 
downregulation. Additionally, the Iso effect on WNK4 was entirely blocked by ICI11851 
(specific β2AR blocker) but not by metoprolol (specific β1AR blocker). This indicated 
that the β2AR-activated NCC stimulation mediates Na reabsorption in the DCT (Mu et 
al., 2011).  
Similarly, to support this findings, a micro-puncture analysis of Na⁺ reabsorption 
in the DCT showed increased Na uptake during stimulation with Iso (Greven and 
Heidenreich, 1975).  However, a contrasting report by Terker and co-workers showed 
that the infusion of norepinephrine induced salt-sensitive HPT (Terker et al., 2014). 
Such increase was found to be a result of enhanced activity and abundance of NCC, 
a process that was mediated by the β1AR activation through OSR1 and not SPAK 
(Terker et al., 2014). Notably, however, patients with the β2AR polymorphism 
manifested salt-induced HPT, low renin levels and impaired renal Na excretion 
(Pojoga et al., 2006, Snyder et al., 2006).    
As mentioned above, there is evidence that the WNK-SPAK/OSR1 signalling 
pathway can be regulated by hormones. For instance, angiotensin 2 (A2) induced the 
activation of NCC because it reduced the inhibitory effect of WNK4 on NCC through a 
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SPAK-mediated mechanism (Castaneda-Bueno et al., 2012). Also, acute aldosterone 
administration was shown to activate NCC via either a WNK4-SPAK-dependent 
pathway (Ko et al., 2013) or the WNK4 extracellular signalling regulated kinase 1/2 
(ERK1 / 2) signalling cascade (Lai et al., 2012). Additionally, Iso-mediated stimulation 
of NCC and Iso-induced suppression of WNK4 transcription were A2 and aldosterone 
independent suggesting that the β2AR-WNK-NCC pathway could be a novel 
independent regulator of these phenomenons (Mutlu and Factor, 2008). Therefore, it 
would be interesting to find whether the β2AR stimulation induced salt-sensitive HPT 
could be mediated via WNK-SPAK/OSR1-NCC signalling in the DCT. To date, there 
has not been any direct links between the β2AR and the WNK-SPAK/OSR1 
kinases. Intriguingly, analysis of the amino acid sequence of the human β2AR 
revealed that it has a SPAK/OSR1 consensus binding sequence, Arg239-Phe240-
His241-Val242, located on ICL3 (Figure 1.18). This suggests that the human β2AR 













































Figure 1.18: Structure and arrangement of the human β2AR. The diagram 
shows the 7TM structure of the β2AR with extracellular T-terminus and intracellular 
C-terminus ends. Yellow residues indicate amino acids involved in ligand binding. 
The conserved DRY sequences are in orange. The green amino acids form the 
Fab antigen and it also contain the SPAK/OSR1 binding sequences (Arg239-
Phe240-His241-Val242). The figure was adapted from (Rasmussen et al., 2007). 
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1.4 Research aims and objectives: 
 
I. Hypothesis 
The intracellular β2AR RFHV tetrapeptide (amino acids. 239-242) may mediate 
the binding to SPAK and OSR1 kinases, which could modulate its function through a 
phosphorylation-(in) dependent mechanism. 
II. Research aims: 
The overall aim of this project is verifying the possible cross talk between 
SPAK/OSR1 kinases and the human β2AR. This goal to be achieved by addressing 
the following main points: 
I. Verifying the binding of the SPAK/OSR1 kinases to the human β2AR. 
II. Determining whether SPAK/OSR1 kinases phosphorylate the β2AR. 
III. Exploring the role of SPAK/OSR1 activation and inhibition on the β2AR 
internalization. 
IV. Establishing the effects of the β2AR binding on catalytic activity of SPAK/OSR1 
kinases.  
V. Determining the effects of the β2AR activation on endogenous SPAK/OSR1 
kinase activity and expression. 
 
III. Research objectives: 
 
Aim I Objective 1: Use in silico modelling to examine the binding of the β2AR- 
RFHV peptide to OSR1. 
 Objective 2: Use affinity-pull down assays to determine the binding of 
SPAK and OSR1 kinases to the β2AR- RFHV peptide.  
 Objective 3: Use mass spec to determine whether SPAK/OSR1 kinases 
bind the β2AR. 
 
                                                                                                                                  
65 
 
Aim II Objective 4: Use In vitro kinase assays to determine if the β2AR is 
phosphorylated by OSR1. 
 
Aim III Objective 5: Use membrane labelling, pulldown, ELISA and flow 
cytometry techniques to determine the effects of SPAK/OSR1 
activation and inhibition on the β2AR internalization.  
 
Aim IV Objective 6: Use In vitro kinase assays to establish the effects of the β2AR 
binding on the catalytic activity of OSR1. 
 
Aim V Objective 7: Use Western blotting to examine the effects of the β2AR 
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Chapter  2 : Materials and Methods 
 
 
2.1 Materials and reagents. 
2.1.1 Chemicals and reagents: 
STOCK1S-50699 was purchased from Vistas-M laboratory. Verteporfin 
(catalogue number: SML0534), isoproterenol hydrochloride (catalogue number: 
I6504), propranolol hydrochloride (catalogue number: P0884) were purchased from 
Sigma, Gillingham, UK. ICI118551 hydrochloride and PCG20712 (catalogue number: 
1874 batch 6) were purchased from Tocris, Bristol, UK. ADP-GloTM kit was purchased 
from Promega, Southampton, UK. The biotinylated 18-mer RFQV containing peptide 
(biotin-C6-SEEGKPQLVGRFQVTSSK, catalogue number; 331938). AFQV containing 
peptide (biotin-C6-SEEGKPQLVGAFQVTSSK, catalogue number: 372447). RFHV 
containing peptide (biotin-C6-DKSEGRFHVQNLSQ, catalogue number: 372432), and 
AFHV containing peptide (biotin-C6-DKSEGAFHVQNLSQ, catalogue number: 
372438) as well as CATCHtide (RRHYYYDTHTNTYYLR-TFGHNTRR) were 
purchased from GLS Peptide synthesis, Shanghai, China. Dulbecco’s modified 
Eagle’s media (DMEM) (catalogue number: D6429), 100 units/ml penicillin and 0.1 
mg/ml streptomycin (Pen/Strep, catalogue number: P4333), Dulbecco’s phosphate 
buffer saline (PBS), (catalogue number: D8662), dimethyl sulfoxide (DMSO), 
(catalogue number: D2650) were purchased from Sigma, Gillingham, UK. Fetal bovine 
serum (FBS), (catalogue number: 10270106) and Trypsin-EDTA 1x0.25 % (catalogue 
number: 25200056) were purchased from Gibco. Linear polyethylenimine (PEI) 
(catalogue number: 23966-1) was purchased from Polysceince Inc, Bergstrasse, 
Germany. Cell culture plasticware and pipettes were purchased from Corning.  




2.1.2.1 Antibodies used in Western blotting (WB) and immunoprecipitation 
(IP). 




Rabbit anti-GAPDH (D16H11, CST). 37 1:5,000 
Rabbit anti-pan cadherin (4073, CST). 130-150 1:1,000 
Sheep anti-OSR1 (S636B, Dundee) 58 10µg/mg (IP) 
Sheep anti-SPAK (S551D, Dundee) 63 2µg/ml (WB) 
10µg/mg (IP) 
Sheep anti-SPAK- phospho-Ser373 (S670B, 
Dundee) 
63 2µg/ml 
Sheep anti-SPAK-phospho-Thr233 (S668B, Dundee) 63 2µg/ml 
Sheep anti-NKCC1 (DU 6146, Dundee). 130-180 2µg/ml 
Sheep anti-NKCC1-phospho-
Thr203+Thr207+Thr212 (S763B, Dundee). 
130-180 2µg/ml 
Sheep anti-NKCC2-phospho Ser91 (S451C, 
Dundee). 
/ 2µg/ml 
Sheep anti-NKCC2-phospho-Thr105 (S378C, 
Dundee). 
/ 2µg/ml 
Sheep anti-NKCC2-phospho-Ser130 (S432C, 
Dundee). 
/ 2µg/ml 
Rabbit anti-β-catenin (9582, CST). 92 1:1,000 
Mouse anti-FLAG-HRP (ab2493, Abcam) / 1:5,000 
Mouse anti-FLAG (F1804, Sigma) / 1:1,000 
Mouse anti-FLAG monoclonal M2 (F3165, Sigma).  / 10µg/mg (IP) 
Rabbit anti-LKB1 (3047, CST) 54 1:1,000 
Rabbit anti-LKB1-phospho-Ser428 (3482, CST). 54 1:1,000 
Rabbit anti-β2AR (SAB4500577, Sigma) 46 1:500 
Rabbit anti-GST (2622, CST) / 1:1,000 
Table 2.1: Primary antibodies with dilutions for probing proteins by western blot (WB) and 
immunoprecipitation (IP) according to manufactural instructions and were also confirmed by 
my work. Antibody specificity has been determined si-RNA by the company as provided in 
data sheet. 




Secondary antibody Dilution 
Rabbit anti-mouse IgG HRP antibody (7076, CST). 1:2,000 
Goat anti-rabbit IgG HRP antibody (7074, CST). 1:2,000 
Rabbit anti-sheep IgG HRP antibody (ab97130, Abcam). 1:10,000 
Table 2.2: Secondary antibodies with dilutions for immunoblot. 
 
 
2.1.2.2 Antibodies used in enzyme linked immunosorbent assay (ELISA):  
The primary antibody used was a mouse anti-FLAG monoclonal M2 (F3165, 
Sigma). It was used at 1:1,000 dilution while the secondary antibody was goat anti-
mouse IgG Alkaline phosphatase linked (ab97020, Abcam). It was used at 1:10,000 
dilution. Monoclonal mouse IgG (NCG01) (ab81032, Abcam) was used as an isotype 
control. 
 
2.1.2.3 Antibodies used in flow cytometry: 
The primary antibodies were the rabbit anti-β2AR (SAB4500577, Sigma), which 
was used at 1:500 dilution or the mouse anti-FLAG monoclonal M2 Ab (F3165, 
Sigma), which was used at 1:2,000 dilution. The secondary antibodies were the goat 
anti-rabbit-FITC 488 antibody (ab77050, Abcam), which was used at 1:1,000 dilution 
or the goat anti-mouse FITC 488 antibody (ab6785, Abcam), which was used at 
1:1,000 dilution. 
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2.1.3 DNA plasmids. 
All of cDNA plasmids were purchased from the MRC Reagents and Services 
(Dundee) except when stated otherwise. For the expression of proteins in mammalian 
cells the following constructs were used pCMV5-GST-EV (DU41864), pEBG-HA-
SPAK (DU2923), pCMV5-FLAG-NKCC2-FL-WT (DU10098), pcDNA5-FRT/TO-
FLAG-NKCC2-R20A (DU17023), pCMV-FLAG-NKCC2 (1-174)-WT (DU13857), 
pcDNA5-FRT/TO-FLAG-β2AR-WT (lot:390869S, Genscript), pCMV5-FLAG-β2AR-
R239A (DU39345), pEBG-HA-OSR1T185E (DU6130), pEBG-HA-
OSR1T185E+L473A (DU6699), pEBG-HA-OSR1-T185E+D459A (DU6696). For 
bacterial E. coli protein expression, the following cDNA clones were used; pGEX-
NKCC2 (1-174) (DU13763), pGEX-OSR1-T185E full length (DU 6231) and pGEX-
MO25α (DU2945). 
 
2.2 Buffers and Medias 
2.2.1 Mammalian cells lysis buffer: 
Three different lysis buffers were used in this work. Lysis buffer 1 (LB1) was 
used for harvesting non-transfected cells, SPAK, OSR1 or NKCC2 transfected cells 
and mouse heart. It was made of 50 mM Tris/HCl (pH 7.5), 1 mM sodium 
orthovanadate, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 0.27 M sucrose, 5 
mM sodium pyrophosphate, 1 % (w/v) Nonidet P40 plus protease inhibitors 0.1 mM 
phenylmethanesulfonylfluoride (PMSF), 1 mM benzamidine, and 0.1 % (v/v) 2-
mercaptoethanol (de Los Heros et al., 2014). Lysis buffer 2 (LB2) was LB1 
supplemented with 1 % (w/v) n-dodecyl β-D-maltoside (catalogue number; 89902, 
ThermoFisher). Lysis buffer 3 (LB3) was used to solubilize β2AR-transfected 
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mammalian cells and it contained 50 mM HEPES (pH 7.5), 0.5 % Nonidet P40, 145 
mM sodium chloride, 2 mM EDTA, and 10 % (v/v) glycerol, 0.1 mM PMSF, 1 mM 
benzamidine, 0.1 % (v/v) 2-mercaptoethanol and 1 % (w/v) final concentration of n-
dodecyl β-D-maltoside was freshly added before cell lysing (Han et al., 2012). 
 
2.2.2 Hypotonic low Cl buffer (HLB): 
This buffer was used for stimulating the WNK-SPAK/OSR1 signalling pathway 
and it contained 7.5 mM HEPES (pH7.5), 67.5 mM sodium gluconate, 0.25 mM CaCl2, 
2.5 mM potassium gluconate, 0.5 mM Na2HPO4, 0.25 mM MgCl2 and 0.5 mM Na2SO4 
(de Los Heros et al., 2014). 
 
2.2.3 Preparation of PEI for cell transfection: 
Polyethylenimine (PEI) was used for protein expression in mammalian cells and 
it was prepared as a solution of 1 mg/ml PEI in 25 mM HEPES pH 7.5 and 150 mM 
NaCl, which was filtrated through 0.45 µM and aliquoted to several tubes then were 
stored at -20 °C.    
2.2.4 SDS sample buffer (4x): 
This consisted of 240 mM Tris/HCl (pH6.8), 40 % glycerol, 8 % sodium dodecyl 
sulphate (SDS), 5 % 2-mercaptoethanol and 0.04 % bromophenol blue.  
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2.2.5 Buffer A: 
This consisted of 50 mM Tris/HCl (pH7.5), 0.1 mM EGTA and 0.1 % (v/v) 2-
mercaptoethanol (AlAmri et al., 2017a). 
  
2.2.6 Western blotting running buffer: 
This consisted of 25 mM Tris/base (pH7.5),1.92 M glycine and 34.6 mM SDS 
,(AlAmri et al., 2017a, AlAmri et al., 2018)..  
 
2.2.7 Western blotting transfer buffer: 
This consisted of 48 mM Tris/base, 39 mM glycine supplemented with 20% (v/v) 
methanol immediately before use (AlAmri et al., 2017a, AlAmri et al., 2018). 
 
2.2.8 TBST buffer: 
This consisted of 50 mM Tris/HCl (pH7.5), 150 mM NaCl, 0.2 % (v/v) Tween-
20 with the final buffer pH adjusted to 8.3 by adding concentrated HCl (AlAmri et al., 
2017a, AlAmri et al., 2018). 
2.2.9 Western blotting blocking buffer: 
This consisted of 10 % (w/v) of dried skimmed milk dissolved in TBST buffer 
(AlAmri et al., 2017a, AlAmri et al., 2018). 
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2.2.10 Kinase reaction buffer: 
This consisted of 10 mM MgCl₂, 50 mM Tris/HCl (pH 7.5), 0.1 % (v/v) 2-
mercaptoethanol and 0.1 mM ATP (AlAmri et al., 2017a, AlAmri et al., 2018). 
2.2.11 ELISA blocking buffer: 
This consisted of serum free MDEM media supplemented with HEPES (pH 7.4) 
and 0.01 % BSA (Han et al., 2012).   
 
2.2.12 Preparation of LB (Lennox) media: 
LB Lennox (catalogue number; L7275-100TAB, Sigma, Gillingham UK) media 
for bacterial culture was prepared according manufactures manual; 1 tablet per 48 ml 
of dH₂O in pre-autoclaved bottle. The media was then autoclaved at 190 °C and stored 
in dry dark place. 
 
2.2.13 Preparation of LB with agar: 
LB with agar Lennox (catalogue number; L7025-100TAB, Sigma, Gillingham 
UK) media was prepared by dissolving 1 tablet per 48 ml of dH₂O in pre-autoclaved 
bottle after which the media was autoclaved at 190 °C. It was then kept in dry dark 
place and heated up and poured into 10-cm plates when needed. 
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2.2.14 Bacterial cells lysis buffer: 
This consisted of 50 mM Tris/HCl (pH7.5), 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 0.27 M sucrose, 0.1 mM PMSF, 1 mM benzamidine, 2 mM dithiothreitol (DTT), 
0.01 % 2mercaptoethanol, 0.5 mg/ml lysozyme and 0.3 mg/ml DNase (AlAmri et al., 
2017a, AlAmri et al., 2018). 
 
2.2.15 Normal buffer: 
This was the same to the bacterial lysis buffer but missing the lysozyme and 
DNase, it was used for washing steps in protein isolation from bacteria (AlAmri et al., 
2017a, AlAmri et al., 2018). 
 
2.2.16 High salt buffer: 
This was the same to the normal buffer, but it contained a final NaCl 








2.3.1 Cell culture: 
2.3.1.1 Maintenance of mammalian cell lines: 
Mammalian cells, such as human embryonic kidney 293 (HEK293), at passage 
range 5 - 25, were cultured in T-75 flasks, 10-cm or 6-well plates. The cells were 
cultured in DMEM supplemented with 10 % (v/v) FBS and 1 % (v/v) Pen/Strep. Once 
they reached 80-90 % confluency (log phase), the cells were regularly passaged in 
1:5 ratio every 2-3 days. The cells were washed once by 3-5 ml of PBS after the 
removal of the media. Then, they were detached with 2 ml trypsin. Typically, the cells 
were grown in 12-15 ml media in T75, 7 ml media in 10-cm dishes or 3 ml media in 
the 6-well plates. All of the flasks and plates were maintained at 5 % CO2 humified 
incubator at 37 °C. For the ELISA assay, HEK293 cells were cultured and transfected 
in T-75 flasks. After 24 hrs, the cells were detached with 2 ml PBS and transferred into 
pre-coated 96-wells plates at 10,000 cells/well in 100 µl media.  
 
2.3.1.2 Cells storage and recovery: 
Cells were frozen for storage when they were 90 % confluent. The cells were 
washed and detached with 2 ml trypsin and incubated for 5 min. After adding 10 ml 
media, the cells were centrifuged at 1,500 g for 10 min at 4 °C. The cellular pellet of 
single T75 flask was resuspended in 1 ml of freezing medium, containing FBS with 10 
% DMSO. The cells were then transferred into cryovials and kept within Mr Frosty at -
80 °C for overnight. In the next day, the cryovials were stored at -80 °C.  
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For cell recovery, the cryovials were thawed and warmed up to room 
temperature or in a water bath at 37 °C. After completely defrosting, the contents were 
immediately transferred into a T75 flask containing 12-15 ml media. Next day the 
media was replaced, and the cells maintained in the incubator as above.    
 
2.3.1.3 Mammalian cells transfections: 
For protein expression in mammalian cells, HEK293 cells (passage ranged 5 -
25) were plated either in 6-well plates or 10-cm dishes. Once the cells reached 40-50 
% confluency, they were transfected using the PEI method (Vitari et al., 2005). 1 µg of 
cDNA clones with 2 µl of 1 mg/ml PEI was mixed in a ratio of 1:2 in 200 µl FBS-free 
DMEM media per well of 6-well plates. 3 µg cDNA with 20 µl 1 mg/ml PEI in 1 ml FBS-
free DMEM media for a single 10-cm dish. Then, the mixture was vortexed gently and 
left at room temperature for 25 min. This mixture was then added to the cells carefully 
to avoid their detachment and the cells were incubated at 37 °C. 36-48 hrs post-
transfection, the cells were harvested, or undergone treatment as needed. 
 
2.3.1.4 Preparation of cell samples: 
A. Total cell lysate preparation: 
In order to prepare samples for SDS-PAGE and Western blotting. The cells 
were seeded at 0.3 X106 or 2.2 X 106 in 6-well plates or 10-cm dishes respectively. 
Once were confluent, they were washed once with 1 ml or 2 ml of PBS respectively 
after removal of the media. 120 – 400 µl of Ice-cold lysis buffer was then added to 
each well. After detaching the cells by cell-scraper, the suspension was centrifuged at 
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12,000 g for 10 min at 4 °C. The total protein concentration was then measured by 
Bradford assay or alternatively stored at -80 °C until needed. After measuring the 
protein concentration, the samples were immediately prepared for the SDS-PAGE 
experiment by adding SDS 4x sample buffer and water to reach a 1x final 
concentration of SDS and 1 mg/ml total protein concentration. Then, the samples were 
mixed and heated on dry heater at 90 °C for 7 min. Finally, the samples were stored 
at -20 °C or used immediately in Western blotting. 
B. Immunoprecipitation of FLAG-β2AR: 
HEK293 cells were cultured and transiently transfected in 10-cm plates using 
PEI. 36-48 hrs post-transfection, the cells were washed once with 2 ml ice-cold PBS 
and detached by adding 400 µl/plate of ice cold LB3. Following cell detachment by 
scrappers, the suspension was vortexed and incubated on rotator shaker for 2 hrs or 
overnight at 4 °C (Han et al., 2012). The lysate was subsequently centrifuged at 12,000 
g for 10 min at 4 °C. The supernatant was collected, and samples were prepared for 
SDS-PAGE to check receptor expression while the remaining lysate was stored at -80 
°C. 
In order to isolate FLAG-β2AR from cell lysate, pre-clearing of the cell lysate 
was first performed three times by incubating 1 mg cell lysate with 100 µl of 50 % slurry 
of protein-G-Sepharose beads (GE Health care life sciences, catalogue number: PG5-
161501) on rotator shaker at 4 °C for 10 min. After this, the beads were collected by 
centrifuging at 1,000 g at 4 °C for 5 min. Anti-FLAG antibody (F3165, Sigma) 
conjugated to the protein-G Sepharose beads was added to the pre-cleared lysate at 
a ratio of 1:100, (10 µg conjugated-antibody: 1 mg cell lysate) (Vitari et al., 2005). After 
incubation for 1 hr on rotator shaker at 4 °C, the solid beads were collected by 
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centrifuging at 1,000 g for 5 min at 4 °C. The beads were then washed twice by 
resuspending in 1 ml of LB3, centrifuging at 1,000 g for 5 min at 4 °C. For preparing 
samples for kinase assay, beads were washed two more washes  with LB3 contained 
0.5M NaCl. After the last spin the beads were subsequently washed twice by 
resuspending in 1 ml buffer A and centrifuging at 1,000 g for 5 min at 4 °C. For Western 
blotting, proteins were eluted from the beads, by adding 60-80 µl of 1x SDS-sample 
buffer, mixed well by a bench vertex and heated in a dry heater at 90 °C for 10 min. 
Then samples were stored at -20 °C. 
C. Bradford assay for protein concentration measurement: 
The Bradford assay was used for measuring protein concentrations by 
computing the absorbance using BMG FLUOstar Omega 96-wells plate reader after 
adding the Bradford reagent (catalogue number: B6916, Sigma) to samples. As 
standards, known concentrations (0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml and 1 mg/ml) 
of the pure Bovine serum albumin (BSA) (catalogue number: A2153, Sigma) were 
used.   
2 µl of the total cell lysates were placed into 96-wells plates in triplicates. 5 µl 
BSA of known concentrations, see above, were also added in triplicates. Then 280 µl 
of Bradford reagent was added for each well. The absorbance was read on a BMG 
FLUOstar Omega plate reader. Then the protein concentration was determined in 
relation to the known BSA concentrations. 
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2.3.1.5 Preparation of samples from mouse heart: 
A. Total lysate: 
Initially, the homogenizer and all of the equipment were sterilised as they were 
washed with deionized H2O and 70 % ethanol. Then, the mouse heart was prepared 
as follows: 
1- The heart was cut down in to small pieces. 
2- The heart was homogenised in 1 ml of either LB1 or LB2. 
3- The both lysates were incubated for 1 hr on rotator shaker at 4 °C.  
4- Samples were centrifuged at 12,000 g at 4 °C for 20 min. 
5- The supernatant was collected, and protein concentration was measured by 
the Bradford assay.  
6- Then, the samples were either prepared for SDS-PAGE or snap frozen and 
stored at -80 °C. 
B. Immunoprecipitation of endogenous OSR1/SPAK: 
To immunoprecipitate endogenous SPAK and OSR1 kinases from the mouse 
heart, pre-clearing steps were carried out as before. Then, 50 µg of conjugated anti-
OSR1 or anti-SPAK antibody was added to 5 mg of total protein lysate (Vitari et al., 
2005). After incubation for 1 hr on rotator shaker at 4 °C, the beads were collected by 
centrifuging at 1,000 g for 5 min at 4 °C. The beads were washed twice by 
resuspending in 1 ml LB1, then centrifuging at 1,000 g for 5 min at 4 °C. After the last 
spin, the beads were washed twice by resuspending in 1 ml buffer A and centrifuging 
at 1,000 g for 5 min at 4 °C. Then, 60 µl of 1x SDS-sample buffer was added to the 
beads and mixed well by bench vertex. Subsequently, the samples were either 
prepared for SDS-PAGE as before or stored at -20 °C.  
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2.3.2 Conjugation of antibodies to protein-G Sepharose beads: 
Overall, to enable protein elution and reduce antibody contamination, all of the 
antibodies used in immunoprecipitation experiments were covalently cross-linked to 
protein-G-Sepharose (catalogue number: PG5-161501, GE Healthcare) using 
dimethyl pimelimidate dihydrochloride (DMP), (catalogue number: D8388, Sigma) via 
the following procedure (Vitari et al., 2005).  
1- The beads were washed three times with 1 ml PBS, centrifuged at 1,000 g 
for 5 min at 4 °C and collected. 
2- The antibody was added to the beads at a 1:1 antibody, mixed well and 
incubated for 1 hr at 4 °C on rotator shaker.   
3- The suspension was then centrifuged at 1,000 g for 5 min at 4 °C, the 
supernatant removed, and the beads were collected. 
4- The antibody-beads conjugates were washed three times with 1 ml PBS and 
centrifuged at 1,000 g for 5 min at 4°C. 
5- After removing the supernatant, the conjugates were resuspended and 
washed twice with 1 ml of 0.1 M sodium borate buffer (pH 9). 
6- This was followed by resuspending the beads in in 1 ml DMP freshly-
prepared buffer [20 mM DMP in 0.1 M sodium borate buffer, pH 9] and 
incubated on rotator shaker at 4 °C for 30 min. 
7- The beads were then collected by centrifuging at 1,000 g for 5 min at 4 °C. 
8- Steps 6 and 7 were repeated twice. 
9- After that, the antibody-beads conjugate was washed twice by resuspending 
in 1 ml 50 mM glycine (pH 2.5) and centrifuging at 1,000 g for 5 min at 4°C. 
10- Finally, after the last spin the antibody-beads conjugate was resuspended 
in 1 ml PBS, stored at 4 °C, and used within 24-48 hrs.   
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2.3.3 SDS-PAGE and Western blot: 
All gels used in this study were resolving (10 % to 12 % acrylamide) and 4 % 
acrylamide stacking, and they were self-prepared following the recipe described in 
(Table 2.3 and Table 2.4). Glass gel formers with space of 1.0-1.5 mm and 10- or 15-
wells combs were used. All of the prepared gels were used either in the same day or 
stored at 4 °C for next day usage. The amount of total proteins loaded in each well 
was 20 µg/well for total cell lysate and 35 µg/well for samples from IP or pulled down 
samples. For each gel, 4-5 µl of molecular weight protein ladder (catalogue number: 
S6-0024, Genflow Ltd, Lichfield, UK) was used. Protein separation by electrophoresis 
was carried out at voltage ranged 160-185 mV for 50-70 min. Then, the proteins were 
transferred to nitrocellulose membranes 0.45 µM (catalogue number: 10600007, GE 
Healthcare) within a Western blot sandwich, which was soaked and assembled in 
transfer buffer containing 20 % methanol. The transfer was performed at 85 mV for 90 
min at 4 °C. Protein transfer was confirmed by soaking the membranes in Ponceau 






1.5 M Tris/HCl (pH8.8) 5ml 5 ml 
30 % acrylamide 4ml 6 ml 
Deionized H2O 5.9ml 3.9 
ml 
20 % SDS 75µl 75 
µl 




TEMED 25µl 25 
µl 
Table 2.3: Recipe of both 10 % and 12 % of SDS-PAGE resolving gels. 
 







       
 
          
Table 2.4: Recipe of 4 % stacking gel of SDS-PAGE. 
 
The transferred membranes were loaded with the proteins were blocked in 
blocking buffer for 1 hr on a table shaker at room temperature. After washing the 
membranes by TBST buffer three timers at 5 min interval, they were incubated with a 
dilution of the relevant primary antibody [5 ml of 5 % non-fat skimmed milk for sheep 
raised antibodies or 5 % BSA in TBST for goat and rabbit raised antibodies] at room 
temperature for 1 hr or overnight at 4 °C on rotator shaker. After this primary antibody 
incubation, the membranes were washed with TBST three times and then incubated 
in 5 ml dilution of the relevant secondary antibody for 1 hr on rotator shaker at room 
temperature. This was followed by washing the membranes with TBST three times 5 
min for each wash. The enhanced chemiluminescent (ECL) reagents A and B 
(catalogue number: 9770467, Amersham) were mixed (1:1) and added on the 
membranes. Then, the membranes were exposed to autoradiographic films 
(catalogue number: 28906839, Amersham). The films were then developed using 
automatic processor (SRX-101, Konica Minolta Medical) and finally the films were 












Deionized H2O 3.82 
ml 
20 % SDS 25 µl 
10 % APS 50 µl 
TEMED 5 µl 
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2.3.4 Biotin-RFxV pulldown of SPAK and OSR1: 
Once HEK293 cells cultured in 10-cm dishes were 80-90 % confluent, they 
were harvested and lysed. Then 1-5 mg of the total cell lysates was incubated with 3 
µg of either the RFQV-peptide, the RFHV-peptide, the AFQV-peptide or the AFHV-
peptide for 15 min at 4 °C on rotator shaker. After incubation, 40 µl of streptavidin 50 
% slurry (which had been washed and equilibrated in lysis buffer) was added to each 
sample. The samples were then incubated on rotator shaker for 15 min at 4 °C.  (Vitari 
et al., 2006). After that, the beads were collected by centrifuging at 1,000 g for 2 min 
at 4 °C. The beads were subsequently washed twice with 1 ml LB1 and washed again 
twice with 1 ml buffer A. Finally, the beads were prepared for SDS-PAGE as described 
above. 
 
2.3.5 GST pull down:  
Once cultured HEK293 cells in 10-cm dishes reached 50 % confluency, they 
were transfected with glutathione S-transferase (GST)-tagged proteins e.g. SPAK and 
OSR1 alone, or co-transfected with other FLAG-fusion proteins. 36 hrs post-
transfections, the cells were harvested by adding 0.4 ml of suitable lysis buffer. Then, 
the cell suspensions were collected and clarified from cellular debris by centrifugation 
at 12,000 g for 10 min at 4 °C. The supernatants were collected, and protein 
concentration was measured by the Bradford assay and the samples were prepared 
for SDS-PAGE to assess protein expression while the remaining lysates were stored 
at -80 °C. 
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Pulldown of GST-tagged proteins was carried out by using glutathione 
Sepharose high performance (GST) beads (catalogue number: 17-527-01, GE 
Healthcare). GST beads were washed with 1 ml PBS three times by incubating with 
PBS and then centrifuging at 1,000 g at 4 °C for 5 min. After this, the collected GST-
beads equilibrated in PBS at 50 % slurry. 0.5 mg of the cell lysates was incubated on 
rotator shaker in a 20 µl slurry of GST-beads either overnight at 4 °C or 1 hr at room 
temperature (Vitari et al., 2006). The beads were then collected by centrifugation at 
1,000 g at 4 °C for 5 min. The collected beads were washed twice with 1 ml LB1 and 
twice with 1 ml buffer A. Finally, the beads were prepared for SDS-PAGE 
electrophoresis as described above.   
2.3.6 Identification of proteins by mass spectrometry: 
To identify OSR1 associated proteins in cardiac tissues, OSR1 was 
immunoprecipitated from mouse heart as described in section 2.3.1.5 B. 35 µl of 
control (empty beads) and OSR1-pulled down sample were loaded onto 10 % 
acrylamide gel. After subjecting the proteins to electrophoresis, the gel was stained by 
Colloidal Blue stain (catalogue number: LC6025, Invitrogen) according to 
manufactures instructions for 6 hrs. Then, the gel was washed by dH₂O for at least 12 
hrs on bench shaker. On the following day, the protein bands were excised (Figure 
3.7) and submitted to the Advanced Mass Spectrometry Facility in School of 
Biosciences at University of Birmingham. Following tryptic digestion of each band 
separately, protein identification by Orbitrap Elite mass spectrometer equipped with 
nano-flow liquid chromatographic (LC) system (LC-MS/MS) was performed. The raw 
files were analysed by Mascot (http://www.matrixscience.com) and the significant 
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probability of identified proteins was P > 95.0 % with at least two unique peptides were 
identified (Chung et al., 2013, Ohta et al., 2013). 
 
2.3.7 ADP-Glo OSR1-T185E kinase in vitro assay: 
The protein kinase OSR1-T185E, MO25α and NKCC2 (1-174) were expressed 
and purified from LB21 E coli section 2.3.8.6 and FLAG-β2AR was 
immunoprecipitated from transfected HEK293 cells section 2.3.1.4 B. Cold ATP was 
used in this assay. The kinase reaction was performed in 1.5 ml tubes at a final volume 
of 25 µl/reaction in triplicate. Each reaction contained 0.4 µM OSR1-T185E with the 
presence or absence of 2 µM MO25α. The substrates were either 250 µM CATCHtide 
(RRHYYYDTHTNTYYLR-TFGHNTRR), 5 µM GST-cleaved NKCC2 (1-174) that were 
used as positive control, or 10 µg beads conjugated to immunoprecipitated β2AR. 
After all proteins were freshly prepared in kinase buffer which containing 10 mM MgCl, 
and 0.1 mM ATP (AlAmri et al., 2018). The samples were incubated on 30 °C for 40 
min on gentle agitation. Then, the samples were transferred into a 96-wells plate and 
developed according manufacturer’s instructions (ADP-Glo kit, Promega). This 
involved adding 25 µl of reagent-1 to each sample and incubation for 40 min at room 
temperature. Then, 50 µl of reagent-2 was added to each sample followed by 
incubation for 1 hr at room temperature (AlAmri et al., 2017a). The luminesce was 
subsequently measured by reading the plate on BMG FLUOStar Omega plate reader. 
The results were analysed by Graph Pad Prism and the data was presented as mean 
± SD of three independent experiments.    
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2.3.8 Molecular biology: 
2.3.8.1 Generation of competent bacterial cells: 
DH5α strain of E. Coli (E. coli) was used for DNA cloning and amplification of 
cDNA for use in mammalian cells whereas LB21 E. coli strain cells were used for 
protein expression in bacteria. Both cells were stored at -80 °C. Once needed, they 
were thawed on ice and 10 µl of DH5α or BL21 cells were added into 10 ml of LB 
media in 50 ml falcon tube. The solution was incubated overnight at 37 °C/200 rpm. 
Next day, to set up the bacterial culture, 1 ml of overnight culture was re-cultured in 
50 ml LB. Then, the new culture was left to grow at 37 °C/180 rpm for overnight. On 
the next day, the optical density (OD) was measured at 600 nm in cuvette 
spectrophotometer, when OD reached about 0.6, the bacterial cells were pelleted at 
1500 g for 10 min at 4 °C. The supernatant was discarded, and the pellets were 
collected and resuspended in 5 ml ice-cold 0.1 M calcium chloride (CaCl). Then, they 
were incubated on ice for 1 hr. Then centrifugation of pellet at 2,000 g for 10 min at 4 
°C. Then, the pellets were resuspended in 2 ml ice-cold 0.1 M CaCl and incubated in 
ice for 15 min. 1 ml of pre-autoclaved 80 % glycerol was added to 2 ml cell solution. 
Finally, cell suspensions were aliquoted and stored at -80 °C.    
 
2.3.8.2 Transformation of E. coli: 
All of the bacterial-related work which includes the media preparation and 
procedures of the transformation were performed under aseptic techniques. E. coli 
cells (DH5α or LB21) were thawed on ice, 50 µl of cells was taken in to pre-autoclaved 
Eppendorf tube. Then, 2-5 µl of the relevant cDNA was added. After gentle mixing, the 
cell suspension was incubated on ice for 10 min and the cells they were subjected to 
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heat shock at 42 °C for 90 seconds. Then, the cells were incubated on ice for 10 min. 
50 µl of transformed E. coli were spread onto pre-warmed LB agar plate that contains 
100 µg/ml ampicillin (catalogue number: A9518, Sigma). The plates were 
subsequently incubated, upside-down, at 37 °C for overnight. On the next day, a single 
colony from the plane was selected and transferred into 250 ml of LB media 
supplemented with100 µg/ml ampicillin. The bacterial culture was incubated at 37 °C 
overnight at 180 rpm. On the following day, for bacterial stock preparation, 500 µl of 
80 % sterile glycerol was added and mixed with 500 µl of E. coli culture, then stocks 
were immediately stored at -80 °C. The remaining DH5α culture was used for DNA 
extraction while LB21 for protein expression. When the bacterial stock was required, 
a single drop of E. coli was transferred in to 50 ml LB media, which was then incubated 
at 37 °C for overnight at 180 rpm, on the next day 10 ml of overnight culture was 
transferred into 250 ml media and continue as mentioned below.   
2.3.8.3 DNA extraction and purification: 
For large scale extraction of plasmids, Qiagen Plasmid Maxi kit (catalogue 
number: 12163, Manchester, UK) was utilized. A 250 ml of overnight transformed 
DH5α culture was transferred to 300 ml centrifuge tube, then it was harvested by 
centrifugation at 6,000 g for 15 min at 4°C. After discarding the supernatant, the 
pelleted cells were resuspended in 10 ml of Buffer P1, which had been supplemented 
with RNase. Then, the flask content was transferred into 50 ml falcon tube and 10 ml 
of Buffer P2 (lysing buffer) was added and mixed thoroughly by inversion until a blue 
colour developed, which indicates full lysis. After this, the suspension was incubated 
at room temperature for 5 min. Subsequently, 10 ml pre-chilled P3 (neutralising buffer) 
was added followed by vigorous mixing until the blue colour turns to white. The 
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suspension was then incubated for 20 min on ice. Then, the suspension was 
centrifuged at 16,000 g for 30 min at 4°C to remove cell proteins, debris and 
precipitated genomic DNA. The provided extraction column was equilibrated and 
washed with the supplied buffer QBT. The purified supernatant was applied to column 
and allowed to flow through the column by gravity. Then, it was washed twice with 30 
ml of buffer QC. The bound DNA plasmid was eluted by adding 15 ml of buffer QF 
(elution buffer) and 10.5 ml of isopropanol was subsequently added to the filtrate to 
precipitate the plasmid DNA. The solution was centrifuged at 16,000 g for 30 min at 
4°C. After careful disposal of the supernatant, the pelleted DNA was washed with 5 ml 
of 70 % ethanol and it was then centrifuged at 16,000 g for 10 min at 4 °C. Ethanol 
was discarded and the pelleted plasmid DNA was left to dry for 5 min then 
resuspended in to 1 ml nuclease-free water (catalogue number: P1193PRO, Promega, 
Southampton, UK). The purified DNA was subsequently quantified as described 
below. 
 
2.3.8.4 DNA quantification: 
The concentration of the purified DNA was performed by using BMG LABTECH 
LVis plat (a low volume microplate). The microplate was cleaned and 2 µl of the 
samples were then loaded followed by 2 µl of nuclease-free water. The absorbance 
was determined by a BMG LABTECH PHERAStar plate reader. All of the samples 
were run in duplicates. The significant purity of DNA was determined as 260/280 1.8, 
and any DNA displayed less than that value was considered to be contaminated with 
proteins or debris and thus discarded. All of the purified DNAs were aliquoted to reduce 
the thawing/freezing cycle and stored at -20 °C.  
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2.3.8.5 DNA sequencing: 
All of the purified plasmid DNAs were subjected to sequencing for identity 
confirmation. This was carried out by Functional Genomic Proteomic and Metabolic 
Facility of School of Bioscience at University of Birmingham. When the results were 
obtained, they were analysed by Chromas 2.1.1, Technelysium and the nucleotide 
sequences were aligned by BLAST versus nucleotide database.  
 
2.3.8.6 Expression and purification of MO25α, OSR1-T185E and NKCC2(1-174): 
Competent LB21 E. coli cells were transformed with MO25α, OSR1-T185E or 
NKCC2 (1-174) as described above. The cells were transferred to LB agar plates and 
after growth at 37 °C, a single colony was selected and transferred in to 200 ml LB 
supplemented with ampicillin (100 µg/ml). The culture was incubated at 37 °C for 
overnight at 180 rpm. On the next day, 50 ml of the overnight culture was transferred 
into 1 L of LB with ampicillin (100 µg/ml) and the flask was incubated at 37 °C with 180 
rpm shaking. The OD of the incubated culture was measured every 30-40 min at 600 
nm. When the OD reached 0.7, 250 µM of isopropyl β-D-1-thiogalactopyranoside 
(IPTG) was added and the cells were incubated for a further 16 hrs at 26 °C with 180 
rpm shaking. On the following day, the cells were harvested by centrifugation at 3,500 
g for 30 min at 4 °C. Each flask pellet was resuspended in 50 ml ice-cold bacterial lysis 
buffer and incubated for 30 min on ice. The bacterial cells were lysed by sonication; 
six cycles of 30 seconds each. Then to remove residual debris, the homogenised cells 
were centrifuged at 14,500 g for 30 min at 4 °C. Following the filtration of the 
supernatant though pre-washed 0.45 µM filters, the supernatant was incubated 
overnight on rotator shaker at 4 °C with pre-washed GST-beads (at ratio of 1.5 ml 
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beads per 1 L of bacterial culture). On the next day, the GST-beads were collected by 
centrifugation at 3,000 g for 2 min, then they were washed with normal buffer twice. 
The washing steps were repeated with high salt buffer then with buffer A. After the last 
wash, 1:1 ratio of buffer A was added to the beads. The GST-fused protein, which was 
attached to the beads, was incubated by PreScission protease (40 µg protease for 1 
ml beads) for 30 min at room temperature followed by incubation for overnight at 4 °C. 
After that, to elute the proteins, the beads-protein suspension was transferred to 
column and washed three times with normal buffer under gravity. The collected filtrate 
was concentrated by centrifugation at 3,000 g at 4 °C to using columns with integrated 
3 KDa molecular weight cut-off. The purity of the proteins was characterized by 15 % 
SDS-PAGE and their concentrations was determined by the Bradford assay. The 
proteins were stored at -80 °C.   
 
2.3.9 Quantification of the β2AR by biotin cell membrane labelling: 
Cell surface proteins could be quantified using Western blotting after being 
selectively isolated from whole cell lysates using a thiol-cleavable amine-reactive 
biotinylation reagent, EZ-LinkTM Sulfo-NHS-SS-Biotin (catalogue number: 21331, 
Thermo Fisher). For this purpose, HEK293 cells were firstly cultured in 6-well plates 
and once they reached 50 % confluency, they were transiently transfected with FLAG-
β2AR. 36 hrs post-transfection, the cells were either left unstimulated or stimulated 
with the relevant conditions. After this, they were washed by 1 ml PBS and detached 
in 1 ml PBS by cell scraper. The cells from each well were subsequently transferred 
into 1.5 ml Eppendorf tubes and centrifuged at 400 g for 5 min at 4 °C. Then, the cells 
were resuspended in 1 ml ice-cold PBS and 80 µl of 10 mM the biotinylation reagent 
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was added to each tube to reach a final concentration of 0.8 mM (~ 0.48 mg/well) 
(Moore et al., 2004). The cells were then incubated on rotator shaker at room 
temperature for 30 min then pelleted by centrifugation at 400 g for 5 min at 4 °C. To 
quench the biotinylation reaction, the cells were washed twice with 1 ml 30 mM Tris 
(pH 8.0) by resuspension and centrifugation at 400 g for 5 min at 4 °C. The cells were 
homogenised in 120 µl of LB3 (supplemented with 1% (w/v) final concentration of n-
dodecyl β-D-maltoside, but without the reducing agent 2-mercaptoethanol). Then, the 
suspension was vortexed and incubated on rotator shaker for 2 hrs at 4 °C. The lysate 
was clarified by centrifuging at 12,000 g for 10 min at 4 °C. To collect the biotinylated 
surface proteins, 80 µl of streptavidin slurry was added to each sample and then 
incubated for 4 hrs on rotator shaker at 4 °C. After that, the streptavidin beads were 
pelleted by centrifuging at 1,000 g for 2 min. The beads were subsequently washed 
twice with 1 ml of LB3 that lacks 2-mercaptoethanol and centrifuged at 1,000 g for 2 
min. After two more washes in 1 ml of buffer A were performed, the disulphide bonds 
were cleaved off to release the biotinylated proteins from the streptavidin beads. For 
this, the final pelleted beads were resuspended in 80 1x SDS sample buffer 
(containing 5% 2-mercaptoethanol) then incubated at 90 °C for 10 min and centrifuged 
at 12,000 g (Moore et al., 2004). Then samples were stored at -20 °C. After the results 
have been obtained by immunoblotting, the protein bands were quantified using 
ImageJ and they were plotted by GraphPad prism v.5. Data presented as mean ± SD 
of two separate experiments. 
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2.3.10 Flow cytometric detection of surface the β2AR: 
HEK293 cells were cultured in 6-well plates and when they were 50 % 
confluent, they were transiently transfected with FLAG-β2AR using the PEI method. 
36 hrs post-transfection, the cells were treated by the appropriate drugs according to 
the experimental design and for the indicated times. Then, the cells were washed once 
by 1 ml PBS and were detached by adding 1 ml of 10 mM EDTA in PBS per well and 
incubated for 10 min at 4 °C. Subsequently, the cells were centrifuged at 400 g for 5 
min at 4 °C. The pelleted cells were resuspended in 200 µl blocking buffer (0.5 % BSA 
in PBS) and 200 µl of 0.5 % BSA/PBS. Cell count was performed using hemocytometry 
and about 250,000 cells were transferred into fresh 1.5 ml tubes followed by 
centrifugation at 400 g for 5 min at 4 °C. After removal of the supernatant, the cells 
were resuspended in 100 µl primary anti-FLAG antibody (prepared in 0.5 % BSA/PBS) 
and the cells were incubated for 60 min at 4 °C. Then, they were washed three times 
with 200 µl of 0.5 % BSA/PBS followed by centrifugation at 400 g for 5 min at 4 °C. 
The cells were resuspended and incubated with 100 µl of the secondary FITC-tagged 
antibody (prepared in 0.5 % BSA/PBS) in dark for 1 hr at 4 °C. Subsequently, the cells 
were pelleted at 400 g for 5 min at 4 °C and washed three times with 200 µl of 0.5 % 
BSA/PBS. Finally, they were transferred into flow cytometry polypropylene tubes (final 
volume of 400 µl 0.5 % of BSA/PBS) and assed in same day using ADP Cyan flow 
cytometer (Beckman). The obtained data was analysed by FlowJo.V10. 
2.3.11 Detection of surface β2AR by ELISA: 
HEK293 cells were cultured and transfected with FLAG-β2AR using PEI. The 
cells were plated in pre-coated 96-well plates, labelled with antibodies and the 
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quantification of the receptors was performed by measuring the absorbance in a Bio-
Rad plat reader. 
2.3.11.1 Coating the plates with attachment factor: 
Poly-D-lysine (PD-L) (catalogue number: P6407, Sigma) was used for plate 
coating. In a cell culture cabinet, 100 µl/well was added and incubated for 30 min. 
Then, the PD-L was aspirated, and plate was washed three times with 200 µl/well with 
sterile dH₂O. After the last wash, dH₂O was aspirated and the plate was left in the hood 
for 2 hrs until the water was completely evaporated. The plate was then stored at 4 
°C. 
2.3.11.2 Monitoring the internalization of the β2AR by ELISA: 
HEK293 cells were plated in T75 flask and when they reached 50 % confluency, 
they were transfected with 7 µg of FLAG-β2AR using PEI. On the next day, the cells 
were detached with 2 ml PBS and transferred into a PD-L pre-coated 96-well plate 
and were seeded at 10,000 cells/well in 100 µl media. On the following day, the cells 
were pre-labelled with primary mouse anti-FLAG antibody (catalogue number: F3165, 
Sigma) at 1:1,000 dilution in ELISA blocking buffer. Simultaneously, some samples 
were also pre-incubated with either 10 µM St STOCK1S-50699 (St) or 1 µM 
propranolol (Pro) for 1 hr at 4 °C. After that, the cells were washed three times with 
200 µl PBS, then either left unstimulated or treated by 1 µM Isoproterenol (Iso) and 
hypotonic low chloride buffer (HLB) for 1 hr at 37 °C.  Subsequently, the cells were 
washed three times with 200 µl PBS and then labelled with secondary goat anti-mouse 
(alkaline phosphatase) antibody (1:5,000 dilution in ELISA blocking buffer) for 1 hr at 
4 °C. After incubation, unbound antibodies were removed by washing three times with 
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200 µl PBS. To develop the colour, 100 µl of one-step p-nitrophenyl phosphate 
disodium salt (catalogue number: 37621, Thermo Fisher) was added. The plate was 
then gently mixed by agitation for 30 min until colour developed. After this, the reaction 
was stopped by adding 50 µl of 2N NaOH. Finally, the absorbance was measured at 
405 nm on plate reader (Bio-Rad). The background control samples were transfected 
cells labelled with mouse-IgG isotype control. The plot of membrane β₂AR was 
generated by Graph Pad Prism 5 and the quantity of the surface receptors was 
normalised to untreated samples and presented in mean of single experiment.    
2.3.12 Peptide docking by AutoDock: 
Docking of the RFQV- and RFHV-peptides into OSR1-CCT domain was carried 
out using AutoDock Vina1.12 (AlAmri et al., 2017a). For this, the PDB file of the OSR1 
CCT domain was prepared by AutoDock tool 1.5.6. Unbiased docking of the RFHV-
peptide into OSR1-CCT (PDB ID: 2V3S) was performed and the interactions were 
confirmed by re-docking of RFQV-peptide as well in the same binding site (AlAmri et 
al., 2018).   
2.3.13 Statistical analysis: 
All of the plotted diagrams were generated using GraphPad Prism 5 and the 
data was presented as the average of a minimum of three independent replicates ± 
SD, unless indicated otherwise with the n value (number of replicates) shown in the 
figure’s legends. To determine statistical significance, the samples were compared 
against the control, and P values were calculated using one-way ANOVA for more 
than two samples and Student T-test for two samples where P < 0.05 was considered 
to be significant. 
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Chapter  3 : Results and discussion 
 
  
3.1 Characterization of the WNK and β2AR signalling pathways 
Before getting into dissecting the relationship between the WNK and β2AR 
signalling cascades and exploring the effect of each protein on the other, the drugs, 
buffers and antibodies that will be used for such studies needed to be characterised.  
3.1.1 Optimisation and characterization of WNK signalling. 
Since WNK kinases are inactive under resting conditions and they became 
activated under osmotic stress or by changes in chloride concentration as mentioned 
in the introduction, we first had to establish and optimise the conditions of WNK-
signalling activation. Endogenous WNK1 could be stimulated by either hyperosmotic 
agents such as sorbitol (Sor) or by hypotonic low chloride buffer (HLB) (Richardson 
and Alessi, 2008). This is known to induce phosphorylation of WNK1 at Ser382 and 
subsequent direct phosphorylation of Thr233 and Ser373 of SPAK and Thr185 and 
Ser325 of OSR1, which we could be used as the readout for WNK activation 
(Richardson and Alessi, 2008). 
As Sor can stimulate other signalling pathways which are mediated by other 
kinases such as ERK1/2, JNK and p38, (Zagórska et al., 2007) and the underlying 
mechanism by which WNK kinase stimulation is not yet elucidated (Rodan and Jenny, 
2017), HLB was used in this study to trigger WNK-signalling. To test the HLB activation 
of WNK-signalling, HEK293 cells were treated for 30 minutes (min) with HLB (Figure 
3.1). To validate WNK1 signalling activation, STOCK1S-50699 (St) (a SPAK/OSR1 to 
WNK binding inhibitor) (Kikuchi et al., 2015) was added after exposure to HLB at 10 
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or 30 µM for 30 min (de Los Heros et al., 2014). As expected, the activation of WNK-
signalling cascade was clearly observed following HLB treatment as judged by SPAK 
Ser373 phosphorylation (lane 2). This phosphorylation was inhibited completely by the 
addition of 10 or 30 µM St, (lane 3 and 4, Figure 3.1), as compared to the control 
(untreated cells) (lane 1, Figure 3.1). 
Figure 3.1: WNK signalling pathway stimulation by HLB and its inhibition by STOCK1S-
50699. (C) Immunoblot analysis of treated HEK-293 cells with HLB for 30 min which induced 
WNK signalling activation and SPAK phosphorylation at Ser373 residue (lane 2). Pre-treatment 
of cells with STOCK1S-50699 (St) for 30 min with the indicated concentrations 10 and 30 µM 
(lanes 3 and 4 respectively), blocked the WNK1-mediated activation of SPAK. Phosphorylation 
of SPAK in (C) was evaluated by densitometry (A) and (B) which it was normalized to total 
SPAK. (A) Phosphorylated SPAK in 63 kD was activated by HLB and was inhibited with addition 
of St, that indicating WNK-mediated SPAK Ser373 phosphorylation. (B) This SPAK 
phosphorylation also increased with HLB but however did not respond to St pre-treatment which 
unlikely to be a phosphorylated Ser373 residue (de Los Heros et al., 2014). The figure shows 
single experiment (n = 1). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as 




                                                                                                                                  
96 
 
To further validate the activation and inhibition of WNK-SPAK/OSR1 signalling, 
the specificity of WNK-signalling inhibitors (AlAmri et al., 2017b, Yamada et al., 2016) 
and antibodies that recognise phospho-proteins e.g. phospho-NKCC1, were 
assessed. The WNK ATP-competitive kinase inhibitor WNK463 (AlAmri et al., 2017b, 
Yamada et al., 2016) was added to HEK293 cells at the indicated doses for 30 min 
and St was used a as a positive control while the negative control was HLB-only 
treated cells (Figure 3.2). As demonstrated in previous report by Yamada et al, our 
results re-confirmed the fact that WNK463 is able to produce a significant WNKs 
inhibition in HEK293 cells (Yamada et al., 2016), which prevents the WNK-mediated 
NKCC1 phosphorylation and activation at approximately 5 µM as compared to 20 µM 
with St (lane 3). Moreover, the high level of WNK activation was noticed by exposing 
cells to HLB (lane 2) and this was reduced or completely prevented by addition of 3 















Figure 3.2: Optimisation of WNK kinases inhibition by WNK463.  
(A) Representative Western blot analysis of endogenous NKCC1 phosphorylation 
in extracts from HEK293 cells. The analysis includes unstimulated (vehicle was 
DMSO only treated cells), HLB treated cells or cells treated with WNK463 at the 
indicated doses. In comparison to 20 µM St, WNK463 induced WNK1 inhibition at 
5 µM (lane 7), as it prevented NKCC1 phosphorylation by HLB. (B) Densitometric 
analysis of NKCC1 phosphorylation in (A), demonstrated a surge activation of 
NKCC1 with HLB and this stimulation was completely prevented with 20 µM St and 
5 to 20 µM WNK463. Data represent mean ± SD of two independent experiments 
(n=2). ** P < 0.0025, *P < 0.05, (ANOVA with post-Bonferroni’s test). GAPDH 
(1:5,000), NKCC1 (2 µg/ml), NKCC1-pT203+T207+T212 (2 µg/ml). 
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3.1.2 Characterization of β2AR signalling pathway: 
3.1.2.1 Optimization of the β2AR expression in mammalian cells: 
Generally, most of the GPCRs including β2AR have very low abundance in 
native tissues (Maeda and Schertler, 2013). This makes studying the signalling and 
biological structures of these receptors a stern challenge. Therefore, establishing an 
effective protein expression system for these GPCRs is essential to obtain a suitable 
amount of the protein for biological analysis (Maeda and Schertler, 2013). Among 
these systems is GPCRs expression in mammalian cell lines, which has several 
advantages as it provides a natural environment for the requirement of membrane-
protein expression e.g. lipid composition, post-translation modifications, and protein 
folding (Maeda and Schertler, 2013). A prime example of the expression of GPCRs in 
mammalian cells is that of rhodopsin, which could be expressed in HEK293S cells at 
~ 10 mg/L, where these cells lacking N-acetylglucosaminyl transferase 1 (GnTI) and 
they have been developed in suspension, to be adapted to express a variety of  
mammalian receptors (Chaudhary et al., 2012).  
In this work, HEK293 cells were predominantly used for exploring the link 
between WNK signalling pathway and β2AR. The endogenous expression of β2AR is 
extremely low approximately 0.02 pmol/mg in HEK293 cells (Han et al., 2012), a 
finding also confirmed during the optimization steps of the receptor expression in these 
cells (Figure 3.3, lane 1 and 2). Thus, overexpression of the β2AR was used for the 
purpose of the study. The choice of HEK293 cells for this work was also supported by 
the fact that these cells express endogenously all of the components of the WNK-
signalling cascade; WNK1 and 4, SPAK, OSR1, MO25, Cul3, KLHL3 and the various 
ion co-transporters (e.g. NKCC1) (Vitari et al., 2006, Filippi et al., 2011, Ohta et al., 
2013). 


















The N-terminally FLAG-tagged β2AR was transiently expression in HEK293 
cells using PEI (Method Chapter). To optimise the overexpression of the β2AR in 
HEK293 cells, the cells were first cultured in 6-well plates and then they were 
transfected with different ratios of β2AR cDNA clone and PEI (Figure 3.3). The cells 
were harvested by lysis buffer 2 (LB2), which contains 1 % NP40 and supplemented 
with 1 % (w/v) n-dodecyl β-D-maltoside (DDM). The cell lysates subsequently 
Figure 3.3: Optimization of FLAG-β2AR expression in HEK293 cells. 
Immunoblot analysis of FLAG-β2AR expression in extracts from HEK293 cells. 
Untransfected cells (lane 1) and 12 µg PEI only (lane 2) did not show expression 
of the β2AR. Transfected cells using cDNA: PEI ratios of 1:2 and 1:4 showed the 
best expression ratio (lanes 3 and 5 respectively). The validation of β2AR 
expression was confirmed using both anti-FLAG and anti-β2AR antibodies. 
Please note that the result represents a single experiment (n=1) which was 
performed to determine the best cDNA: PEI ratio for HEK293 transfection.  
1 Un-transfected cells. 
2 PEI only treated cells (12 µg).  
3 Transfected cells at ratio 1:2. 
4 Transfected cells at ratio 1:3. 
5 Transfected cells at ratio 1:4. 
6 Transfected cells at ratio 1:5. 
FLAG (1:1,000), β-catenin (1:1,000), β2AR (1:500). 
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underwent SDS-PAGE electrophoresis and the membranes were probed for the β2AR 
using anti-FLAG and anti-β2AR antibodies. This showed that the receptors were 
successfully overexpressed with a MW ~ 48 kD and these bands were not present in 
the untransfected cells (lanes 1 and 2, Figure 3.3). This experiment showed the cDNA: 
PEI ratios of 1:2 and 1:4 resulted in significant overexpression of the β2AR with the 
1:2 ratio being the most efficient. Hence, going forward in this work, for the 












After the overexpression conditions of β2AR in HEK293 cells were optimized, 
the extraction of receptors from the cell lysates was occasionally poor and needed to 
be optimised (Figure 3.4). This is because GPCRs generally possess both 
amphipathic character; lipophilic surfaces which enable them to interact with lipid 
               
Figure 3.4: Poor solubilization and extraction of β2AR.  
Immunoblot analysis of the β2AR solubilisation and extraction from HEK293 cells. 
Cells were transfected with FLAG-β2AR and then treated with HLB, isoproterenol 
(Iso), propranolol (Pro) or left unstimulated (NS). After that, they were lysed using 
LB2 and prepared for SDS-PAGE. The receptors were probed for using the anti-
β2AR antibody. As shown, the unstimulated and Iso treated samples had low 
expression of the receptors that because of lysis buffer (LB2) was not efficient for 
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membrane and hydrophilic areas that are directed towards to aqueous intracellular 
and extracellular environments (Loll, 2014) as well as inherent instability when not 
bound to membranes (Maeda and Schertler, 2013). These features affect the 
receptor’s solubility and isolation from cell membranes (Loll, 2014). 
To improve the extraction of the β2AR from cell membranes, there was a need 
to identify a suitable lysis buffer that not only facilitates the receptor extraction from 
membrane bilayer, but it also helps to maintain receptor solubility and stability in the 
aqueous solution by adsorption of receptor’s lipophilic sides within the detergent 
micelles (le Maire et al., 2000). These complexes are highly dynamic molecules as the 
detergent monomers are in equilibrium between the free form state and aggregated in 
to the detergent-receptor complexes. Therefore, to overcome the receptor’s 
hydrophobicity, the availability of free detergent monomers must be maintained in the 
aqueous solution (Loll, 2014). To reach this point, the detergent concentration in the 
solution should be kept higher than the critical micellar concentration (CMC) (Loll, 
2014). However, extremely elevated concentrations of the detergent could induce 
receptor inactivation. This highlights the necessity of adjusting the detergent 
concentration. Moreover, the solubility of membrane receptors depends on the 
biophysical and biochemical properties of the detergent (Prince and Jia, 2013).  
Finding of a suitable lysis buffer that has ability to extract the receptors from 
membranes and maintain both receptor folding and protein interactions is necessary. 
Previous reports indicated that supplementing lysis buffer 3 (LB3) with DDM and 
incubating samples for least 2 hrs was very effective in solubilizing the β2AR (Han et 
al., 2012). For the characterization of LB3, LB3 was initially tested versus LB2 and 
RIPA (Figure 3.5). LB3 produced a significant change in term of receptor solubilization 
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and isolation from biological membranes of HEK293 cells (Figure 3.5) and it gave the 












Subsequently, LB3 was mainly used and receptor expression was primarily 
assessed by the use of anti-FLAG antibody before continuing with the downstream 
procedures. The β2AR was identified by mouse anti-FLAG antibody which has 
negligible cross reactivity. Interestingly, the β2AR existed in two forms; higher 
migrating monomers and homodimers, which they have been observed at ~ 50 kD and 
~ 100 kD respectively in 10 % SDS-PAGE (Figure 3.6) (Bulenger et al., 2005).       
 
 
                
Figure 3.5: Western blot analysis of LB3 characterization for β2AR 
solubilisation in HEK293 cells. HEK293 cells were either left untransfected 
(lane1) or transfected with FLAG-β2AR-WT (lanes 2-4). The cells were lysed by 
different lysis buffers: lanes 1 and 2 cells harvested with LB3, LB2 (lane 3) or RIPA 
(lane 4). β2AR was probed for by anti-FLAG antibody. The receptors were only 
detected in LB3 harvested cells with a MW at ~ 48kD reflecting the monomeric form 
of the receptor (n=1). FLAG (1:1,000), β-catenin (1:1,000). 
 















3.1.2.2 Characterization of the β2AR signalling cascade: 
In addition to the assessment of receptor’s expression, the compounds that 
have been used in this study to manipulate the β2AR had first to be characterised. 
These include Isoproterenol (Iso), a full βAR agonist, ICI118551(ICI), a high affinity 
β2AR inverse agonist and propranolol, a non-selective βAR antagonist. To determine 
an appropriate concentration of Iso for receptor stimulation, Iso was added to the β2AR 
transfected HEK293 cells at different concentrations (Figure 3.7). From then the 300 
nM and 1 µM were chosen for β2AR stimulation and internalization respectively 
throughout the study. To identify the β2AR activation, probing for phosphorylated 
serine residues e.g. Ser345 and Ser346 have been performed by using specific 
antibodies against these residues (Gao et al., 2014). Unfortunately, phosphorylation 
at these sites was not detected (Figure S1). As agonist-stimulated β2AR elevates 
cAMP and activates PKA, which phosphorylates the liver kinase B1 (LKB1) at Ser428 
(Sapkota et al., 2001, Zheng et al., 2009), we next probed for LKB1 pS428. We were 
 
Figure 3.6: Western blot analysis of the 
FLAG-β2AR expression in HEK293 cells. 
HEK293 were cultured in 10-cm plates and 
transiently transfected with the β2AR cDNA 
clone. After 48 hrs, the cells were lysed in ice 
cold LB3 and incubated for 2 hrs at 4 ˚C. Then, 
they were subjected for SDS-PAGE. β2AR was 
probed by anti-FLAG antibody. Monomeric 
β2AR was detected at 50 kD and bands around 
100 kD indicated homodimer formation (n =1). 
FLAG (1:1,000).  
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able to detect the phosphorylated LKB1 Ser428 through β2AR activation pathway. 
Thus, LKB1 was used for detection agonist-stimulated β2AR, and this phosphorylation 




To obtain optimum inhibition of Iso-mediated activation of the β2AR, ICI was 
added to cells prior exposure to Iso at various concentrations 10 nM, 30 nM, 100 nM 
and finally 1 μM (Figure 3.8). This resulted in that 30 nM of ICI showed inhibition of 
Figure 3.7: Isoproterenol dose-dependent stimulation of the β2AR.  
(A) Representative Western blot of LKB1 phosphorylation in HEK293 cells. Cells 
were transfected with FLAG-β2AR-WT and 48 hrs post-transfection, they were 
treated with Isoproterenol (Iso) at the indicated concentrations for 30min. 
Phosphorylation of LKB1 at Ser428 was observed from 3 nM and gradually 
increased to reach 1 μM then reduced at 10 μM. GAPDH and β-catenin were used 
as housekeeping proteins (B) Densitometry analysis of LKB1 phosphorylation was 
carried out, where phospho-LKB1 was normalised to total LKB1, and data present 
in mean ± SD of three independent experiments  (n=3). FLAG (1:1,000), β-catenin 
(1:1,000), LKB1 (1:1,000), pLKB1(1:1,000), GAPDH (1:5,000). 
 
                                                                                                                                  
105 
 
phosphorylation of LKB1 and thus the activation of the β2AR, a finding is in the 
agreement with previous reports (Kitagawa et al., 1995). Going forward, 1 μM of the 



















Figure 3.8: ICI118551 inhibition of Isoproterenol stimulation of β2AR.  
(A)HEK 293 cells were transiently transfected with FLAG-β2AR-WT and after 48 
hrs, the cells receptors were at first either left unstimulated or treated with 
ICI118551 (ICI) at indicated concentration for 60 min. These cells were then either 
left unstimulated or treated with 300 nM of Iso for 30 min. (B) ICI118551 blocked 
the effect of 300 nM Iso from 30 nM as judged by the inhibition of LKB1 
phosphorylation at Ser428. Data represented a single experiment (n=1). FLAG 
(1:1,000), LKB1 (1:1,000), pLKB1 (1:1,000), GAPDH (1:5,000). 
 
                                                                                                                                  
106 
 
3.2 Molecular interaction of SPAK and OSR1 to β2AR: 
3.2.1 Molecular docking of β2AR-derived RFHV into OSR1 CCT: 
Human OSR1 and SPAK protein kinases share 68 % sequence homology and 
possess two high conserved regions; an N-terminal kinase domain and a CCT domain 
that has 79% sequence similarly between SPAK and OSR1 (Villa et al., 2007). The 
CCT domain enables SPAK and OSR1 to interact with RFxV tetrapeptide motifs from 
upstream activators, i.e. WNK isoforms, and of downstream substrates NKCC1, 
NKCC2 and NCC (Alessi et al., 2014). This interaction takes place in the primary 
pocket of the CCT domain (Richardson and Alessi, 2008). Truncation of the CCT in 
both kinases abolishes the binding of SPAK and OSR1 to their upstream and 
downstream proteins (Vitari et al., 2006). 
Interestingly, the crystal structure of the β2AR revealed that the receptor 
possesses a single RFHV motif (239-242) at ICL3, which matches the SPAK and 
OSR1 RFxV tetrapeptide binding motif (Rasmussen et al., 2007). To investigate 
whether the β2AR’s RFHV peptide interacts with the same residues of OSR1 CCT that 
bind to RFQV, we initially performed molecular docking of the RFHV tetrapeptide into 
the structure of OSR1 CCT domain (Figure 3.9 A). The docking results showed that 
the WNK kinases RFQV and the β2AR’s RFHV peptides docked in the same primary 
pocket on OSR1 CCT domain. Like the RFQV tetrapeptide interactions, the Arg, Phe 
and Val of the β2AR’s RFHV peptide were found to be important for forming 
interactions with the OSR1 CCT domain.  This also showed that Asp459 and Lys473 
of OSR1 CCT domain formed key interactions of the RFHV peptide of the β2AR 
(Figure 3.9 B). This is an interesting finding, as a single pointed mutation in these two 
residues was shown to abolish the binding of OSR1 to the RFxV motif of either NKCC1 
or WNK1/4 (Vitari et al., 2006). These results indicated that the β2AR’s RFHV 
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tetrapeptide is likely to bind OSR1 CCT domain akin to how the WNK RFxV peptides 


















Figure 3.9: Molecular docking of β2AR-derived RFHV into OSR1-CCT domain. 
The cartoon showing interaction of RFQV and RFHV with OSR1-WT (A) The 
protein surface of OSR1-CCTRFHV (pink) showed to have same binding site as 
RFQV (green) in OSR1(PDB code: 2V3S). Arg, Phe and Val of both peptides 
shared similar docking. While His of RFHV is protruded outward like Gln of RFQV. 
(B) Diagram illustrate the most crucial two residues, lys473 and Asp459 of CCT 
that are involved in the interaction with RFQV. Figures were generated by 
AutoDock Vina. This docking experiment was performed by Mubarak Alameri.     
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3.2.2 Binding of the β2AR-derived RFHV peptide to endogenous SPAK  
In order to examine the proposed interaction of the β2AR’s RFHV peptide to 
SPAK/OSR1 CCT, we investigated the binding ability of N-terminally biotinylated wild 
type (WT) RFHV and its mutant AFHV peptides to endogenous SPAK in HEK293 cells. 
Initially, 1 mg of HEK293 cell lysate was incubated with 3 µg of the indicated peptide 
followed by biotin-streptavidin pulldown. This initial attempt showed that endogenous 
SPAK did bind the RFQV peptide as expected, but its binding to the RFHV was very 
low (Figure S2). To optimise this assay, SPAK was then pulled down by incubating 1-
10 mg of total cell lysate with 3 µg of either the RFQV or the RFHV peptides. The 
peptides were pulled down by adding streptavidin beads and SPAK binding to the 
peptides was assessed by blotting for SPAK (Figure 3.10). As expected, endogenous 
SPAK bound the RFHV peptide at 1, 5 and 10 mg of total cell lysates while 5 mg of 
total cell lysate was the best concentration for both peptides binding to SPAK as RFQV 
appeared to have less binding ability to SPAK with less than 5 mg of total protein cell 
lysate in contrast to the previous finding. 
   
Figure 3.10: Optimization of the interaction of the RFHV peptide to 
endogenous SPAK in HEK293. 3 µg of indicated RFxV peptides was incubated 
with different concentrations of HEK293 cell lysate as indicated. This was followed 
by biotin-streptavidin pull down of the biotinylated peptide and blotting for 
endogenous SPAK. TL: Total lysate (n =1). SPAK (2 µg/ml). 
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Next, to verify the binding of the β2AR’s peptide to SPAK, 5 mg cell lysate was 
incubated with either WNK4-derived RFQV peptide (positive control), AFQV peptide 
(negative control), RFHV-peptide or AFHV-peptide. After pulling down the peptides 
with streptavidin beads, SPAK was probed for by immunoblotting.  The results 
revealed that SPAK successfully bound to RFQV-peptide while AFQV failed to bind to 
SPAK. Similarly, the RFHV was also shown to bind endogenous SPAK similar to the 
RFQV while mutant AFHV did not (Figure 3.11). These findings validated our 
hypothesis that the β2AR’s RFHV-peptide interacts with SPAK at cellular level. This is 
in agreement with previous studies that showed that RFxV tetrapeptides bind SPAK 





Figure 3.11: The biotinylated RFHV-peptide interacts with endogenous SPAK.                 
Representative IB analysis of SPAK binding to the RFHV peptide. 5 mg lysate from 
untransfected HEK293 cells was incubated with biotinylated RFQV, AFRV, RFHV or 
AFHV-peptides. This was followed by biotin-streptavidin pulldown and Western blot 
for endogenous SPAK. Results represented of three independent experiments (n=3). 
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3.2.3 D459A and L473A mutations in OSR1 CCT inhibit the binding to the 
RFHV peptide 
To further confirm the interaction between CCT OSR1 and the β2AR’s RFHV 
peptide in more detail, we investigated the ability of RFHV-peptide interaction with full 
length GST-OSR1-T185E, or with two OSR1 CCT domain single point mutations 
namely GST-OSR1-T185E-D459A and GST-OSR1-T185E-L473A. The choice of 
these two OSR1 CCT domain mutants was due to their ability to abolish the binding 
to the RFQV peptide (AlAmri et al., 2017a, Villa et al., 2007). In our experiments, the 
WNK4 RFQV peptide was used as positive control. Following the overexpression of 
these proteins in HEK293 cells, the binding of these proteins to biotinylated RFQV or 
RFHV peptides was assessed using biotin-streptavidin. The results revealed that the 
β2AR-derived RFHV peptide binds only to OSR1-T185E and not those with the CCT 
domain mutants (Figure 3.12). This indicated that the β2AR’s RFHV peptide docks 
into OSR1 CCT domain akin to how the WNK4 RFQV peptide does and such docking 
involves the interaction between the RFHV peptide to the OSR1 CCT domain D459 
and L473 residues. This interaction is similar to how the WNK4 RFQV peptide binds 
the primary pocket of CCT-OSR1 as verified by numerous reports in the literature 
(Gagnon et al., 2007b, Piechotta et al., 2002). As the β2AR’s RFHV peptide is located 
in the intracellular loop ICL3 of the receptor and SPAK and OSR1 kinases are 










3.2.4 Identification of OSR1 associated proteins in the heart: 
Encouraged by the possible β2AR binding to SPAK and OSR1 kinases from 
the data discussed above, we subsequently planned to explore such binding at the 
endogenous level. First, we performed immunoprecipitation (IP) of endogenous OSR1 
from mouse (Mus Musculus) heart lysate, using a highly selective anti-OSR1 antibody 
that had been covalently conjugated to protein-G-Sepharose beads (Methods 
Chapter). The isolated proteins were stained by Colloidal blue stain after samples 
were separated by SDS-PAGE gel electrophoresis. Then, the gel was cut into twenty-
Figure 3.12: The RFHV-peptide binds to OSR1 but not OSR1 CCT domain 
mutations D459A or L473A. HEK293 cells were transfected with GST-OSR1-
T185E (FL), GST-OSR1-T185E+D459A or GST-OSR1-T185E+L473A. 48 hrs post 
transfection, the cells were lysed, and affinity purification was performed by biotin-
streptavidin pulldown. The purified samples (pull down) were subjected to SDS-
PAGE and OSR1 was probed by anti-GST antibody. The input indicates the cell 
lysates before pulldown. The same results have been obtained from three 
independent experiments (n=3). GAPDH (1:5,000), GST (1:1,1000).         
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two pieces without gaps as shown in Figure 3.13.  Lanes 1 to 11 were the empty 
beads (negative control), which was devoid of antibody, to identify proteins that may 
bind non-specifically to the beads while immunoprecipitated samples (OSR1-IP) were 
represented in lanes 12 to 22 (Figure 3.13). The samples were subsequently 
subjected to trypsin digestion and analysis by mass spectrometry (MS). To identify the 
proteins from which the peptide came from, the mass spec raw data were analysed by 
Mascot (Ohta et al., 2013).  
 
Once the Mascot files were obtained, the proteins that were identified in the 
empty beads were extracted from the proteins in samples 12-22. Then, the amino acid 
sequences of the remaining proteins were analysed to identify whether they have 
RFxV/I motif (Delpire and Gagnon, 2007). This led to the identification of 27 proteins 
that contain such motif (Table 3.1), but only 17 of which have a significant mascot 
  
 
Figure 3.13: OSR1 immunoprecipitation 
from mouse heart lysates.  
Mouse heart was harvested by LB2 and 
OSR1 was immunoprecipitated from 5 mg 
lysate, using anti-OSR1 antibodies 
covalently conjugated to Sepharose beads. 
Following the electrophoresis of samples, 
proteins were visualised by Colloid Blue 
staining. Molecular weight is on the right-
side, empty beads (negative control) (lanes 
1 to 11) while immunoprecipitated sample 
was OSR1-IP (lanes 12 to 22). Lysis buffer 
2 (LB2). Results were obtained from single 
experiment (n =1).  
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score 67 (P < 0.05) with at least 2 peptides matched, a criteria often used in analysing 
such mass spec data (Table 3.1) (Ohta et al., 2013).  
Encouragingly, we were able to identify the WNK isoforms with high mascot 
scores WNK1 (830), WNK2 (144), WNK3 (89) and WNK4 (97). Since WNK kinases 
are established and verified as SPAK and OSR1 kinases’ binders, the results gave us 
confidence in the outputs of this OSR1 IP experiment. Analysing the other positive 
OSR1 binders from this IP showed that the β2AR protein was not present. 
Nevertheless, several proteins whose functions are associated with the β2AR 
signalling have been identified. Indeed, several novel proteins were identified as 
possible binders to OSR1, most of which are related to molecular transport. These 
include ryanodine receptors 1, 2, and 3 (RYR), which are protein channels mediating 
Calcium (Ca) release from sarcoplasmic reticulum to cytosol and promoting cardiac 
contractility. These proteins have multiple RFxV motifs and have high mascot scores 
ranging from 101 to 1321 Table 3.1. RYR form homo-tetramers that create large ion-
channels. Notably, RYR2 is mostly expressed in heart and it is regulated by PKA and 
Ca/calmodulin-dependent kinase-2, which phosphorylate of RYR at Ser2808, Ser2814 
and Ser2030 as a result of βAR activation and cAMP elevation (Denniss et al., 2018). 
However, studying these proteins represents technical challenges as they have large 
molecular weights, human RYR1 (570 kD), human RYR2 (569 kD) and human RYR3 
(557 kD).   
Among the other protein hits identified from the OSR1 IP experiment was the 
anion related protein carrier known as the voltage dependent anion -selective channel 
protein (VDAC1), which has a Mascot score of 441 and VDAC3 which had a lower 
score of 42 (Table 3.1). Both VDAC1 and 3 contain an RFGI-motif that could enable 
OSR1 binding. VDAC1 is located at outer membrane of mitochondria, and it regulates 
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Ca transport in and out of the mitochondria (Shoshan-Barmatz et al., 2017a). 
Moreover, it controls the movement of numerous metabolites like succinate, malate 
and pyruvate between the mitochondria and the cytoplasm (Shoshan-Barmatz et al., 
2017a). VDAC1 is also involved in several signalling and metabolic pathways though 
interaction to many protein proteins as thoroughly reviewed by Shoshan (Shoshan-
Barmatz et al., 2017b). Remarkably, VDAC1 was found to be associated with the 
β2AR in proteomic analysis (Chung et al., 2013). Thus, our mass spec link between 
VDAC1 and OSR1 could provide a molecular mechanism of the proposed VDAC1 and 
β2AR signalling interplay.  
Interestingly, the Na/K pump β1-sbunit and glucose transporter member-4 
(GLUT4) were also identified to have RFDV and RFLI motifs respectively from the 
OSR1 IP (Table 3.1). The Na/K pump consists of α- and β-subunits and could link 
OSR1 to other ions regulating pathways such the β2AR. Activation of the β2AR 
elevates the cellular activity of the Na/K pump through the cAMP-PKA pathway in 
alveolar cells, and this activation was mediated by increased assembly of Na/K pump 
α-subunit in plasma membrane (Bertorello et al., 1999, Mutlu and Factor, 2008). As 
the β-subunit  of this pump is the one that contains a RFxV/I motif, this indicates that 
OSR1 could bind the β-subunit, which is required for a fully functional Na/K pump (Xie 
et al., 2013). Due to the versatility of GPCRs, this could propose that the signal may 
be transduced from β2AR to Na/K pump α-subunit and β-subunit via the activation of 
PKA and OSR1 respectively.  
GLUT4 enhances glucose entrance into muscle cells and adipocytes in 
response to insulin, where insulin stimulates GLUT4 trafficking to the plasma 
membrane through involvement of several proteins such as sortilin, VAMP2, IRAP and 
LRP1 (Bogan, 2012). Intriguingly, as mentioned earlier (Introduction Part), 
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hyperinsulinemia, systemic insulin resistance, is associated with increase salt 
reabsorption in kidney due to elevated activity of the WNK-SPAK/OSR1-NCC cascade 
(Nishida et al., 2012). This metabolic syndrome is also manifested by the disruption of 
glucose absorption as a result of  reduction of GLUT4 in addition to down regulation 
of the β2AR in patients with cardiac complications of diabetes (Mishra et al., 2010).  
Moreover, OSR1 could be linked with many other proteins that involved in 
several metabolic pathway which could be associated with the β2AR, such as 
Succinyl-CoA ligase, NADH-dehydrogenase and Acetyl-Co-A carboxylase-2 (Chung 
et al., 2013). These enzymes were found to have RFxV motif (Table 3.1) and showed 
high Mascot scores. This reveals the importance of OSR1 in the cell metabolism 
beside ion homeostasis. Altogether, this exercise did not only highlight the novel role 
of OSR1 in cellular processes but also encouraged our pursuit of the possible 
association of WNK-SPAK/OSR1 to the β2AR signalling pathway.  
As mentioned above, the β2AR was not detected in our MS results despite the 
high Mascot score of OSR1 (1504) and the fact that MS is the method of choice for 
the identification of protein-protein interactions (Daulat et al., 2009). MS as a 
technique, however, has some limitations in identification of GPCR protein partners 
because of the low expression levels of β2AR in the heart as it consists only 20 % of 
βAR and obstacles of working with such proteins. This difficulty is also related to the 
structural features of the β2AR, which has high hydrophobicity and inherited flexibility 
that makes the receptor poorly extractable from native tissue and less soluble or 
misfolded in the solution, which ultimately reduces  the receptor’s interactions with its 
protein partners (Helbig et al., 2010, Rabilloud, 2009).  
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  Gel 
lane 









  18 Serine/threonine kinase (OSR1) 58.46 1504 117 33 / 
1 * 12 Ryanodine receptor 2 (RYR2) 569.64 1321 114 99 RF[R/A][I/V] 
2 12 Serine/threonine-protein kinase WNK1  251.8 830 46 38 RF[I/Q/S]V 
3 * 19 Succinyl-CoA ligase beta subunit (SUCB2) 47 569 28 20 RFFV 
4 * 21 Gap junction alpha 1 (CXA1) 43.49 563 29 11 RFWV 
5 * 22 Voltage dependent anion-selective channel 
protein (VDAC1) 
32.5 441 21 13 RFGI 
6 * 22 NADH dehydrogenase (NDUA9) 42.61 404 22 14 RFRV 
 
17 STE20/SPS1-related proline-alanine rich 
kinase (SPAK) 
60.79 203 10 8 
 
7 * 12 Spectrin beta chain erythrocytic (SPTB1) 245.89 200 18 18 RF[Q/D]I 
8 12 Serine/threonine-protein kinase WNK2 228.9 144 12 11 RF[K/S]V 
9 * 19 Sodium/potassium transport ATPase beta1 
subunit (AT1B1) 
35.57 138 11 8 RFDV 
10* 12 Ryanodine receptor 3 (RYR3) 556.9 134 21 19 RF[A/W][V/I
] 
11 * 22 Serine/threonine-protein phosphatase 
(PP1B) 
37.9 131 7 5 RFNI 
12 * 12 Ryanodine receptor 1 (RYR1) 570.38 101 16 16 RFAV 
13  12 Serine/threonine-protein kinase WNK4 133.3 97 7 7 RF[Q/T][V/I]  
14 * 12 Acetyl-CoA carboxylase 2 (ACACB) 277.96 93 12 11 RF[V/F][V/I]  
15 12 Serine/threonine-protein kinase WNK3 195.4 89 9 9 RFQV 
16 * 21 Facilitated glucose transporter member4 
(GLUT4) 
54.94 90 5 5 RFLI 
17 * 21 Creatine kinase M-type (KCRM) 43.2 51 4 4 RFCV 
18 * 21 Phosphorylase B kinase gamma catalytic 
chain (PHKG1) 
45.3 50 3 3 RFLV 
19 * 13 Serine/threonine-protein kinase MRCK beta 
(MRCKB) 
196.5 46 4 4 RFYI 
20 * 22 Voltage dependent anion-selective channel 
protein (VDAC3) 
31  42 2 2 RFGI 
21 * 13 1-phopshatidylinositol 4,5 bisphosphate 
phosphodiesterase (PLCH2) 
189.6 29 9 9 RFLV 
22 * 12 E3 ubiquitin protein ligase (HERC2) 533.9 24 11 11 RF[L/M/T]I/
V] 
23 * 19 Glycerol kinase (GLPK) 62 22 3 3 RFLV 
24 * 15 Inositol hexakisphosphate 
diphosphoinositol-pentakisphosphate 
kinase 
128.4 22 5 5 RF[F/H]V 
25 * 12 Ubiquitin-like modifier-activating enzyme 1 
(UBA1) 
119 16 2 2 RFEV 
26 * 13 E3 ubiquitin protein ligase  227 16 8 7 RFVV 





Table 3.1: Identification of OSR1-associated proteins in the heart by mass 
spectrometry. The labelled lanes in (Figure 3.13) were excised, and proteins were 
defined by mass spectral peptide mass fingerprint. The identified proteins that have > 67 
mascot score (P < 0.05) and peptide match > 2, were considered to be significant. 
Proteins arranged according to their mascot score. (*) refers to the novel proteins that 
have identified in this study. Molecular weight (MW), RFxV/I-peptide; OSR1/SPAK 
binding motif. Results had been obtained from a single experiment (n=1).   
 
 
                                                                                                                                  
117 
 
To overcome such difficulties, Kobilka’s group developed a new strategy for 
mimicking cell membranes, where receptors are integrated in lipid bilayer 
environment, by the reconstitution and preparation of the β2AR in high density 
lipoprotein (HDL) molecules (Chung et al., 2013). This allows the reconstituted β2AR 
to be in a folded form and stabilised by insertions into the lipid bilayer to mimic its 
conformation and stability in vivo. These molecules were then utilized as a bait to 
attract protein partners from the lysate of bovine heart (Chung et al., 2013). Among 
the many proteins identified by MS to bind the reconstituted β2AR, endogenous SPAK 
was identified as a possible binder (Chung et al., 2013). Notably, in the Kobilka study, 
they did not further verify the β2AR interaction with SPAK and OSR1. Still, this finding 
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3.2.5 Identification the interaction of β2AR to SPAK in the heart: 
Since the direct interaction between the β2AR and SPAK/OSR1 kinases was 
not confirmed by MS, we then moved on to the use of Western blot. Indeed, to further 
verify the Kobilka finding discussed above, we performed the IP of endogenous SPAK 
from mouse hearts that had been homogenized using two different lysis buffers, LB1 
or LB2 (Method Chapter). The samples were then separated by SDS-PAGE and the 
proteins were identified by immunoblotting for endogenous β2AR. Encouragingly, no 
β2AR were detected in the empty beads (EB) lanes (Figure 3.14). Notably, the β2AR 
was detected at approximately 48 kD in both SPAK IP samples (Figure 3.14). 
Furthermore, β2AR seems to be highly dissolved in LB2 as its abundance was more 
than that in LB1. This confirms the fact that the interaction between SPAK/OSR1 and 
the β2AR takes place in biological systems. This IP result emphasized the molecular 
docking and peptides pulldown experiments which revealed that like RFQV-motif, the 
RFHV-peptide in this case, has the same binding affinity to SPAK/OSR1 CCT domain. 
Moreover, this result also supports previous literatures that demonstrated 
SPAK/OSR1 binding to their protein partners, NKCC, NCC and WNK isoforms, was 
mediated by the RFxV motif (Piechotta et al., 2002, Richardson et al., 2008).  
 







Figure 3.14: Western blot analysis of the β2AR binding to SPAK at 
endogenous level in mouse heart lysate. To determine the solubility of receptors, 
mouse heart was harvested by two different lysis buffers, LB1 and LB2. Then SPAK 
protein was immunoprecipitated (SPAK-IP) by conjugated anti-SPAK antibody, 
samples were subjected to SDS-PAGE gel, and β2AR was probed by anti-β2AR 
antibodies. EB was negative control. Before IP was performed, the interested 
proteins were probed top blot, SPAK and OSR1 successfully identified, SPAK 
arrow indicated while (*) for non-specific bands most likely due to OSR1 cross 
reactivity. Please consider that mouse SPAK is ~ 10 kDa larger than human. 
GAPDH housekeeping protein. Abbreviations: Empty beads (EB). Lysis buffer1 and 
2 (LB1) and Lysis buffer2 (LB2). The result was obtained from single experiment 
(n=1). GAPDH (1:5,000), SPAK (2 µg/ml), OSR1 (2 µg/ml), β2AR (1:500).  
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3.2.6 The interaction of SPAK and the β2AR is mediated by RFHV-motif: 
By inspecting the crystal structure of the human β2AR, it was noted that it 
contained a single RFxV-motif, (RFHV, residues 239 -242 at ICL3) (Rasmussen et al., 
2007) which is a highly conserved sequence for binding SPAK/OSR1 kinases (Delpire 
and Gagnon, 2007, Villa et al., 2007). To validate the interaction of this GPCR with 
SPAK and provide evidence whether the interaction is mediated though the RFHV 
motif, FLAG-β2AR WT or FLAG-β2AR R239A were co-expressed with GST-SPAK full 
length in HEK293 cells. Furthermore, FLAG-NKCC2 WT full length, which contains the 
RFQV motif (RFQV, sequences 20-23) or NKCC2 R20A full length (where Arg20 was 
mutated to Ala) have been used as positive and negative controls respectively (Figure 
3.15).  To assess the interaction, overexpressed SPAK was isolated by GST-pull down 
and Western blotting with an anti-FLAG antibody was performed. The results showed 
that the β2AR-WT as well as NKCC2-WT did bind SPAK (Figure 3.15). However, this 
binding was abolished by single pointed mutation, β2AR R239A, although this 
mutation did not interfere with the receptor expression (Figure 3.15). Similarly, NKCC2 
R20A reduced the binding as observed previously by others (Richardson et al., 2011). 
As noted, the β2AR monomers were around 48 kD while the top bands at about 100 
kD could represent oligomeric and glycosylated forms of the receptor (Figure 3.15) 
(Ng et al., 2012, Mialet-Perez et al., 2004).  
Depire’s group have been demonstrated that SPAK/OSR1 interacted with 
NKCC1, NKCC2 and KCC3 through yeast 2 hybrid experiments, and the binding was 
confirmed by pulldown and co-immunoprecipitation assays which it took place through 
physiological docking of RFxV/I motifs of these co-transporters into CCT of 
SPAK/OSR1 (Piechotta et al., 2002, Villa et al., 2007, Vitari et al., 2006). And this 
docking was necessary for their phosphorylation and activation (Richardson et al., 
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2011), and single pointed mutations within the motif not only abolished their binding, 
but also inhibited their subsequent phosphorylation (Gagnon et al., 2007b, Vitari et al., 
2006). Herein, our pulldown revealed that the wild type of both NKCC2 and β2AR 
interacted with SPAK in biological system while a single point mutation of Arg20 and 
Arg239 of NKCC2 and β2AR respectively to Ala abolished their binding to SPAK and 
OSR1 kinases. This confirms the binding of SPAK to β2AR is principally mediated 




































Figure 3.15: The molecular binding of SPAK to β2AR is mediated by RFHV-motif. HEK293 
cells were transiently co-transfected with GST-SPAK and either with FLAG-NKCC2-WT, FLAG-
NKCC2-R20A, FLAG-β2AR-WT or FLAG-β2AR-R239A. 48 hrs post-transfection, cells were 
harvested by LB1 and LB3 (for β2AR solubilization), then collected lysates (input) were 
subjected to SDS-PAGE and IB where GST-tagged and FLAG-tagged proteins were probed by 
anti-GST and anti-Flag antibodies respectively for confirming their expression (left blot). (Right 
blot) shows GST-SPAK purification by GST pulldown assay, and FLAG-tagged proteins were 
detected by anti-FLAG antibody. FLAG-NKCC2-WT and FLAG-β2AR-WT bind to GST-SPAK 
(lanes 3 and 5), while mutation of R to A of RFxV-motif of both proteins reduces the interaction 
significantly (lanes 4 and 6). Lanes 1 and 2 were negative controls total cell lysate (input) and 
GST-empty vector (GST) respectively. Same results have obtained in three independent 
experiments (n=3). GST (1:1,1000), FLAG (1:1,000).   
 
                                                                                                                                  
123 
 
3.2.7 Characterization of the β2AR interaction to SPAK CCT domain: 
To explore the interaction of the β2AR to SPAK/OSR1 CCT domain in more 
details and to validate whether the docking of the β2AR’s RFHV-motif takes place in 
the primary pocket of SPAK/OSR1 CCT domain. A competition experiment was 
conducted where HEK293 cell were co-transfected with FLAG-β2AR-WT and GST-
SPAK and following cell lysis the lysates were cleared by incubation with empty GST 
beads. Then, RFQV-peptide or AFQV-peptide were added to compete the binding of 
overexpressed FLAG-β2AR to overexpressed GST-SPAK (Method Chapter). To 
assess the interaction, GST-SPAK was isolated by GST beads pulldown assay in the 
absence or presence of the peptides and pulled down material underwent Western 
blotting for the β2AR using ant-FLAG antibody. Untransfected and GST-empty vector 
transfected cells were used as negative controls. The results showed that FLAG-β2AR 
interacted with GST-SPAK further confirming our previous studies, while the addition 
of the RFQV peptide prevented such binding (Figure 3.16). The AFQV peptide, as 
anticipated, did not inhibit the binding of SPAK to the β2AR (Figure 3.16). This is in 
line with previous studied where such mutations was shown to make the peptide 
incompatible for binding to OSR1 and SPAK CCT domains (Vitari et al., 2006). In the 
same context, surface plasmon resonance (SPR) analysis and pulldown assays 
utilizing numerous single point mutations in RFQV peptide revealed that the RFQV 
and RFxV peptides have similar affinity to OSR1 CCT domain (Vitari et al., 2006). This 
further indicates that the β2AR’s RFHV peptide is able to interact with SPAK/OSR1 
and could be competed out by the WNK RFQV peptide. Moreover, it was 
demonstrated that SPAK/OSR1-binding peptides inhibited the binding of endogenous 
NKCC1 to those enzymes by a competition mechanism as NKCC1 contains two RFxV-
motifs (Vitari et al., 2006, Villa et al., 2007). As the β2AR has a single RFHV sequence, 
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the RFQV peptide was sufficiently able to inhibit the binding. However, the RFHV 
binding to SPAK was also abolished by the AFQV peptide though why this occurred 
in this case remains unclear.  Overall, this set of results further supports out hypothesis 
that  the β2AR binds SPAK and OSR1 kinases by the docking of the receptors RFHV 
motif into SPAK and OSR1 kinases’ CCT domains akin to how WNK kinases bind 
















Figure 3.16: RFQV-peptide competes the binding of overexpressed 
FLAG-β2AR to GST-SPAK. Representative IB demonstrates the effect of 
RFQV and AFQV-peptides on SPAK-β2AR interaction. HEK293 cells were co-
transfected with GST-SPAK and FLAG-β2AR. 48 hrs post transfection cells 
were lysed, and 1 mM RFQV or AFQV were added to 500 µg cell lysate. GST 
pulldown assay was performed to assess the interaction between SPAK and 
β2AR. Anti-FLAG antibody was used to probe the receptor, FLAG-β2AR bound 
to GST-SPAK in absence of peptide (lane3), adding RFQV prevent the binding 
as well as adding AFQV which was unexpected. Experiment was done nine 
times (n=9). Arrow indicates GST-SPAK expression. Abbreviation: UnT, un-
transfected cells. GST-EV, GST-empty vector. GST (1:1,1000), FLAG 
(1:1,000).        
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3.3 OSR1 phosphorylates the β2AR in vitro: 
SPAK and OSR1 kinases phosphorylate their substrates, e.g. NKCC1, NKCC2 
and NCC, by docking the RFxV motifs of these ion co-transporters into SPAK and 
OSR1 CCT domains. After the interaction between SPAK/OSR1 and the β2AR has 
been established, we explored whether SPAK and OSR1 kinases phosphorylate the 
β2AR in vitro. To do this, we overexpress FLAG-β2AR WT and FLAG-β2AR R239A in 
HEK293 cells performed their pulldown using anti-FLAG antibody and used them in 
SPAK and OSR1 in vitro kinase assays.  
After the conjugated antibody was added to 1 mg HEK293 cell lysate at the 
indicated concentrations (Figure 3.17), the samples were incubated and then washed 
and prepared for SDS-PAGE. Several controls were used, the negative controls were 
untransfected total lysate, IP from untransfected lysate and empty beads. The positive 
control was total lysate of β2AR WT transfected cells. The result indicated the 
successful immunoprecipitation of β2AR WT as the receptor was detected at ~ 50 kD 
in IP sample where the ratio of antibody: cell lysate with 30 µg: 1 mg ratio showing the 
least of the receptor quantity being pulled down as compared to 5,10 and 20 µg of 











Figure 3.17: Western blot demonstrated the expression and immunoprecipitation 
of FLAG-β2AR in HEK293 cells. (A) HEK293 cells were left un-transfected or either 
transiently transfected with FLAG-β2AR-WT or FLAG -β2AR-R239A. Then cells were 
harvested with LB3 and samples were subjected to SDS-PAGE and expressed proteins 
were probed by anti-FLAG antibody that shown a great specificity as no bands were 
observed on un-transfected cells (lane 1) and receptors were detected on wild type (WT) 
and mutant samples (lane 2 and 3) at MW 48 and 75 kD which represented monomeric 
and dimeric receptors respectively. (B) FLAG-β2AR-WT was immunoprecipitated with 
anti- FLAG antibody from 1 mg cell lysate. The ratio of antibody: cell lysate 
concentrations have been optimized, antibody concentration started with 5 µg to 30 µg 
while cell lysate was 1 mg (lane 5 to 8). Also, IP was done from un-transfected cells (lane 
4) which was used as negative control beside the empty beads, that were utilised to 
identify non-specific bound proteins. Another, controls have been also used to determine 
antibody efficiency and specificity, for this purpose total cell lysates of un-transfected 
and transfected (input) have been used. The immunoprecipitated proteins were probed 
by both anti-β2AR (top blot) and anti-FLAG (bottom blot). This experiment was 
preformed once (n = 1), to determine the best concentration of anti-FLAG antibody to be 
used for IP of FLAG-β2AR. GAPDH (1:5,000), FLAG (1:1,000), β2AR (1:500). 
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To explore whether the β2AR could be phosphorylated by SPAK/OSR1, an in 
vitro OSR1 ADP-Glo kinase assay (Zegzouti et al., 2009) was carried out where the 
immunoprecipitated WT and mutant β2AR were washed and prepared as substrates 
for the reaction. The constitutively active GST-OSR1 T185E, where threonine (T) 185 
was mutated into glutamic acid (E) to mimic WNK1 phosphorylation, and the 
scaffolding protein MO25 were expressed and purified from E. coli (Filippi et al., 2011). 
Moreover, cation chloride co-transported peptide (CATCHtide), a stretch 198-217 of 
human NKCC1 (Vitari et al., 2006), was also used as positive SPAK and OSR1 peptide 
substrate. 
As shown in Figure 3.18 A, OSR1 T185E phosphorylated β2AR WT with a 
similar phosphorylation efficiency the SPAK and OSR1 peptide substrate CATCHtide. 
Interestingly, a single pointed mutation of R239A in OSR1-binding motif of β2AR 
reduced significantly the phosphorylation of the receptor by about 45 % (Figure 3.18). 
This suggested that the docking of the β2AR RFHV-motif into OSR1-CCT domain is 
not only crucial for the binding to OSR1 but it also important for receptor 
phosphorylation. 
Although OSR1-T185E has ability to phosphorylate CATCHtide which devoid 
of RFxV-motif, the integrity of binding motif is crucial in the phosphorylation of RFxV 
containing substrates  (Vitari et al., 2006). It was previously reported in comparison 
analysis between CATCHtide and NKCC1(1-260), RFQV-motif containing protein, that 
OSR1-T185E truncated CCT-domain was able to efficiently phosphorylate CATCHtide 
while NKCC1(1-260) was poorly phosphorylated (Vitari et al., 2006). Moreover, the 
phosphorylation of NKCC1, NKCC2 as well as NCC by SPAK/OSR1 was dependent 
on RFxV/I motif docking into their CCT domains and the phosphorylation of these co-
transporters had been strikingly reduced by mutation of the R to A at their RFxV/I-
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motif. This highlighted the importance of the RFxV to both the binding and the 
phosphorylation of endogenous substrates (Moriguchi et al., 2005, Richardson and 
Alessi, 2008, Richardson et al., 2011, Vitari et al., 2006). In agreement with this, our 
results where OSR1 regulates the phosphorylation of human β2AR in vitro, and this 
phosphorylation is mediated by the β2AR’s RFHV-motif binding to the OSR1 CCT-
domain. Interestingly, we also demonstrated that a single individual mutation R239A 
in this motif results in a significant reduction in the phosphorylation of the receptor.  
Figure 3.18: ORS1-T185E phosphorylates β2AR WT and R239A mutation reduces its 
phosphorylation in vitro. Representative ADP-GloTM kinase assay of 250 µM 
CATCHtide, 10 µg β2AR-WT and 10 µg β2AR-R239A. Substrates were incubated with 
OSR1T185E and MO25α for 30 min. Luminescence was detected by plate reader. (A) 
β2AR-WT (lane 3) was phosphorylated similarly to CATCHtide (lane 2) by OSR1-T185E. 
The control (lane 1) was CATCHtide in kinase buffer in absence of OSR1. B) Data of β2AR-
R239A in (A) was normalized to β2AR-WT (WT), to stress the significant decrease of β2AR 
phosphorylation by R239A mutation. Results represent mean ± SD of triplicate samples 
from three independent experiments (n =3). P value was calculated by ANOVA with post-
Bonferroni’s test in (A) and Student’s t-test in (B). P < 0.05 was determined as statistical 
significance. *** P value < 0.0001 and ** P value < 0.0025. Red dotted line in (B) indicates 
50 % of maximum phosphorylation activity. FLAG (1:1,000). 
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In order to further validate the phosphorylation of the β2AR is dependent on the 
catalytic activity of OSR1 T185E,  we performed an in vitro kinase assay to which 
Verteporfin (VP), a SPAK and OSR1 kinase inhibitor, was added (AlAmri et al., 2018). 
VP is used clinically as a therapy of diabetic retinopathy and tumours (Scott and Goa, 
2000). Firstly, we investigated the inhibitory effect of VP on OSR1-T185E activity using 
NKCC2 WT (1-174) as a substrate (Figure 3.19). The results revealed that NKCC2 
(1-174) phosphorylation was inhibited by VP in a dose-dependent manner.   
Figure 3.19: Verteporfin inhibition of OSR1-T184E In vitro kinase assay.  
In vitro ADP-GloTM kinase assay showing the inhibition effect of Verteporfin (VP). (A) 5 
µM NKCC2 (1-174) was incubated either alone (lane 1) or with 0.4 µM GST-OSR1-T185E 
in absence of VP (lane 2) or in presence of the drug in indicated doses (lanes 3-6), which 
resulted in a dose dependent reduction of the catalytic activity of OSR1-T185E. B) 
Normalised data in (A) to the control (without VP, lane 2 in A). All data represent mean ± 
SD of triplicate samples from single experiment (n = 1). Arrow indicates NKCC1 (1-174) 
in Coomassie Blue stain. Red dotted line in (B) indicates 50% of maximum kinase activity. 
GST (1:1,000).  
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After validation of the VP inhibitory effects on OSR1 T185E kinase activity in 
vitro, we run the kinase assay of using the β2AR as a substrate and a parallel assay 
that employs NKCC2-(1-174) as control (Figure 3.20). Notably, the assay was run in 
the absence or presence of 5 µM VP. Interestingly, the results revealed a noticeable 
phosphorylation of both NKCC2 and β2AR and this phosphorylation was completely 
inhibited by the OSR1 kinase inhibitor VP. Even though the β2AR could be  
phosphorylated by several protein kinases such PKA and GRK (Rosenbaum et al., 
2009), our results suggest that it could also be phosphorylated  by OSR1 though this 
still needs to be confirmed in cells and in vivo. 
             
Figure 3.20: In vitro phosphorylation of β2AR by OSR1-T185E and inhibition 
by VP. In vitro ADP-GloTM kinase assay of NKCC2 (1-174) and FLAG-β2AR-WT 
were incubated with GST-OSR1-T185E without or with presence of 5 μM VP. 
Similar phosphorylation of NKCC2 (1-174) and β2AR-WT was observed with 
OSR1T185E, while 5 μM VP interestingly reduced the phosphorylation significantly. 
All data represented in mean ± SD of triplicate samples from three independent 
experiments (n=3). ANOVA with post-Bonferroni’s test was performed for statistical 
analysis. ***P value<0.0001 and **P value<0.0025. Arrow in Coomassie Blue stain 
indicates NKCC2 (1-174). The dotted red line indicates 50 % of maximum kinase 
activity. FLAG (1:1,000), GST 1:1,000). 
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3.4 Binding of the β2AR does not alter the catalytic activity of SPAK and 
OSR1 kinases:  
In this section, the effect of the β2AR binding to OSR1 on its catalytic activity 
was examined. Specifically, a series of in vitro kinase assays were performed in the 
absence or presence of the β2AR’s RFHV or AFHV peptides. The kinase assays 
employed bacterially expressed OSR1 T185E and the CATCHtide or NKCC2 (1-174) 
as substrates. The results demonstrated that the addition of the β2AR’s RFHV peptide 
did not have any substantial effect on OSR1 T185E’s ability to phosphorylate 
CATCHtide (Figure 3.21 A and B). A similar result was observed with the sample 
supplemented with the AFHV peptide instead of the RFHV peptide. This suggests that 
the docking of the β2AR’s RFHV motif itself into the OSR1 CCT domain does not affect 
the catalytic activity of the enzyme though it is needed for their binding (Figure 3.15).  
To further confirm that the RFHV peptide does not alter OSR1 kinase activity 
but rather it competes with binding of the substrate, a kinase assay that uses the 
NKCC2 (1-174), which contains an RFQV motif, was carried out. Surprisingly, similar 
results as to the ones observed with the CATCHtide were noted in this experiment as 
there was no variation between OSR1’s ability to phosphorylate NKCC2 (1-174) either 
without or with RFHV peptide (Figure 3.21 C and D). Notably, this is contrary to what 
was observed when studying WNK and NKCC2 binding to SPAK and OSR1 kinases 
since the authors demonstrated that the RFQV and RFXV peptides reduce 
dramatically the phosphorylation of NKCC1 (1-260) while CATCHtide phosphorylation 
has not been affected (Vitari et al., 2006). We probably did not reach the same 
conclusion as previous work because we used N-terminally biotinylated peptides 
RFHV peptides and this may have lower binding affinity to OSR1 CCT as compared 
to the untagged peptide. Overall, these experiments showed that the β2AR’s RFHV 
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motif binding to OSR1 does not regulate affect its kinase activity but may influence the 



















Figure 3.21: RFHV-peptide does not alter OSR1-T185E activity in vitro. In vitro 
ADP-GloTM kinase assay demonstrated the effect of RFHV-biotinylated peptide on 
OSR1 activity. (A) 250 μM CATCHtide and 0.4 μM GST-OSR1-T185E were 
incubated either with/without 1mM of indicated [R/A]FHV-peptide at 30 ̊ C for 30 
min. Then the phosphorylation was determined. The phosphorylation of 
CATCHtide has not been affected by either RFHV or AFHV-peptides which 
revealed that RFHV-derived β2AR peptide binding does not alter the catalytic 
activity of the kinase. (B) Data in (A) are presented as relative to control i.e. un-
treated samples (lane 2). No significant reduction of OSR1 kinase activity was 
detected. (C) Same reaction in (A) however NKCC2(1-174) was used instead, no 
alteration of OSR1 activity was also observed with RFHV addition. (D) Normalized 
RFHV data to control. All results represented as mean ± SD for triplicate samples. 
Results shown have been obtained from single experiment (n=1). The red dotted 
line in (B) and (D) represented to 50 % enzymatic activity.  
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3.5 SPAK/OSR1-independent internalization of β2AR in hypotonic stress: 
Like most GPCRs, the β2AR has a typical feature of rapid deactivation and 
internalization following agonist binding (Han et al., 2012). This rapid attenuation is 
mediated by PKA, PKC and GRK phosphorylation of certain Ser/Thr residues in 
receptor’s cytoplasmic domains. Phosphorylated β2ARs fully uncoupled from protein-
G when and associate with β-arrestin which interact with clathrin to initiate the 
receptor’s endocytosis (Iyer et al., 2006). At this stage, the β2AR trafficking is 
considerably regulated by post-endocytic ubiquitination or deubiquitination 
mechanisms that ultimately result in either its degradation or recycling respectively 
(Han et al., 2012).  
As we have shown that OSR1 kinases phosphorylate the β2AR in vitro as 
discussed above, we studied the effect of SPAK and OSR1 activation in cells on the 
internalisation of the β2AR. For this, HEK293 were transfected with FLAG-β2AR WT 
and cell surface proteins were quantified by enzyme linked immunosorbent assay 
(ELISA) or flow cytometry while biotinylated proteins were probed by immunoblotting 
(Lam et al., 2013) 
3.5.1 Identification by Western blotting: 
To determine if HLB activated SPAK/OSR1 is involved in the internalization of 
the β2AR, HEK293 cells transfected with FLAG-β2AR WT were left untreated, as 
negative control, or treated with HLB, to activate WNK-SPAK/OSR1 signalling, or Iso 
to activate the β2AR signalling and lead to the receptor’s internalisation. Also, 
STOCK1S-50699 (St), a SPAK/OSR1 kinase inhibitor, Propranolol (Pro), non-
selective βAR antagonist or ICI (Nasrollahi-Shirazi et al., 2016, Kitagawa et al., 1995), 
were used.  Cell surface proteins were labelled with biotin as reported (Cao et al., 
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2005)  and described in the Method Chapter). This was followed by lysis and 
streptavidin pulldown and Western blotting (Figure 3.22).  
HLB triggers WNK-SPAK/OSR1-NKCC1 signalling cascade, as indicated by 
phosphorylation of endogenous NKCC1 at N-terminal regulatory residues Thr 203, Thr 
207 and Thr 212, also SPAK/OSR1 phosphorylate another key residue Thr217 which 
it was not explored in this work. It was reported that Thr 212 and Thr217 are 
fundamental residues for NKCC1 function, because mutations of either of these two 
residues significantly inhibited the activation of the transporter by hyper- or hypotonic 
stress (Gagnon et al., 2007b, Richardson and Alessi, 2008). Notably, St is strongly 
able to prevent the phosphorylation of these NKCC1 residues by inhibition of WNK1-
mediated SPAK/OSR1 activation (de Los Heros et al., 2014). As illustrated in below 
figure, Iso caused agonist-mediated receptor internalization approximately 55 % of 
total membrane β2AR (P < 0.001) (Figure 3.22 A, lane 4), which it was principally 
inhibited by Pro and ICI (lanes 5 and 6). The activation of β2AR signalling pathway 
was monitored by probing the phosphorylation of LKB1 at Ser428, which only was 
observed with addition of Iso alone. 
Simultaneously, like Iso effect, HLB interestingly induced a significant reduction 
of surface β2AR (P < 0.001) (Figure 3.22 A lane 2). Interestingly, St failed to prevent 
the internalization of β2AR (lane 3), suggesting that this receptor downregulation by 
HLB is nether dependent on SPAK/OSR1 catalytic activity, nor related to the 
SPAK/OSR1-mediated receptor phosphorylation. Because St capable to inhibit both 
WNK-induced and self-intrinsic SPAK/OSR1 catalytic activity (AlAmri et al., 2017a), 
subsequently St blocked the phosphorylation of β2AR by these kinases. 
 
























Figure 3.22: Internalization of β2AR by hypotonic low chloride buffer (HLB) 
independent of SPAK/OSR1 activity. (A) HEK293 cells were transfected with FLAG-β2AR, 
48hrs post-transfection, cells were left un-stimulated (U) or treated with HLB or 1μM 
Isoproterenol (Iso) alone or pre-treated with 10 μM STOCK1S-50699 (St), 1 μM Propranolol 
(Pro) or 1 μM ICI118551 (ICI). All pre-stimulation was for 1 hr and cells stimulation was for 1 
hr. HLB activates WNK-SPAK/OSR1-NKCC1 signalling (lane 2) as denoted by 
phosphorylation of Thr203, Thr207 and Thr212 residues and it surprisingly internalizes β2AR. 
This down regulation is SPAK/OSR1 independent (lane 3) which it had don’t been prevented 
by St. Iso produces phosphorylation of LKB1 at Ser428 and internalizes β2AR which inhibited 
by Pro and ICI. (B) and (C) are cumulative optical density (COD) data represented of cell 
membrane FLAG- β2AR which was normalised to Pan Cadherin. (B) COD data of top band 
of FLAG- β2AR while (C) was of lower band of FLAG- β2AR. Both bar graphs illustrating 70 
% and 55 % reduction of surface β2AR with hypotonic stress and Iso respectively. Results 
represented as mean ± SD of two independent experiments (n = 2), and samples were 
normalized to untreated cells (U). Red line represented the 50 % of total cell membrane 
receptors. One-way ANOVA test was performed and ***P < 0.0001, **P < 0.001, *P < 0.05 
and ns; no significant. FLAG (1:1,1000), NKCC1 (2µg/ 1ml), ps-NKCC1(2µg/ 1ml), LKB1 
(1:1,000), LKB1pSer428 (1:1,000), GAPDH (1:5,000), Pan cadherin (1:1,000). 
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As SPAK/OSR1 activity is involved in regulation of several membrane proteins 
(Rodan and Jenny, 2017), it was not surprising that the activated SPAK/OSR1 elevate 
the amount and activity of ion channels such CCC as well as potassium channels 
(KCNE1) (Elvira et al., 2015). However, on the other hand, this SPAK/OSR1 activity 
could be a negative regulator of other channel proteins such as  Ca-stimulated K 
channels (Elvira et al., 2016), Cl channels (CLC-2) (Warsi et al., 2014), CFTR (Yang 
et al., 2011) and ROMK1 (Elvira et al., 2014). Intriguingly, the catalytic activity of 
protein kinases may not be essential for the internalisation of membrane proteins. For 
instance, it was reported that the role of WNK1 and WNK4 kinases in the 
internalization of ROMK1 was independent of their catalytic activity as they acted just 
as scaffolding proteins that bound both intersectin and ROMK1 to enable ROMK1 
internalization by clathrin (He et al., 2007). Thus, the role of both SPAK and OSR1 
kinases, and maybe WNK kinases, in the β2AR internalization by HLB maybe 
mediated by a scaffolding effect rather than their kinase activity.   
Our finding that under hypotonic conditions, the β2AR gets internalised is in 
itself a novel finding that has not been previously reported in the literature. Saying this, 
it has been demonstrated that GPCRs are highly sensitive to mechanical disturbance 
or fluidity alteration of cell membrane, which lead to the receptor’s conformational 
changes and subsequent agonist-independent activation (Chachisvilis et al., 2006).  
Due to the fact that the hypotonic shock does not only stimulate WNK-SPAK/OSR1 
signalling, but it also induces influx of osmotic water into the cell and that causes cell 
swelling and increases the tension of plasma membrane therefore stimulation of 
GPRCs. Moreover, by assuming an agonist induces 100 % activation of GPCRs, 
various membrane disordered stimuli have been investigated and results revealed that 
hypotonicity, benzyl alcohol and shear stress cause GPCRs activation by 23 %, 9 % 
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and 14 % respectively (Chachisvilis et al., 2006). Thereby, the mechanical stimulation 
of the β2AR may also play a role in receptor internalization in addition to the direct 
effect of hypotonicity. In contrast to hypotonic stress, hypertonicity such as exposure 
to sucrose or hypertonic media stabilizes GPCRs, and these stimuli lead to drastic 
decrease of the formation of clathrin coated pit with a loss of lattice characteristic of 
clathrin (Heuser and Anderson, 1989). In contrast to this, hypotonicity may induces 
receptor down regulation by affecting on similar pathway that is involved in sucrose 
stabilization. These observations indicate that the β2AR internalization is affected by 
several factors other than phosphorylation including ions perturbations that make the 
internalisation mechanism so complicated.  
Additionally, in this experiment NKCC1 phosphorylation by the β2AR 
stimulation could be addressed. It was reported that NKCC1 activity increased in 
response to stimuli other than osmotic stress such as norepinephrine, calyculin, 
phosphatase 1 and 2 inhibitors, or fluoride in a study assessing whether the co-
transporter phosphorylation was mediated by a single kinase (Lytle, 1997). Phospho-
mapping results demonstrated that the four mentioned stimuli promoted 
phosphorylation of similar serine/threonine residues at N-terminus, which led to the 
suggestion that NKCC1 was at least regulated by two different kinases (Lytle, 1997). 
A subsequent study by Darman and Forbush showed that three N-terminal Thr 
residues were phosphorylated by PKA after activation by forskolin, an adenylate 
cyclase activating drug (Darman and Forbush, 2002). Interestingly, these residues 
were Thr184, Thr189 and Thr202 in shark NKCC1 sequences, which are equivalent 
to Thr212, Thr217 and Thr230 in human NKCC1 sequences (Darman and Forbush, 
2002, Richardson and Alessi, 2008). Based on this, there were two shared residues, 
Thr212 and Thr217, between the two different signalling pathways (WNK-SPAK/OSR1 
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and cAMP/PKA cascades) (Gagnon et al., 2007b, Richardson and Alessi, 2008), 
which could indicate that SPAK/OSR1 is a kinase that may be involved in the two 
signalling pathways (Figure 3.22).       
Interestingly, our results revealed that Iso-activated β2AR did not induce 
phosphorylation of NKCC1, at least on the SPAK/OSR1-dependent sites, more 
specifically at the key Thr212 (Figure 3.22 A). Despite this Iso-mediated NKCC1 
phosphorylation has been noted previously as NKCC1 phosphorylation and 
abundance were found to be elevated in Iso-perfused rat tissues such as parotid 
salivary gland, trachea and crypts cells of colon (Flemmer et al., 2002, Russell, 2000). 
 
3.5.2 Quantification of the surface β2AR: 
To further assess the internalization of the β2AR by HLB and whether it is 
SPAK/OSR1-dependent phenomenon, a quantification of the surface β2AR was 
performed. First, flow cytometric analysis was carried out where HEK293 cells were 
transiently transfected with FLAG-tagged β2AR. The cells were then stained with 
FITC-labelled antibodies. The non-specific fluorescence was determined by 
secondary only labelled cells as reported (Cao et al., 2005, Nasrollahi-Shirazi et al., 
2016). The cells were then analysed by fluorescent activated cell sorting (FACS) flow 
cytometry and the data was analysed by FlowJo (Alvarez et al., 2010).  
As an optimization step, the detection of receptor expression was first 
examined. Encouragingly, the receptors were identified with significant levels of 
expression (P < 0.05) (Figure S3) though some cells were poorly labelled. Then, 
several attempts of optimization steps were performed but there were insufficient cells 
labelling because of poor antibody FLAG-epitope interaction. Though the median 
                                                                                                                                  
139 
 
fluorescent intensity (MFI) showed a little reduction of surface β2AR with Iso and HLB 
treatment, which was SPAK/OSR1 independent, the histogram plot revealed 
insignificant reduction of surface receptors by the indicated compounds (Figure S4). 
Numerous repeats had been done on this experiment, but the same results were 
obtained because of poor cells labelling or unhealthy cells. Due to resources and time 
limitations, the progress with this FACS interrogation of the β2AR internalisation was 
not continued.  
However, we alternatively pursued the β2AR internalisation with ELISA, which 
had to be developed and optimized. In this assay, the extracellular FLAG epitopes of 
N-terminus FLAG-β2AR WT was targeted. To evaluate the internalization of the 
receptor with and without WNK-SPAK/OSR1 activation, transfected HEK293 cells 
were cultured in 96-well plates. The cells were then left untreated (control), pre-
incubated with St or Pro for 1 hr before stimulation with HLB or Iso for 1 hr. The 
subsequent absorbance reading revealed that HLB (Figure 3.23) induced a reduction 
in the surface β2AR and St, a SPAK/OSR1 inhibitor, appeared to have no effect on 
this internalization. This suggested that the β2AR internalisation process may be 
SPAK/OSR1-independent mechanism, which is in agreement with the Western blot 
data shown in Figure 3.22. Moreover, Iso as expected induced about 30 % reduction 
of the total surface β2AR (Figure 3.23) through the established clathrin- and dynamin-
mediated endocytosis (Han et al., 2012). Pro completely blocked the Iso-induced 
internalization of the β2AR due to its antagonism of the receptor. 
These results revealed a novel effect of HLB by producing β2AR stimulation 
and internalization in an agonist-independent mechanism, a process that appears to 
be independent of SPAK and OSR1 kinase activity though a non-enzymatic role of 
WNK kinases and SPAK/OSR1 could not be ruled out. The HLB-mediated 
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internalisation of the β2AR that we observed points towards an internalisation 
mechanism that is related to the internal milieu ions disturbance, which could lead to 
the stimulation of several signalling pathways that regulate receptors trafficking and 
recycling. 
 
               
Figure 3.23: SPAK/OSR1-independent internalization of β2AR by hypotonic 
stress. HEK293 cells were transfected with FLAG-β2AR-WT, then cells were 
plated in coated 96-well plate. Cells were labelled with mouse IgG1 anti-FLAG 
antibody, then they were either left rested (control) or pre-treated with 10 μM St or 
1 μM Pro. Then cells were stimulated by HLB or 1 μM Iso for 1 hr. After Alkaline 
phosphatase (AP) conjugated anti-mouse antibody and p-nitrophenyl phosphate 
disodium (PNPP) substrate were added, then the absorbance was read by plate 
reader.  HLB internalized β2AR via SPAK/OSR1 independent mechanism, as 
approved by addition of 10 μM St. Moreover, hypotonic stress is showing a stronger 
internalization effect than Iso. Data represented in mean ± SD of triplicate samples 
from a single experiment (n = 1).  
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3.6 Stimulation of the β2AR does not phosphorylate SPAK Ser373: 
Since the WNK-SPAK/OSR1 plays a vital role in salt homeostasis through 
regulation of ion co-transporters, the regulation of this signalling cascade has gained 
considerable attention. Beside the dietary salt modulation of WNK-SPAK/OSR1 
signalling pathway, hormonal effects were also reported (Sohara and Uchida, 2016).  
Numerous hormones such as angiotensin-2 (Ang2), vasopressin (Vas), insulin and 
aldosterone have been found to activate this signalling cascade in the kidneys (Sohara 
and Uchida, 2016). Additionally, sympathetic system (SPS), which is significantly 
involved in regulation of renal salts reabsorption, has also been implicated in the 
regulation of WNK-SPAK/OSR1 signalling (DiBona, 2005). Moreover, it was found that 
norepinephrine and Iso infusion in mice induced HPT by reduction of renal Na 
excretion along the DCT (Greven and Heidenreich, 1975, Mu et al., 2011).  
A subsequent study showed that this elevation of BP was mediated by 
upregulation of NCC via chronic stimulation of the β2AR, which reduced the 
suppression effect of WNK4 on SPAK/OSR1 by inhibiting WNK4 expression (Fujita, 
2014, Mu et al., 2011). However, the direct link between β2AR stimulation and 
SPAK/OSR1 kinases has not been previously investigated. Thereby, in this part, the 
stimulatory effect of the β2AR by the epinephrine analogue (Iso) on SPAK has been 
explored.  
In cultured HEK293 cells, SPAK is activated under osmotic stress by WNKs 
phosphorylation primarily at its T-loop Thr233 (Richardson and Alessi, 2008, 
Richardson et al., 2008). WNK kinases also phosphorylate SPAK at Ser373 and 
although this phosphorylation does not lead to the direct activation of the kinase, its 
often used as a readout of the kinase activity since the antibodies for pSer373 are 
much cleaner than those of pThr233  (Richardson and Alessi, 2008, Richardson et al., 
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2008). Interestingly these two residues were found also to be phosphorylated by Ang2 
through a WNK4 dependent pathway (Castaneda-Bueno et al., 2012). This 
observation was made after noting that the phosphorylation of these two sites was 
preluded by losartan, a competitive angiotensin receptor type 1 (AT1) blocker (San-
Cristobal et al., 2009, Castañeda-Bueno et al., 2012). Accordingly, SPAK 
phosphorylation at Ser373 has been analysed following the activation of the β2AR by 
Iso. To do this, HEK293 cells were transfected with FLAG-β2AR. 48 hours post-
transfection, the cells were treated with increasing doses of Iso, from 10 picomolar 
(pM) up to 10 micromolar (µM), for 60 minutes (min). The negative control in this case 
was the unstimulated cells (NS) (Figure 3.24). Surprisingly, the data revealed that 
β2AR stimulation may not phosphorylate SPAK Ser373 residue, even at 300 
nanomolar (nM) or higher, however it could phosphorylate other sites than Ser373 
(Figure 3.24). Also, there was not obvious alteration of total SPAK at the highest dose 
of Iso used, 10 µM in this case. Phosphorylation of LKB1 at Ser428 represented the 
activation of PKA as a result of triggering of the β2AR signalling pathway by Iso 
(Figure 3.24).  
The phosphorylation of SPAK at Thr233 residue is crucial because this residue 
is the main on/off switch for the enzymatic activity in response to WNK activation (Vitari 
et al., 2005). As the phosphorylation of Thr233 and Ser373 residues is observed 
simultaneously in WNK mediated activation (San-Cristobal et al., 2009), using SPAK 
Ser373 phosphorylation as a single readout in this experiment is sufficient for WNK-
induced SPAK activation. Nevertheless, several endeavours for optimizing anti-SPAK 
pT233 detection were performed, no success was achieved, and this is consistent with 
what is known in the field in term of the lack of a powerful anti-SPAK pT233 antibody 
(Figure S5 A).  




Our results revealed that β2AR activation may not phosphorylate SPAK at 
Ser373 residue which may indicate that WNK kinases are not activated, although 
WNK-1 activated OSR1 phosphorylates β2AR in vitro (Figure 3.18 and 3.20). 
Nevertheless, this does not exclude the possibility of SPAK to be phosphorylated by 
a kinase other than WNKs during β2AR activation. For instance, Ganon and Delpire 
demonstrated that four protein kinase C isoforms possess SPAK/OSR1 binding motif 
and only two of which, PKCδ and PKCθ, have been experimentally explored and 
Figure 3.24: No effect of Isoproterenol stimulation of β2AR on SPAK-Sre373. (A) 
Immunoblotting analysis of SPAK phosphorylation following β2AR activation in HEK293 cells. Cells 
were transfected with FLAG-β2AR-WT. 48 hrs post-transfection cells were left not-stimulated (NS) 
or stimulated with Iso in dose-dependent manner, started from 10 pM up to 10 μM for 1 hr. No 
changes have noticed either in SPAK phosphorylation at Ser373 or in its abundance. (B) 
Densitometry analysis of SPAK phosphorylation in (A), the quantification analysis also revealed that 
β2AR activation may not phosphorylate SPAK-Ser373. Results presented mean ± SD of two 
separate experiment (n = 2), P value was also calculated by ANOVA with post-Bonferroni’s test (P 
value = 0.9249), it is not statistically significant, (significant P < 0.05). Abbreviations: (NS) not-
stimulated. 1- 10 pM. 2- 30 pM. 3- 100 pM. 4- 300 pM. 5-1 nM. 6- 3 nM. 7- 10 nM. 8- 30 nM. 9- 100 
nM.  10- 300 nM.   11- 1 μM. 12- 10 μM. SPAK (2 µg/ml) SPAK-pSer373 (2 µg/ml), LKB1-pSer428 
(1:1,000), LKB1 (1:1,1000), FLAG (1:1,1000), GAPDH (1:1,000). 
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verified to bind SPAK to date (Gagnon and Delpire, 2012). SPAK was found to be 
associated to PKCθ in naïve Jurkat T-lymphocytes and this association was increased 
by cells stimulation with anti-CD3/CD28 (Li et al., 2004). Moreover, PKCθ had the 
ability to phosphorylate mouse SPAK in an in vitro kinase assay at Ser321 and Ser335 
(Gagnon and Delpire, 2012, Li et al., 2004), where the major phosphorylation residue 
Ser321 corresponds to Ser311 in the human sequence. Interestingly, this 
phosphorylation site is essential in receptor-induced SPAK activation to stimulate the 
transcription factor AP-1 in T-cells (Li et al., 2004). 
In the same context, PKCδ mediates the regulation of NKCC1 through either 
hormonal or hyperosmotic stress in alveolar epithelium (Smith et al., 2008). Three 
independent studies showed that SPAK was as downstream kinase of PKCδ in the 
regulation of NKCC1 activation under hyperosmotic stress (Gagnon and Delpire, 
2012). Although a subsequent study showed that SPAK phosphorylation by PKCδ was 
confirmed both in vitro and in vivo, the exact residues of SPAK that get phosphorylated 
by PKCδ have not been identified (Smith et al., 2008). Additionally, PKCα and PKA 
activate WNK4-SPAK/OSR1-NCC signalling pathway as response to activation by 
Ang2 and Vas (Gagnon and Delpire, 2012). That takes place by the phosphorylation 
of WNK4 directly at multiple Ser sites (Ser47, Ser64, Ser1169, Ser1180 and Ser1196). 
Notably, Ser64 and Ser1169 promoted the kinase catalytic activity, which 
subsequently led to phosphorylation and activation of both SPAK and NCC 
(Castañeda-Bueno et al., 2017). Furthermore, PKC induces the phosphorylation of 
KLHL3 at Ser433, which resulted in an inhibition of WNK4 interaction to and 
degradation by KLHL3 (Shibata et al., 2014). Thus, the levels of WNK4 and NCC were 
elevated (Shibata et al., 2014). Hence, several cellular mechanisms could control the 
total levels and activity of SPAK and OSR1 kinases.  
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Given that the previous study shown in Figure 3.24 was performed at a single 
time point treatment of 1 hr, we performed the same study using different time points.  
The aim of this was to assess whether chronic stimulation of the β2AR may induce 
phosphorylation of SPAK at Ser373. The data shown in Figure 3.25 revealed that 
short (5 min) and long (up to 72 hr) of persistent activation of the β2AR did not lead to 
phosphorylation of SPAK Ser373. This suggested that the Iso-stimulated β2AR may 
not lead to the phosphorylation of SPAK at Ser373. Therefore, the phosphorylation of 
SPAK Thr233 should be investigated. Moreover, it would be interesting if phospho-
mapping of SPAK was carried out following Iso-stimulation to identify whether SPAK 
gets phosphorylated in any other residues. Because of various signalling events that 
take place following the activation of the β2AR, which include the activation of both 
PKA and PKC through the elevation of cAMP, it is likely that SPAK could be 
phosphorylated by either direct or indirect phosphorylation by WNK kinases or other 
protein kinases.  
It is worth noting that when these experiments were being carried out, the cells 
appeared to be stressed as judged by the high expression levels of stress proteins 
including SPAK (Figure S5 B). The reasons for this were unclear. Hence, the 
alteration of SPAK/OSR1 via the β2AR activation was difficult to probe. Because of 
resources and time restrictions, some questions in this study remained unresolved, 
specifically, the effect of β2AR stimulation on SPAK/OSR1 activation and quantity. It 
would be interesting if this work had continued for in depth MS studies that could 
identify novel phosphorylation sites on both SPAK/OSR1 and β2AR after activation of 
either signalling pathway. Furthermore, another important experiment could be done 
that examines the effect of acute and chronic inhibition of the β2AR by Propranolol on 
SPAK/OSR1 abundance and phosphorylation.  











Figure 3.25: Chronic β2AR stimulation does not induce SPAK-Ser373 
phosphorylation. (A) Immunoblotting analysis of SPAK-Ser373 phosphorylation 
following β2AR activation in transfected HEK293 cells. Cells were treated with iso 
for indicated time course up to 3 days (72 hrs) and no SPAK-Ser373 
phosphorylation has been detected however that does not exclude the possibility 
of SPAK phosphorylation by β2AR in other site than Ser-373 as demonstrated in 
densitometry analysis in (B). This phosphorylation may reach the maximum on 24 
and 48 hrs. Results presented in mean SD from three independent experiments 
(n=3). ** P value < 0.0025, *P value < 0.05 was calculated by ANOVA with post-
Bonferroni’s test. SPAK (2 µg/ml), SPAK-pSer373 (2 µg/ml), LKB1-pSer428 
(1:1,000), LKB1 (1:1,1000), FLAG (1:1,1000), GAPDH (1:5,000).  
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3.7 Exploring the proposed β2AR-SPAK/OSR1-NKCC2 signalling pathway 
SPAK and OSR1 mediate NKCC2 and NCC activation by GPCRs in TAL and 
DCT (Morla et al., 2016). For instance, vasopressin (Vas), a hormone secreted by 
hypothalamus, induces salt and water reabsorption in the kidneys through activation 
V2 receptors in TAL and DCT (Morla et al., 2016, Nonoguchi et al., 1995). The V2 
receptors are coupled with Gs proteins that elevate cAMP, which in turn activates PKA 
(Morel et al., 1982). Through these signalling events Vas increases Na reabsorption 
by enhancing NKCC2 and NCC membrane trafficking in TAL and DCT respectively 
(Morla et al., 2016, Rieg et al., 2013). Interestingly, this Vas activation of NKCC2 and 
NCC is intermediated by SPAK/OSR1 activation and not by direct PKA 
phosphorylation (Ares et al., 2011a, Morla et al., 2016). Recent reports have 
demonstrated that Vas induces SPAK and OSR1 phosphorylation in both TAL and 
DCT (Saritas et al., 2013). Therefore, this indicates that SPAK/OSR1 could play a role 
as a second messenger of GPCRs activation in the regulation of NaCl homeostasis.  
As such, exploring the effect of β2AR stimulation ion the activation of NKCC2 
was required. To do this, HEK293 cells were transfected with FLAG-NKCC2 (1-174). 
48 hrs post-transfection, they were pre-incubated first with 10 µM WNK463 (WNK 
kinases inhibitor), 10 µM St, 1 µM ICI for 1 hr, and then they were stimulated with HLB 
or Iso for another 1 hr. The results showed that HLB activation led to the 
phosphorylation of NKCC1 at Thr203, Thr207 and Thr212 by WNK-activated 
SPAK/OSR1, as expected, and this activation was inhibited by WNK463 and St 
(Figure 3.26). Interestingly, Iso treatment did not lead to the activation of NKCC1 but 
when combined with HLB it seemed to enhance the phosphorylation of NKCC1 
(Figure 3.26). The phosphorylation of NKCC2, however, was only detected under Iso-
treatments and not HLB alone.  Intriguingly, this phosphorylation was not inhibited by 
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ICI or the WNK kinases inhibitor, WNK463. The inhibition of NKCC2 was only achieved 
by the treatment of the SPAK/OSK1 kinase inhibitor St. Furthermore, LKB1 S428 
phosphorylation by PKA was inhibited by Pro and not by WNK463 and St. Together, 
this suggested that the observed NKCC2 phosphorylation was WNK- and PKA-
independent but involved SPAK and OSR1 kinases.   
 
 
Figure 3.26: Immunoblotting analysis of NKCC2 phosphorylation during βAR 
activation. HEK293 cell were transiently transfected with FLAG-NKCC2 (1-174). 
48 hrs post-transfection cells were pre-incubated with 10 µM WNK463 (WNK 
kinases inhibitor), 10 µM St, 1 µM ICI for 1 hr, then cells were stimulated with HLB 
or Iso for another 1 hr. Weak phosphorylation of NKCC2 was observed, as detected 
by anti-NKCC1-phophoThr antibodies which recognised with Iso treated cells and 
did not either respond to ICI blocking or WNK463 but it responding to St pre-
treatment. The result represents single experiment (n=1). NKCC1-pT (2 µg/ml) 
NKCC1 (2 µg/ml), LKB1-pSer428 (1:1,000), LKB1 (1:1,1000), FLAG (1:1,1000), 
GAPDH (1:5,000). 
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For more elucidation and to verify the signalling pathway that stimulates these 
Thr residues of NKCC2 (1-174), which are known to be stimulated by SPAK/OSR1, 
several efforts were performed using co-transfected HEK293 cells with FLAG-NKCC2 
(1-174) and FLAG-β2AR. Following transfection, the cells were pre-treated with 
WNK463 (W), St, ICI, Pro, or CGP-20712 (a selective β1AR blocker) (CGP) for 1 hr. 
Subsequently, the cells were stimulated with either Iso or HLB (Figure 3.27). The 
results showed that the only phosphorylation that was detected was that of LKB1 and 
in this case it was in most of the samples with overexpressed FLAG-β2AR. Such 
phosphorylation may be an artificial effect as it is known that overexpression of some 
GPCRs could cause activation of protein kinases, PKA in this case, which 
phosphorylated LKB1 at S428. The probing of phosphorylation of NKCC2 at Ser92, 
Thr 105 and Ser130 was carried out beside NKCC1 phosphorylation, but because of 
either poor protein transfer during Western blot or antibody issues, the results varied 
significantly and were not consistent to support drawing of any conclusions. Moreover, 
the detection of the over-expressed β2AR was difficult in all samples because of an 
antibody artefact. Several attempts of optimization and characterization of phospho-
NKCC-2 antibodies were conducted, but these were not successful within the 
timeframe of this work.  
 
 





Figure 3.27:  Immunoblotting analysis of NKCC2 phosphorylation during 
β2AR stimulation. HEK293 cells were co-transfected with flag-NKCC2 (1-174) 
and FLAG-β2AR. After transfection, they were pre-treated with 10 µM WNK463 
(W), 10 µM St, 1 µM ICI, 1 µM iso, 1 µM Pro or 1 µM CGP20712 for 1 hr, then they 
were stimulated with HLB or Iso for 1 hr. No NKCC2 or NKCC1 phosphorylation 
were detected. The only detectable phosphorylation was LKB1 which was 
unexpectedly stimulated by HLB, the figure obtained from single experiment (n=1). 
Please note that this experiment has been repeated at least four times to detect 
NKCC2 phosphorylation at Ser91, Thr105, and Ser130 but without success. 
NKCC1-pT (2 µg/ml) NKCC1 (2 µg/ml), LKB1-pSer428 (1:1,000), LKB1 (1:1,1000), 
FLAG (1:1,1000), GAPDH (1:5,000). NKCC2 pSer91 (2 µg/ml), NKCC2 pT105 (2 
µg/ml), NKCC2 pSer130 (2 µg/ml). 
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Chapter  4 : Final conclusions and future work 
 
Since discovering the genetic link between WNK kinases and hypertension in 
the early 2000s, great advances have been made in dissecting the WNK-signalling 
pathway. Among the key discoveries was the identification of SPAK and OSR1 
kinases as the physiological substrates of WNKs and the subsequent finding that 
these regulate the function of cation chloride co-transporters (CCCs). To date, almost 
all of the studies relating to WNK-signalling have focused on its ability to modulate the 
function of CCCs.  
At the molecular level, WNK kinases binding to SPAK and OSR1 kinases was 
found to be mediated by the binding of the highly conserved SPAK and OSR1 CCT 
domains to RFxV/I tetrapeptide sequences that are present in the human WNK 
isoforms. Indeed, such interaction was also noted as being responsible for the binding 
of SPAK and OSR1 kinases to the CCCs, which also possess RFxV/I tetrapeptide 
sequences. Equipped with this information, we discovered that the human β2-
adrenergic receptors (β2AR) contains an RFHV tetrapeptide sequence (aa. 239-242). 
This indicated that the β2AR may also bind SPAK and OSR1 kinases. Thus, in this 
work, we sought to verify and confirm the binding of SPAK and OSR1 kinases to the 
β2AR as well as determine the effects of such binding on the WNK- and β2AR-
signalling.   
In the present work, we successfully showed that the β2AR-derived RFHV 
peptide binds to the endogenous SPAK in HEK293 cell lines, an observation that was 
made following the use of peptide pulldown assays. Additionally, the binding of 
overexpressed SPAK and OSR1 kinases to overexpressed β2AR in HEK293 cells was 
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confirmed by GST-tagged protein pull down and by competition assays where adding 
the WNK’s RFQV peptide competed out the β2AR’s RFHV binding to SPAK and OSR1 
kinases. Furthermore, we also showed that SPAK and OSR1 binding to the β2AR was 
inhibited by mutating the arginine residue on the β2AR’s RFHV motif to AFHV or by 
single point mutations on SPAK and OSR1 CCT domains. Together, these 
experiments provided the first evidence of SPAK and OSR1 direct binding to the 
human β2AR. 
Subsequently, we showed that the constitutively active OSR1 was able to 
phosphorylate the human β2AR in vitro, and this phosphorylation was significantly 
reduced when the mutant the β2AR R239A was used as a substrate instead of the 
β2AR wild-type. Additionally, the phosphorylation of the β2AR was inhibited in vitro by 
OSR1 kinase inhibitors in a dose-dependent manner. Although our work provided the 
first evidence of OSR1 and perhaps its homologous, SPAK, phosphorylate the β2AR, 
the exact phosphorylation sites on this receptor remain unidentified. Thus, as part of 
the future work for this project, it is critical that phosphor-mapping in performed to 
identify the SPAK and OSR1 phosphorylation sites on the β2AR.  
In term of investigating the effect of the β2AR modulation on SPAK and OSR1 
kinase activity, isoproterenol stimulated β2AR was used in β2AR-tranfected HEK293 
cells, and this showed that the β2AR stimulation did not induce WNK-mediated SPAK 
and OSR1 activation following short- and long-term β2AR stimulation. Admittedly, this 
study focused on monitoring only SPAK S373, which is a WNK phosphorylation site, 
because it has robust phosphor-antibodies. Therefore, the possibility of the β2AR-
activation leading to the phosphorylation of SPAK on residues other than Ser373 can 
not be excluded. This could be investigated in the future using initially pan-
phosphoserine, phosphor-threonine and phospho-tyrosine antibodies and if they show 
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phosphorylation exact phosphor-mapping could be carried out to identify these 
phosphorylation sites. In cells, the activation of the WNK-SPAK/OSR1-signalling 
cascade by hypotonic buffer led to the internalisation of the β2AR. Although the use 
of a SPAK/OSR1 kinase inhibitor named STOCK-1S50699 did not prevent such 
internalisation, the involvement of WNK-kinases could not be ruled out. This is 
because this inhibitor is rather promiscuous and recently Novartis developed specific 
WNK kinase inhibitors, which should be used in the future to investigate the β2AR 
internalisation. Critically, SPAK and OSR1 kinases may also regulate the β2AR 
through a scaffolding mechanism and this should also be investigated in the future. 
Intriguingly, our work showed that the CCC, NKCC2, a known SPAK and OSR1 
substrate, was phosphorylated as a response to the β2AR and this phosphorylation 
was supressed by the inhibition of SPAK and OSR1 kinases, but not by the inhibition 
of WNK kinases. This suggested that the Iso-mediated phosphorylation of NKCC2 is 
WNK kinases independent, but involves SPAK and OSR1 kinases, and hence these 
latter kinases maybe regulated by other upstream kinases other than WNKs following 
Iso-stimulation.   
 
Work limitations and future experiments 
In this study the RFxV peptides have shown to be bound to endogenous SPAK 
only in HEK293 cell lines which is it could be a limiting factor, so it would be interesting 
to determine the binding of β2AR derived RFHV-tetrapeptide to the kinase in other cell 
lines. Although this work provides the first evidence of binding SPAK kinase to β2AR 
which could link the adrenergic system to WNK-signalling pathway and could explain 
the increase of BP by sympathetic activation, this finding was only validated by over-
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expression of both proteins in HEK293 cells, that could enhance the binding ability of 
two proteins i.e. non-physiological conditions. Although, SPAK binding to β2AR in 
immune-precipitated samples from mouse heart have been identified, further verifying 
the interaction under normal physiological state in human native tissues e.g. lung, 
muscles, kidneys, blood vessels or uterus is also required.  
Some analysis in this study has primarily relayed on Western blot (WB) which 
has some restrictions such as antibody specificity and cross reactivity and poor protein 
transfer from SDS gels to nitrocellulose membranes. These factors could affect the 
data interpretation. For instance, β2AR expression in HEK293 cells was evaluated by 
WB either in total cell crude or membranous fraction, thus other methods for 
determining receptor expression could be used such as flow cytometry, 
immunohistochemistry (IHC) or by si-RNA. Also, there were some issues in using WB 
to determine few phosphorylated proteins such as SPAK phosphorylation at Thr233 
and NKCC2 phosphorylation.  
In present work, our data revealed that OSR1 phosphorylates β2AR in vitro, 
and this phosphorylation was reduced by introducing mutant R239A β2AR or by 
inhibiting OSR1 catalytic activity, while in vivo phosphorylation of the receptor by 
SPAK or OSR1 is needed to be investigated and the sites of phosphorylation are 
required to be identified by phosphor-mapping. Moreover, the effect of this 
phosphorylation on β2AR function had not assessed, it would be interesting examining 
the effect of R239A mutation in receptor function by performing cAMP assay. Also, it 
has noticed that β2AR was internalized by HLB, this internalisation mechanism 
requires more investigations, to confirm whether the scaffolding role SPAK/OSR1 
mediates this mechanism. IHC and fluorescent activated cell sorting (FACS) could be 
used to assess mutant R293A β2AR (non-SPAK and OSR1 binder) function.  
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In conclusion, this work provides the first evidence of the direct interaction 
between SPAK and OSR1 kinases with the human β2AR. Given the important role the 
β2AR plays in the pathogenesis of many human diseases such as heart failure, 
asthma and COPD, our discovery adds a new dimension to the pathogenesis of these 
diseases. Critically, this may eventually highlight the repurposing of WNK-signalling 
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Chapter  5 : Appendix 
 
1- Table S1: Row data of densitometry analysis of SPAK-Ser373 
phosphorylation 
SPAK phosphorylation at Ser373 mediated by HLB-activated WNK1 (Figure 
3.1 C). This phosphorylation has been analysed by densitometry. The results revealed 
that the lower bands are more likely to be Ser373 phosphorylation sites than the upper 
ones which could be phosphorylated residues by kinases other than WNK1/4. Data 
obtained from single experiment (n=1).  
Upper band  6.44 5.53 49.29 26.57 43.43 29.32 32.26 30.56 
Lower band  3.33 4.12 26.15 19.94 4.22 2.38 4.39 4.42 
Table S.1: Row data of densitometry analysis of SPAK-Ser373 phosphorylation. 
 
 
2- Table S2: Row data of densitometry analysis of NKCC1 phosphorylation. 
This work has been carried to optimise the concentration of WNK463 inhibitor 
in HEK293 cells (Figure 3.2). Data represented two independent experiments (n=2). 




Mean ± SD 
Vehicle 4.54 4.16 4.353 0.186 
HLB 77.15 94.25 85.700 8.550 
St 2.20 6.39 4.307 2.091 
WNK463 0.3 µM 95.65 56.32 77.331 18.011 
WNK463 1 µM 94.65 61.36 78.512 17.145 
WNK463 3 µM 36.78 50.76 43.773 6.9869 
WNK463 5 µM 3.95 25.66 14.812 10.856 
WNK463 10 µM 2.62 2.99 2.810 0.1808 
WNK463 20 µM 5.01 4.51 4.763 0.2533 
Table S.2: Row data of densitometry analysis of NKCC1 phosphorylation. 
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3- Table S3: Row data of densitometry of LKB1 phosphorylation by Iso 
stimulation. 
Quantification data of phosphorylation of LKB1 after stimulation of Isoproterenol 
dose dependent course for 30 min in HEK293 cells (Figure 3.7). Data obtained from 











Mean ± SD 
0 0.8846294 4.96329 0.803703 2.217209 1.942056 
0.01 2.1902989 5.29745 10.19936 5.895703 3.296937 
0.03 2.1790347 4.05029 6.173719 4.134351 1.631905 
0.1 3.5696058 18.0996 3.912698 8.527301 6.770086 
0.3 6.8330296 30.23403 8.289744 15.11893 10.70452 
1 11.337408 41.84822 59.72763 37.63775 19.97831 
3 28.406838 78.72484 122.2946 76.47543 38.3625 
10 60.184907 94.86625 79.17605 78.07574 14.17996 
30 65.468709 63.73934 118.5999 82.60264 25.46368 
100 49.842921 39.85731 56.68536 48.7952 6.90985 
300 45.172886 99.86604 99.23594 81.42495 25.63537 
1,000 44.774294 113.1005 107.744 88.53957 31.02389 
3,000 33.524751 105.2303 54.50973 64.42161 30.10102 
Table S.3: Row data of densitometry of LKB1 phosphorylation by Iso. 
 
  
4- Table S4: Row data of densitometry of ICI inhibitory effect. 
Quantification data of ps-LKB1/LKB1 to assess the inhibitory effect of 
ICI118551 (ICI) in transfected HEK293 cells (Figure 3.8). It was obtained from single 
experiment (n=1).  
Samples NS Iso  0.01 ICI 0.03 ICI 0.1 ICI 1 ICI 
psLKB1/LKB1 5.1047 62.9902 64.2716 23.8081 21.0131 23.7114 
Table S.4: Row data of densitometry of ICI effect. 
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5- Figure S1: Immunoblot analysis of Identify β2AR phosphorylation. 
This experiment aimed to determine β2AR phosphorylation at Ser345 and 
Ser346 after HLB and isoproterenol stimulation. The top panel showed β2AR 
expression after transfection in all samples but its phosphorylation at these Ser 














6- Figure S2: Immunoblot analysis attempted to identify the interaction of SPAK 









            
Figure S.1: Immunoblot for identification of β2AR Ser345 and Ser346 
phosphorylation after HLB and 300nM Isoproterenol (Iso) stimulation in transfected 
HEK293 cells. 
 
         
Figure S.2: RFxV binding to endogenous SPAK.  
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7- Table S5: Row data of in vitro ADP-GloTM kinase assay of phosphorylation of 
β2AR by OSR1-T185E, the below table showed data in mean ± SD of three 
independent samples (n = 3). (Figure 3.18 A and B). 
 
Lanes Luminescence (RLU) 
 
% Luminescence (RLU) 
relative to control 
 Mean               ± SD Mean                    ± SD                   
1-Control  43429          7132.357     //// 
2-CATCHtide+OSR1 145589        10953.05   //// 
3-β2AR-WT+OSR1 135244         5559.018 100 
4-β2AR-R239A+OSR1 86783         11237.489 61.031                 4.7324 
Table S.5 : Row data of in vitro OSR1 kinase assay of β2AR phosphorylation.  
 
 
8- Table S6: Row data of in vitro ADP-GloTM kinase assay of the inhibitory effect 
of Verteporfin (VP) on OSR1-T185E activity (Figure 3.19A and B). Data were 
obtained from single experiment in triplicate (n=1).  
 
Lanes Luminescence (RLU) % Luminescence (RLU) 
relative to control 
NKCC2(1-174)  7793 //// 
NKCC2(1-174) + OSR1-T185E 22707 100 
0.1 µM VP 20451 90.04391 
0.5 µM VP 17311 76.30306 
1 µM VP 11629 51.21696 
5 µM VP 8544 37.67089 




9- Table S7:  Row data of in vitro ADP-GloTM kinase assay of β2AR. 
 β2AR phosphorylation by OSR1-T185E and with the inhibitor 5 µM VP, to 
verify receptor phosphorylation is dependent on the kinase activity of OSR1T185E 
(Figure 3.20). Data were obtained from three independent experiments (n=3). 
 




Lanes Luminescence (RLU) Mean ± SD 














3-NKCC2(1-174) + OSR1-T185E+ 






























Table S.7: Row data of In vitro OSR1 kinase assay of β2AR phosphorylation and its 
inhibition by Verteporfin.  
 
 
10- Table S8: Row data of in vitro ADP-GloTM kinase assay of CATCHtide 
phosphorylation by OSR1-T185E and the effect of [A/R]FHV-peptides on OSR1 






relative to control 
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11- Table S9: Row data of in vitro ADP-GloTM kinase assay of NKCC2(1-174) 
phosphorylation by OSR1-T185E and the effect of [A/R]FHV-peptides on OSR1 





















12- Table S10 and S11: Row data of western blot quantification of membrane β2AR 
bands intensity of (Figure 3.22 B and C). 
 
 
Samples 1st Experiment 2nd Experiment Mean ± SD 
U 100 100 100 0 
HLB 17.17 38.77 27.97 15.2 
St/HLB 15.06 33.85 24.45 13.3 
Iso 33.93 88.33 61.13 12.5 
Pro/Iso 69.23 97.76 83.49 15.2 
ICI/Iso 42.63 85.57 64.10 7.36 
Table S.10: Row densitometry data of β2AR upper bands. 
 
 
Samples 1st Experiment 2nd Experiment Mean ± SD 
U 100 100 100 0 
HLB 21.28 32.36 26.82 7.831 
St/HLB 17.60 11.47 14.53 4.329 
Iso 33.52 53.67 43.60 14,251 
Pro/Iso 99.27 95.15 97.21 2.913 
ICI/Iso 93.86 84.72 89.29 6.464 
Table S.11:Row densitometry data of β2AR lower band. 
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13- Figure S.3: Identification of FLAG-β2AR expression by flow cytometry.  































Figure S.3: Detection the expression of β2AR and gating strategy.  
Illustrative flow cytometry plots of transiently transfected HEK293 cells with N-
terminus FLAG-β2AR. 48 hrs post-transfection Cells were prepared for and analysed 
by Cyan ADP of fluorescence activated cell sorting (FACS) and FlowJo v 10. Primary 
mouse anti-FLAG antibody and FITC-488 anti-mouse secondary antibody had been 
used in the study. (A) Cells were analysed based on their size/intracellular granularity 
by forward scatter (FSS)/side scatter (SSC) respectively (left dot plot). More than one 
cells (cell aggregation or doublet) were excluded on pulse width/ FSS plot (middle dot 
plot). The interested subsets were then analysed by measuring the fluorescence of 
FITC labelled specific antibody on log scale versus cell number (red histogram), while 
non-specific signal was determined by secondary only labelled cells (blue area). (B) 
Median Fluorescent intensity (MFI) was calculated from histogram plot in (A) of three 
independent experiments (n=3). Data represented in mean ± SD and receptors 
expression were proved by Student t-test.    
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Figure S.4: SPAK/OSR1 independent internalization of β2AR. 
Flow cytometry plots of FLAG-β2AR transfected HEK293. 48 hrs post-transfection cells were 
left not-stimulated (NS), or pre-incubated with 10 µM St or 1 µM Pro for 1 hr, then cells were 
stimulated either with HLB or 1 µM Iso for 1 hr. Cells were analysed as previous figure. (A) 
Singlet cells were gated, fluorescence analysed on log scale of FITC-labelled antibody (right 
plot). (B)MFI was computed from histogram in (A) and Kruskal-Wallis followed by Dunn’s 
multiple comparison test revealed non-significant difference between samples mean. Data 
presented in mean ± SD of two separate experiments (n=2). Although % of MFI relative to NS 
showed SPAK/OSR1 independent reduction of surface β2AR, and less internalization with 
Iso. However, little effect of treatment against NS (grey area) was observed and most of 
samples showed unequal cells number. Moreover, there was an overlap between samples 
and unstained which indicated less cells labelling particularly in Pro/Iso (dark blue) and Iso 
(green).  
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15- Table S12: Row data of ELISA assay of quantification of membrane surface 
β2AR-WT of (Figure 3.23). Data were obtained from single experiment (n=1). 
 
Lanes % of Relative absorbance 
to control 
 Mean 
1-Untreated cells (control)  100 
2-HLB 78.15055 
3-St/HLB  89.1177 
4- Iso 44.43416 
5- Pro/Iso 46.06071 
Table S.12: Row data of ELISA quantification of surface β2AR.  
 
 
16- Table S13: Row data of densitometry analysis of SPAK phosphorylation by 
Isoproterenol. 
Densitometry data of SPAK phosphorylation by Iso stimulation, in dose 
dependent manner (Figure 3.24). Data have been obtained from two separate 
experiments (n=2). 
 
Samples Mean ± SD 
NS 26.74196 0.878377 
1 30.27842 10.70634 
2 32.82276 18.4529 
3 31.67429 11.23902 
4 38.86027 12.1326 
5 56.24615 15.59387 
6 59.72523 27.96903 
7 44.70796 23.7453 
8 41.04777 7.91969 
9 29.01706 4.295555 
10 27.3344 13.6714 
11 40.23147 16.63579 
12 33.82606 22.67147 
Table S.13: Row data of densitometry analysis of SPAK phosphorylation by 
Isoproterenol in dose dependent manner. 
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17-  Table S14: Row data of densitometry of SPAK phosphorylation by Iso 
stimulation in time-dependent manner.  
HEK293 cells were treated by 300nM Iso in time dependent manner, after 
72hrs cells were treated and data were obtained. Data represented three 
independent experiments (n = 3). 
Samples Mean ± SD 
NS 16.67695 9.92783 
5 min 38.5055 11.38549 
10 min 38.26748 5.880695 
20 min 39.08742 3.764485 
30 min 38.82006 5.271327 
60 min 34.42249 4.033594 
3 hrs 39.55901 13.07957 
6 hrs 46.76407 10.45891 
12 hrs 64.83308 21.79991 
24 hrs 71.83936 17.20266 
48 hrs 73.08802 8.504269 
72 hrs 53.82733 17.32385 
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18- Stimulation of β2AR did not phosphorylate SPAK Ser373 and difficulty to detect 




























                                     
Figure S5: Iso-stimulated β2AR did not phosphorylate Ser373 of SPAK. 
 (A) HEK293 cells were transfected with Flag-β2AR, 48 hrs post-transfection cells 
were left untreated (NS) or pre-stimulated with 10 µM St or 1 µM Pro for 60 mins. 
Then cells were stimulated with HLB or 300 nM Iso for 60 mins. No activation had 
been observed in SPAK phosphorylation at Ser373 or change in protein 
abundance. NKCC phosphorylation for identification of SPAK activation. Also, 
detection of phosphorylation T233 was challenging to be obtained. (B) IB analysis 
demonstrates hyperexpression of endogenous SPAK in HEK293 cells. Please note 
the increased levels of SPAK abundance in (B) over than in (A) which is the normal 
expression level. 
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